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S U M M A R Y
Strains of Staphylococcus aureus have caused a wide variety of ailments and diseases in 
humans and animals for centuries. The original antimicrobial agents of choice for 
treatment of pathogenic strains were the penicillins and cephalosporins, which disrupt the 
bacterial cell wall. The emergence of strains producing p-lactamase enzymes that 
hydrolysed the penicillins and related antimicrobials led to the development of new cell 
wall agents lacking the P-lactam ring for example vancomycin, or have been modified to 
confer p-lactamase resistance, for example methicillin and oxacillin. The prevalence of 
such resistance is now thought to be as high as 90% of all S.aureus strains.
One of the cell wall inhibitors developed in response to p-lactamase activity was 
methicillin. Methicillin was introduced in to the pharmaceutical market in 1960 but by 
1961 a strain of S.aureus displaying reduced methicillin susceptibility (MIC >25pg/ml) 
had already been isolated. Today, resistance to methicillin in staphylococci is wide spread 
and has been reported in strains of S.aureus and coagulase-negative staphylococci. Over 
the years the nmnber of methicillin-resistant S.aureus (MRSA) isolates has increased 
significantly and are particularly problematic within medical institutes although the 
incidence of community-acquired MRSA (CA-MRSA) is increasing. Infection of an 
individual with a strain of MRSA is aided by a deficiency in an individuals immune 
defence system whether it is through injury or surgeiy. The ability of the strain to persist 
in a host can be attributed to the difficult eradication of the infection by antimicrobial 
agents as nuinerous resistance mechanisms are carried by strains of MRSA.
In many instances the drug of choice to treat acute cases of MRSA infection is the 
glycopeptide vancomycin, which until relatively recently has been very successful. The 
occurrence of vancomycin resistance among entero cocci has been known for many years 
but its resistance mechanisms have only been demonstrated to be transferable to S.aureus 
in vitro. The prospect of vancomycin resistance spreading to multi-resistant strains of 
staphylococci is one not many clinicians like to consider as this would further limit the 
spectrum of agents available to treat infected individuals. In 1997, the first strain of
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MRSA displaying reduced susceptibility to vancomycin was isolated from a patient in 
Japan and it has rapidly been succeeded by strains in the United Kingdom, United States 
and across Europe. The mechanism of resistance employed by these strains has not been 
elucidated as the van genes that confer high-level vancomycin resistance in strains of 
enterococci are not carried by these isolates of S.aureus. However, the United States have 
recently isolated the vanA gene from two clinical isolates of S.aureus confirming the 
potential for acquisition o f genes conferring high-level resistance to vancomycin by 
S.aureus.
With the high prevalence of MRSA in many countries the need for new and improved 
antimicrobial agents with novel modes of action has been highlighted. Among this group 
of new antimicrobials are the oxazolidinones, for example linezolid, the streptogramin 
quinupristin/dalfopristin (Synercid), and the lipopeptide daptomycin each with a unique 
mechanism of action. Studies using the aforementioned antimicrobials have been carried 
out, and have given encouraging results in animal models of endocarditis and bacteremia, 
and in compassionate use programs leading to the launch of linezolid in 1999 and phase III 
clinical trials of daptomycin that are due for completion in the near future.
In this study, we examined the investigational protein synthesis inhibitors linezolid and 
quinupristin/dalfopristin, and daptomycin, a disrupter of cell membrane potential, along 
with cefpirome, a cell wall inhibitor, against strains of S.aureus displaying vancomycin- 
intermediate resistance (VISA). Six VISA strains were chosen from three countries, Japan 
(Mu3 and Mu50), United Kingdom (3700w and 3759v) and the United States (5827 and 
5836) along with an epidemic strain of MRSA, EMRSA-16, and a standard methicillin 
sensitive S.aureus (MSSA) Cowan. Sub-inhibitory concentrations of cefpirome, 
daptomycin, linezolid and synercid were used to investigate their effects on cell growth 
and morphology, virulence factor expression, and strain susceptibility to 
opsonophagocytosis. Characteristics of individual strains in the absence of antimicrobial 
stress were compared to standard strains EMRSA16 and MSSA in addition to 
antimicrobial treatment being compared to the antibiotic free control for individual strains.
It was found that each strain of VISA has distinctive characteristics and that the 
vancomycin resistant genotype does not confer the same phenotypic characteristics on 
every strain. A feature observed by other researchers and confirmed here, was the 
existence of much thickened cell walls in selected VISA strains. The lack of surface 
protein A was also apparent by its presence on VISA 5827 only in addition to the MSSA
and EMRSA-16 strains. Extracellular protein A was also not uniformly detected but was 
expressed by four of the VISA strains. Exposure to sub-inhibitory concentrations of all 
four of the antimicrobial agents was generally found to reduce the expression of the surface 
proteins, clumping factor and protein A, in the majority of strains but produced variable 
responses in their effects on alpha-haemolysin and toxic shock syndrome toxin 1 (TSST-1) 
expression. Analysis of mRNA transcription of the protein A gene, spa, revealed increased 
levels of mRNA in response to antimicrobial stress however, the levels of mature protein 
were reduced confirming that linezolid and quinupristin/dalfopristin are inhibitors of 
protein synthesis.
With regard to opsonophagocytosis, through microscopic visualisation, each strain 
appeared to be ingested to similar degrees by polymorphonuclear cells (PMNL) with the 
exception of Mu50 which was ingested to significantly higher degrees following exposure 
to cefpirome, linezolid and synercid. Using chemiluminescence as an indicator of 
phagocytic ingestion strain 3759v induced significantly less chemiluminescence in 
comparison to all of the other strains, including the standards, whereas, Mu3 and Mu50 
induced greatly enhanced results. Exposure of the cell cultures to any of the antimicrobial 
agents did not have a uniform effect on opsonophagocytosis of the strains but 
chemiluminesence was found to be reduced in strains where antimicrobial agents exerted 
an effect.
Protein A, amongst others, is regarded as an antiphagocytic protein. The absence of 
protein A on the surface of the majority of VISA strains was not found to increase the 
susceptibility of strains to opsonophagocytosis. Several strains possessed thickened cell 
walls that may be compensatory for the lack of protein A and affect phagocytosis as 
expression of thickened cell walls in response to antimicrobial stress reduced the level of 
chemiluminescence observed in several of the strains. Thus, the effects of different 
antimicrobial agents on a bacterial cell are not necessarily those exerted upon all bacterial 
strains. The characteristics assayed for here only represent a small fraction of a wider 
picture of the interaction between bacteria and antimicrobial agent.
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C H A P T E R  O N E
I N T R O D U C T I O N
1.1 staphylococci
Staphylococci are relatively large (0.8pm in diameter) Gram-positive, clump forming, 
facultative aerobic cocci. The genus comprises of both animal and human specific strains 
some of which are potentially serious pathogens. At present, there are greater than twenty 
strains of staphylococci with strains of the same species having 80-100% sequence 
identity. In humans there are two major species; Staphylococcus epidermidis 
(S.epidermidis) found as a commensal organism of the skin and mucous membranes or as a 
contaminant of artificial devices, and Staphylococcus aureus (S.aureus).
Staphylococcus aureus has been associated with a wide variety of ailments and diseases 
including abscesses, food poisoning, pneumonia, bacteraemia, endocarditis, osteomyelitis, 
meningitis, toxic shock syndrome (TSS), and scalded skin syndrome (SSS), thus causing a 
high degree of morbidity and mortality. Not all strains of S.aureus are pathogenic. Many 
people carry the bacterium asymptomatically in their nasal cavity, throat and skin. The 
development of a diseased state in a host can arise as a result of the acquisition of 
additional genetic material by the bacterium or by the expression of a phenotype encoded 
by the genetic material, for example the expression of extracellular enzymes and toxins 
(“virulence factors”). In other instances a compromised host immune system is all that is 
required for an opportunistic pathogen to cause an infection.
Genetic analysis of the S.aureus genome shows the presence of l-60kbp plasmids that can 
be grouped into 4 general classes (Table 1).^ ^^  Additional genetic material such as 
resistance plasmids and virulence genes can be acquired by conjugation and transduction 
influencing the pathogenic status of the organism. Other species that carry toxin genes on 
mobile genetic elements include Escherichia coli (E.coli), Vibrio cholerae and 
Corynebacterium diphtheriae, however genetic elements acquired by Gram-positive 
bacteria tend to be more stably integrated in to the bacterial genome.
Plasmid Group
I l-5kb; high copy number; single antibiotic resistance
11 20-40kb and copy number; P-lactamase and inorganic ion resistance; 
comprised mainly of transposons
III 40-60kb; multiple antibiotic resistance markers; comprised mainly of 
transposons
IV Intermediate size; heavy metal and antibiotic resistance
Table 1. Staphylococcal plasmid groups and their characteristics
The acquisition of DNA encoding methicillin resistance {mecA operon) by S.aureus 
(MRSA) is currently giving rise to potentially life-threatening illnesses and therefore 
causing major concerns in clinical institutions. The emergence of MRSA as a nosocomial 
pathogen was initially reported in Europe during the 1960s soon after the introduction of 
methicillin. The first reported isolate in the United Kingdom was by Jevons^^^ and 
Barber^  ^ in 1961. An early case study into the prevalence of MRSA by Parker and Hewitt 
classified strains resistant to methicillin with an MIC>25ug/ml by broth micro-dilution.^^^ 
They discovered the ability of MRSA to express large quantities of penicillinase and 
display resistance to several non-penicillin antibiotics. It has also become apparent that 
strains are not confined to exposed populations as community acquired-MRSA (CA- 
MRSA) has been reported. Isolates have also been reported from countries where 
methicillin and penicillinase-resistant penicillins were not available such as Poland, 
Turkey and India, and in populations with no apparent risk factors to the acquisition of 
methicillin resistance.^^^ ^  ^ ,207,330
A decline in the isolation frequency of multi-resistant strains occurred in the 1970s 
possibly due to a reduction in the use of tetracycline during this time.^* However, from 
1978 ‘new’ MRSA strains emerged causing intra- and inter-hospital outbreaks in Australia, 
the Republic of Ireland and the United States of America, and in 1981 epidemic MRSA 
strain-1 (EMRSA-1) emerged in London hospitals spreading across the country. Since 
then, and particularly from 1991, different strains of EMRSA have continued to appear and 
are continually being isolated from patients. At present there are seventeen strains of 
EMRSA in the UK many of which have heterogenous resistance.*^ All strains of MRSA 
express an additional 78KDa cell wall protein PBP2a (or 2’) active at concentrations of
antibiotics that inactivate other PBPs retaining its transpeptidase activity 236
The treatment of these highly resistant strains is sometimes dependent upon the antibiotic 
vancomycin however, strains of enterococci already display high-level vancomycin 
resistance and strains of S.aureus and coagulase-negative staphylococci (CNS), with 
intermediate to high-level resistance have been i s o l a t e d . ^ T h e  first reported strain of 
vancomycin intermediate resistant S.aureus (VISA) with an MIC of 2pg/ml was in Japan 
in 1997 by Hiramatsu (hVISA Mu3) followed by its clonal variant VISA Mu50 
(MIC=8pg/ml) and two cases in the United States of America from patients receiving 
extended vancomycin treatment, strains 5827 and 5836 (MIC=8pg/ml)/^'"*^'*^ * To date, 
more strains of VISA have been isolated in the United States and across 
Europe.^°’^ ’^^ ^^ ’^ ^^ ’^ ^^  In the UK, the first VISA strain did not appear until 1998 when a 
strain of EMRSA-15 (vancomycin MIC=4pg/ml) was recovered from a patient receiving 
vancomycin therapy in Bristol. This was followed in 1999 by the isolation of two 
strains, 3700w and 3759v (MIC=6pg/ml), within days of each other from different patients 
at Glasgow Royal Infirmaiy.
Analysis of glycopeptide resistant strains, in particular Mu50, has revealed major 
alterations in its cell wall composition. Increased levels of glutamine non-aminated 
murapeptides, PBP2 and PBP2’ expression, reduced levels of peptidoglycan cross linking 
and dimer:monomer muropeptides and an overall thickened cell wall have all been 
described, but not all together and not in all Additional
features such as longer mean generation times, small colony size on solid agar, reduced 
methicillin resistance, and reduced ‘cellular amounts’ of PBP4 with increasing 
vancomycin MtC’s have also been described. '^*'^^ '^^* ’^^ ^^
1.2 Staphylococcal Proteins and Toxins
The initiation of a diseased state is dependent upon the penetration of the host’s physical 
barriers and the ability to survive the inhibitory effects of antimicrobial secretions and 
cells of the immune system (section 1.7). Over time bacteria and other microorganisms 
have developed ways of evading or overwhelming host defences. Many species of bacteria 
display proteins on their cell surface that aid attachment of the bacterial cell to host cells 
as well as protect it from phagocytosis. Selected extracellular proteins or toxins function 
to destroy target host cells facilitating the infection process. The expression of virulence 
factors in S.aureus is multifactorial and subject to enviromnental and internal regulation
3
(section 1.3). The systems that eventually succumb to staphylococcal infection depend 
upon the genetic makeup of the infecting strain and its environment. Table 2 summarises 
the range of proteins and toxins expressed by S.aureus and their role in human disease.
Mode of Action Hi, Diseose
a-, (3-, ô-haemolysin Red and white cells Haemolysis Abscesses
Y-haemolysin Leukocytes Leukolysis Abscesses
Panton -Valentine 
leukocidin (PVL)
Leukocytes Leukolysis Abscesses, 
Necrotising pneumonia
Toxic shock syndrome 
toxin (TSST-1)
Tcells Release of cytokines. 
Systemic shock
Toxic shock syndrome 
(TSS)
Enterotoxins A to O Intestinal cells Induce vomiting, 
diarrhoea, shock
Food poisoning
Exfoliative toxin A and B Epidermis Desquamation of skin, 
shock
Scalded skin syndrome 
(SSS)
Staphylococcal 
enterotoxin- like protein 
(SET-1)
? ? ?
Coagulase Fibrinogen Induces fibrin clotting Resistance to 
phagocytosis
Protein A Fc portion of IgG 
antibodies
Reduced activation of 
complement pathways 
and opsonisation
Resistance to 
phagocytosis
Table 2. Proteins and toxins produced by S.aureus.
1.2.1 Cell Surface Proteins
Cell surface components are often implicated in bacterial adherence to host cells, a 
number of which have been designated microbial surface components recognising 
adhesive matrix molecules or MSCRAMM. Fibronectin-binding protein A (FnBPA), 
collagen-binding protein and fibrinogen clumping factor A are only a few of such proteins 
that mediate adherence to plasma clots and collagenous tissues, and are important for 
colonisation and infection. Other non-MSCRAMM surface proteins are involved in the
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evasion of cell recognition and phagocytosis by the host immune system, for example 
coagulase and protein A, as is the expression of polysaccharide capsules.
1.2.1.1 Clumping Factor and Coagulase
Currently, staphylococci are classified as either coagulase-negative or coagulase-positive 
depending upon their ability to coagulate fibrin at their surface. The majority of 
pathogenic staphylococci readily produce coagulase, alSkDa heat-labile protein, although 
coagulase-negative staphylococci (CNS) have been isolated from infections particularly in 
infants and immunocompromised individuals.
There are two types of coagulase: surface bound (clumping factor) and free coagulase. 
Free coagulase is a fibrin-clotting enzyme that binds to prothrombin (68kda) in plasma to 
fomi staphylothi'ombin (89kda). Staphylothi'ombin mimics thrombin, stimulating plasma 
clotting of fibrinogen to insoluble fibrin, a form more resistant to the action of fibrinolysin 
than a normal fibrin clot. Fibrin is deposited around the surface of bacterial cells thus 
protecting them from phagocytic attack. In contrast, staphylococcal clumping factor does 
not form true plasma clots, but acts directly upon fibrinogen to induce cell clumping. 
Cells in the centre of the clump are provided with a degree of protection from 
phagocytosis. The role of free coagulase or clumping factor in virulence has not been 
concluded due to contradicting data. Strains of coagulase-negative staphylococci (CNS) 
are known to be less virulent than coagulase-positive strains however mutations within the 
coagulase gene do not alter virulence. Both forms of coagulase are not always expressed; 
some strains are known to produce one or the other.
1.2.1.2 Protein A
Greater than 90% of coagulase positive S. aureus strains express protein A as a cell wall 
component, comprising up to approximately 7% of the total cell wall, although expression 
is v a r i a b l e . I n  strains of MRSA as many as 50% do not express cell bound protein A, 
but secrete it extracellularly, as do some strains of
The gene encoding protein A, spa, generates a protein with a molecular weight of 42kDa 
although size heterogeneity exists among serologically distinct s t r a i n s . T h e  gene 
comprises three distinct regions: the Fc portion, X region containing vaiying numbers of
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highly polymorphic 24bp repeats differing in number and sequence between strains, and a 
C - t e r m i n u s . T h e  development o f typing techniques using the polymorphic X-region for 
MRSA typing in outbreak situations has provided promising results,^^^’^ ^^  although its use 
in discriminating between epidemic and sporadic strains of MRSA has provided variable 
r e s u l t s / S t r u c t u r a l  determinants of the Fc portion promote binding to host 
immunoglobulins (Ig) to form protein A-Ig complexes through binding to discontinuous 
epitopes within the Fc region of human IgG antibodies, reactions with heavy chain variable 
regions of VhIII antibodies, or through protein A-specific antibody.
Negatively regulated by the regulatory locus agr (section 1.3), optimal expression occurs 
during late logarithmic phase and decreases during the stationary phase. The absence of 
protein A on dividing cell septum during cell division indicates late incorporation into the 
outer cell wall.^^  ^ Characteristically, cell bound and extracellular protein A are very 
similar and it has been suggested that they are synthesised from the same niRNA template. 
The incorporation of protein A into the cell wall occurs in one of two ways: linked to 
cytoplasmic or membrane bound peptidoglycan monomers which are then transported 
through the cell membrane and inserted into the pre-existing peptidoglycan network; or are 
transported through the membrane as a single molecule then linked into growing 
peptidoglycan chains or an already completed chain via covalent bonds. Free protein A is 
the proportion of protein not incorporated into the cell wall. '^^^
The expression of protein A in either form confers antiphagocytic properties on bacterial 
cells through the formation of protein A-IgG complexes in competition with host 
phagocytic cells. Bacterial cell surface complement activation in the absence of IgG and 
C3b fixation is a crucial requirement for rapid phagocytic ingestion (section 1.7).^^  ^
Protein A-IgG complex formation reduces IgG-mediated opsonisation of cells via the 
activation of both the alternative and classical complement p a t h w a y s . E n h a n c e d  
phagocytosis of protein A deficient strains, such as S. aureus Wood 46 compared to rich 
strains in normal serum gives evidence to this, as is the relationship between the degree of 
protein expression and resistance to p h a g o c y t o s i s . D o s s e t t  et al (1969)^° and Spika et 
al (1981)^^^ have suggested that the expression of protein A may function to mask 
alternative complement-activating sites or prevent the attachment of specific opsonins 
through non-specific reactions with IgG, as isolated protein A will inhibit phagocytosis of 
S.aureus and E.coli.
The precise role of protein A as a virulence factor is highly debated as experimental results 
vary depending on the animal model used. No toxin or enzymatic activity has been 
associated with protein A/"^  ^ however spa mutants have been found to be less virulent in 
mouse models of peritonitis and skin abscesses, mortality rate is reduced and skin lesions 
from subcutaneous injection are significantly smaller. Contrary to this it does not appear 
to be a major virulence factor in the staphylococcal keratitis rabbit m o d e l . A  report by 
Jung et a l (2001) suggested the ability of protein A to bind cytoskeletal (3-actin in 
epithelial cells. These authors proposed that protein A might facilitate the adherence 
and invasion of S. aureus in oral epithelial cells through the polymerisation of actin 
filaments, however the presence of the appropriate receptors on epithelial cells and 
S. aureus has not been proven. It has also been considered as the cause of hypersensitivity 
reactions, inflammation and tissue damage through complexes with
immunoglobulins. ’  ^ ^
1.2.1.3 Polysaccharide Capsule
It has been predicted that approximately 90% of S. aureus strains produce a polysaccharide 
capsule (CP) of some kind attached to the exterior of the cell wall.^^^ Several capsule 
polysaccharides (CP) have been identified belonging to strains of S. aureus where type CP5 
or CP8 occurs in >80% of clinical isolates.^^^
Reports from Dassy et al (1993)^^ and Luong et al (2002)^^^ show that CP5 and CP8 
production is positively regulated by agr and reduced in agr mutant strains, as well as 
being influenced by enviromnental conditions such as iron limitation, alkaline conditions, 
CO2, and anaerobiosis.^^’^ ^^  Promoter regions upstream of CP5 and CP8 share almost 
identical sequence homology resulting in similar regulation mechanisms. Agr is the 
predominant regulator here, although SarA (section 1.3) does exert minor control at the 
transcription level, but SarA also plays a role at the post-translation level affecting CP8 
integrity.
Expression of CP8 during the stationary phase along with the exotoxins, suggests a role in 
infection, however contradictory reports exist.^^^ Mutation studies with CP5" strains have 
indicated no loss of virulence compared to the parental strain while CPS'*" or CP8^ strains 
did not confer resistance to opsonophagocytic killing by human PMNL.^’^ ^^  Several
authors, however, have reported that CP5 and CP 8 are indeed antiphagocytic by interfering 
with opsonisation via the classical and alternative complement pathways and enhanced 
virulence.’ Nilsson et a l (1997)^^'’ and Thakker et a i (1998)^^^ also reported 
that CP5’’' strains caused a higher incidence of arthritis and bacteraemia than non­
producers. Bacterial strains grown on solid media have been reported to produce >100 
fold more CP5 and CP8 than broth grown cells.^’’^ ’^ ^^  This may account for the conflicting 
data as Albus and Baddour used broth cultures whereas Nilsson and Thakker both used 
agar cultures.
Extracellular polysaccharide material loosely associated with the bacterial cell, slime, 
plays an important role in the adhesion of cells to biologically inert surfaces e.g. plastics 
and animal cells that are also largely polysaccharide, and bone.^^^’^ ’^’ Coagulase negative 
staphylococci, a common cause of catheter related infections, once adhered to a surface 
may use the slime layers to establish finner adhesion initiating the formation of 
microcolonies and eventually biofilms, thus providing increased access to organic nutrients 
and a protective barrier from antibacterial agents.
1.2.2 E x trace llu la r Toxins
Extracellular toxins are a heterogeneous group of proteins of which there are two principal 
groups: enzymes such as proteases and nucleases; and toxins including exfoliative toxins, 
enterotoxin, PV-leucocidin (PVL), and toxic shock syndrome toxin (TSST-1). The 
necessity to produce these products is probably driven by the need to extract nutrients from 
available resources for bacterial growth and survival, an effect of which is the 
establishment of a diseased state within a host environment. Only the toxins produced by 
S. aureus are discussed here.
1.2.2.1 Haemolysins
Four staphylococcal haemolysins have been described to date, alpha (a), beta ((3), delta 
(5), and gamma (y)-haemolysin. All four haemolysins are positively regulated by the agr 
locus therefore expression is growth phase dependent, with maximal expression during late 
logarithmic phase to early stationary p h a s e . A l p h a - h a e m o l y s i n  transcription is
somewhat more complex and is believed to be influenced by at least two additional 
regulatory systems as well as osmotic regulation and catabolite repression (section
2 3 ^ 54 ,58,265,348
Alpha-haemolysin; Of the haemolysins a-haemolysin (34kDa), encoded by the 
chromosomal hla gene, is the most dominant being produced by 95% of S.aureus strains 
forming 33% of the total bacterial protein expressed/’’"^’ Primarily coagulase-positive 
strains tend to be a-haemolysin positive, whereas coagulase-negative strains are negative 
for the a-haemolysin gene/^'^"’ First sequenced in 1984 by Gray and Kehoe,’"” a- 
haemolysin exerts cytolytic, haemolytic, necrotic and lethal effects on numerous cells 
particularly those with membranes rich in phosphatidylcholine and sphingomyelin, 
including epithelial cells and cells of the immune system/^'^^'^^ Lateral aggregation of 
toxin monomers into heptonieric structures within target membranes results in pore 
formation (l-2mn diameter) allowing the rapid efflux of potassium and influx of sodium 
and calcium. Ion imbalance consequently causes swelling and rupture of cells as well as 
indirectly stimulating cytokine release and apoptosis.^’’’^ '^^ '’^  The specificity of the toxin 
for membranes comprised of phosphatidylcholine and sphingomyelin can be linked to a 
number of clinical features observed in a host including vascoconstriction, increased 
vascular permeability, and pulmonary oedema.
In vitro, rabbit erythrocytes are 100 fold more sensitive to a-haemolysin than those from 
sheep and hunians,^^’^  ^whereas P- and 5-haemolysins preferentially lyse sheep and human 
erythrocytes r e s p e c t i v e l y . T h i s  demonstrates the special attention required in 
choosing an appropriate animal model for studying a-haemolysin. The relevance of a- 
haemolysin in human disease has been questioned due to its poor activity against human 
erythrocytes. However, human platelets and monocytes are more susceptible than 
erythrocytes to a-toxin activity and may provide the primary target in vivo. ’ ' For 
example, high toxin levels of 10-50 haemolytic units (HU) consume components C3 of the 
classical complement pathway reducing their opsonic activity whilst low doses potentiate 
phagocytic and bactericidal activities of human Animal models of
S.aureus keratitis in rabbits, murine sepsis and murine septic arthritis have all shown toxin 
related cell damage, while mutagenesis studies with hla' mutant strains display reduced 
virulence compared to the parental strains following intraperitoneal or intravenous 
inoculation.'^^’'’*"’^ ^^ ’^ '^^  Evidence that the regulation of hla expression is not a simple one
has been demonstrated by Goerke et al (2001) in a guinea pig model of device-related 
infection.’^ *" Here, hla transcription was induced independently of agr and sarA but was 
dependent upon sae regulation (section 1.3). In vitro, hla expression is dependent upon 
the activity of all three regulatory systems. Despite the evidence of alpha haemolysins 
biological activity in a variety of animal models, its common occurrence within the 
staphylococcal genome and complex regulation, the perceived role of a-haemolysin as a 
major virulence factor in disease pathogenesis remains ambiguous.
Beta-haemolysin ((3) is an Mg^^-dependent sphingomyelinase C (“hot-cold” haemolysin), 
expressed by 11% of staphylococcal strains, predominantly bovine strains, although it has 
been isolated in h u m a n s . A c t i v i t y  is through the degradation of sphingomyelin in the 
outer phospholipid layer of erythrocyte membranes, particularly those of sheep due to their 
high sphingomyelin content.^^^ Haemolytic action of p-haemolysin does not actually 
involve cell lysis, but sensitises cells to the action of other agents.^^^ Selected strains of 
glycopeptide intermediate S.aureus (GISA) and a g f  strains have been shown only to 
express (3-haemolysin.^^’’
Delta-haemolysin (5) is a 26 amino acid peptide secreted as part of the RNAIII transcript 
during agr activation fonning cationic-selective channels in phospholipid bilayers, in 
particular those of human erythrocytes/^^ The toxin has also been identified as a putative 
contributor to TSS pathogenesis. Lyon et al. (2000) have shown that strains of GISA do 
not express ô-haemolysin due to a loss of agr function or truncated AgrA (section 1.3).^ ®’’
Gamma haemolysin (y) differs from the other three haemolysins in that it is secreted as 
two individual proteins tenned ‘S’ and ‘F’ for slow and fast eluting proteins. The luk locus 
encodes these components on two transcription units with the first encoding a single open 
reading frame (ORF) and the second encoding two ORFs. Two forms of the ‘S’ 
component exist, HlgC and HlgA, whilst there is only one form of the ‘F’ component, 
HlgB, giving the potential formation of two toxin combinations.^^ Preferential binding to 
membranes containing phosphatidylinositol results in activity against mammalian 
erythrocytes, neutrophils and macrophages. Detection of y-toxin is possible in 99% of 
S.aureus strains and is predominant in the culture supernatants of TSS isolates.^^’^ ^^
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Most suscefitible M oie  o f Aothm
:
a-haemolysin Rabbit Phosphatidylcholine and
sphingomyelin
membranes
Pore formation
P-haemolysin Sheep Sphingomyelin
membranes
Degrades sphingomyelin
ô-haemolysin Human, Horse Phospholipid bilayers Cationic channel 
formation
y-haemolysin Rabbit Phosphatidylinositol
membranes
Granule secretion and the 
release of inflammatory 
mediators by leukocytes
Table 3. Haemolysin activity
Panton-Valentine Leukocidin (PVL)
PV-leukocidin is a phage (<j)SLT) encoded toxin similar to y-haemolysin but is only 
expressed in approximately 2% of S.aureus strains/^’^ ^^  As with y-haemolysin PVL is a 
two-component toxin. PVL components lukS-PV and lukF-PV, when expressed together 
with y-haemolysin, are capable o f forming up to six different combinations of toxin with 
HlgA, HlgB and HlgC.^^  ^ Individually, these components are relatively inactive and, 
depending upon the combination of ‘S’ and ‘F’ components, elicit varying levels of 
activity against variable targets; LukS-PV + LukF-PV, LukS-PV + HlgB > HlgC +LukF- 
PV, HlgC + HlgB > HlgA + LukF-PV, HlgA + HlgB exert activity towards PMNL, 
monocytes and macrophages of rabbits and human; hIgA + hlgB also display activity 
towards human Teel Is and erythrocytes; HlgA + LukF-PV has no erythrocyte
activity 103, 199,284
Pathogenesis of PVL and y-haemolysin involves the sequential, irreversible, binding of the 
‘S’ component followed by the ‘F’ component to target membranes resulting in the
formation of hexameric pores. 74,235 The activation of calcium channels and increased
permeability to monovalent cations leads to leukocyte destruction by granule secretion, the 
release of inflammatory mediators, and tissue necrosis as evidenced in cases of 
furunuculosis, impetigo, cellulitis and cutaneous absesses.^'’’’'^ '^^ ’^ ’^ ^^  In in vivo studies,
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intradermal administration of PVL elicits a severe inflammatory lesion, PMN infiltration 
and skin necrosis in rabbits/^^’^ ’^
In France, a study of community acquired MRSA (CA-MRSA) revealed a prevalence of 
PVL in 100% of community-acquired MRSA with a total of 2% of all clinical isolates 
being PVL-producing strains/^ Susceptibility to PVL"^  strains appears not to be in 
immunocompromised individuals but in young healthy individuals who present no obvious 
risk factors for the acquisition of MRSA. Infections appear to be secondary to an 
influenza-like illness that rapidly develops into severe pneumonia and leucopenia.’^  ^ PVL 
has also been isolated from strains associated with antibiotic-associated diarrhoea 
(AAD).'^’
1.2.2.2 Superantigens
Around 40% of S.aureus isolates and 6% of CNS isolates from healthy carriers and clinical 
infection are capable of expressing one or more superantigen, while most healthy adults 
will have antibody titres to common superantigens, probably following exposure to 
concentrations that are not associated with clinical effects.^’” ’^^ '’^
O f the staphylococcal toxins, enterotoxins A tlirough E, and H, exfoliative toxins A and B, 
and toxic shock syndrome toxin (TSST-1) are all classed as superantigens (SAg) along 
with the streptococcal pyrogenic exotoxins (SPE) A, B, and C.’^  The SAgs are a class of 
small non-glycosylated polypeptides that share 22-80% amino acid sequence identity, with 
TSST-1 being the most d i v e r g e n t . T h e  biological properties that set them aside from 
other staphylococcal toxins are outlined in Table 4. Genetically, the toxin genes are 
plasmid, bacteriophage or pathogenicity island borne and are regulated by the agr and 
staphylococcal accessory regulatory {sar) systems (section 1.3).
12
Pathogenicity
Enhancement of susceptibility to endotoxin shock (up to 100,000 fold)
Non-specific T-lymphocyte mitogenicity
B-lymphocyte suppression
Erythrophagocytosis
Tumour Necrosis Factor (TNF) and Interlukin-1 (IL-1) release from macrophages
Table 4. Biological properties of superantigens
The presence of foreign bodies within the host are recognised by cells of the immune 
system, ingested by antigen presenting cells (APC) and presented to T-lymphocytes as 
major histocompatibility complex (MHC) class II peptide products (section 1.6). Specific 
binding between Tcell receptors (TCR) and the processed antigen triggers Tceli 
proliferation and release of cytokines initiating an immune response. Superantigens differ 
in their mode of Tcell activation in that they do not require processing by APCs.
A superantigenic toxin will non-specifically bind directly with MHC class II molecules 
bridging the gap between it and particular vP TCRs blocking antigen-specific Tcell 
recognition (Figure 1).^  ^ This high frequency binding stimulates the proliferation of 
CD4^CD8‘ Theipe/delayed type hypersensitivity T cells, and CD8^CD4' Tcytotoxic/suppressor 
T cells and release excess quantities of cytokines such as, interleukin-1 (11-1), Interferon 
gamma (IFN-y) and tumour necrosis factor (TNF), the causative agents of hypotension and 
shock through an overwhelming inflammatory r e s p o n s e . F e v e r  has been attributed 
directly to the stimulation of the hypothalamus fever response control centre, or indirectly 
by the release of 11-1 and TNF from monocytes and macrophages. An interesting response 
to superantigen exposure is the failure of the majority of patients to develop neutralising 
antibodies upon recovery. Other characterised effects of superantigen release include the 
inhibition of immunoglobulin (Ig) secretion through the induction of a non-specific T- 
suppressor factor, and the enhancement of host susceptibility to endotoxin such as the
Gram-negative lipopolysaccharide (EPS). 16
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Figure 1. Model for the MHC class II-Tcell receptor interactions with (A) conventional antigen, (B) 
superantigen. (A) A processed antigen presented by MHC class II attracting specific Tcell with antigen specific 
Tcell receptor (TCR) variable (v(3) domain. (B) A superantigen binding directly to the outside of the MHC 
molecule cross-linking it to the v^-chain. Initiating non-specific cell activation.
1.2.2.2.1 Toxic Shock Syndrome Toxin 1 (TSST-1)
TSST-1 is symptomatically related to the staphylococcal enterotoxin group, but shares 
little sequence homology with staphylococcal enterotoxins or streptococcal pyrogenic 
enterotoxins/^ The protein is also the only SAg capable of passing through mucosal 
membranes in an intact form.*''*
The synthesis and secretion of the low molecular weight polypeptide occurs primarily 
during late logarithmic phase via positive regulation by the agr locus, not as a result of cell
lysis. 197,302
(1983)^ *** and has been located to pathogenicity island-1 (SaPIl) by Lindsay et al.
The chromosomally encoded TSST-1 gene {tst) was cloned by Kreiswirth et al.
(1998).^*^ As yet, tst has never been detected in strains of CNS, but has been detected in a
bovine strain of S.aureus on pathogenicity island SaPIbov. 105
Bergdoll et al. (1981)^* and Schlievert et al. (1981)^^* first identified T S S T -1 ,in itia lly  
named staphylococcal enterotoxin F (SEP) and pyrogenic exotoxin C respectively, as being 
associated with cases of menstrual toxic shock syndrome (TSS). Today, TSST-1 is 
associated with 100% of menstrual cases and 50% of non-menstrual cases such as post- 
surgical wound infection, and staphylococcal scalded skin syndrome (SSSS)-like illness
especially in AIDS patients. 87.301 Reports have also indicated a putative role in sudden
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infant death syndrome (SIDS) cases along with SEA, B, and C, and Kawasaki syndrome, 
an acute febrile disease of children under 5 years of age where symptoms resemble TSS, 
but the presence of TSST-f^ strains has not been conclusive.^ *.372,378
In addition to agr regulation, TSST-1 transcription is subject to temperature regulation 
with toxin levels detectable at 37^C to 40°C, but not at 30^C. The possible role of a 
temperature regulated transport mechanism such as an activating factor for example, a 
protease required for toxin modification that is activated at 37"C but not at 30”C, or a 
repressor has been suggested/^^ Low glucose concentrations, magnesium ions, and 
elevated concentrations of oxygen and carbon dioxide are also required for optimal 
expression/**’^ ^^ ’^ ^^  All these conditions are established in the vagina, and are associated 
with tampon usage. TSST-1 is also a negative regulator of exoprotein gene transcription, 
repressing most other exoproteins whilst positively regulating its own transcription.^^*"
Enterotoxin B has similar properties. 356
Numerous authors have attempted to recreate the pathogenesis of TSS in animal models, 
but the contribution of other factors released as a consequence of TSST-1 
superantigenicity hinders the recreation of a true TSS model. Strains of TSST-f*" MS SA 
and MRSA do not exert lethal effects in a murine sepsis model and TSST-1 has been 
reported to be a poor immunogen in r a b b i t s . H o w e v e r ,  the toxin causes reactivation 
of cell wall induced arthritis, induces systemic symptoms of food poisoning in rabbits, and 
produces in mice many clinical features o f TSS except for the rash and desquamation.^**^
1.2.2.2.2 Enterotoxins
There are currently eleven staphylococcal enterotoxins (SEA through SEK) that have been 
associated with human food poisoning however, enterotoxins SEL through SEO have 
recently been identified but further investigations into their biological activity are required. 
To date, all enterotoxins possess emetic properties and are the only SAg with this 
activity.*^ Enterotoxin genes have been detected on the bacterial chromosome, on 
plasmids and on bacteriophage. Transcription is generally independent and not regulated 
by a polycistronic transcript.
Within the enterotoxins, SEA, SED, SEE, SEG, SHE and SEJ share 53-83% sequence 
homology, and SEB, SEC] and streptococcal pyrogenic exotoxin A (SPEA) share 42-67%
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h o m o l o g y D e s p i t e  the relatedness between each enterotoxin, antibodies to one 
enterotoxin do not necessarily confer immunity to food poisoning or to the other 
enterotoxins/^’*^  The more recently described enterotoxins I, K and L differ structurally 
from SEA-E by their lack of a cysteine loop, a region thought to be important for emetic
activity. 247,270 SHE and SET are the most divergent of the enterotoxins. Homology to the
SEA-E group and the SEB-C group have both been described with significant regions of 
homology across the groups thus making it difficult to assign SHE and SET to a particular
g ro u p . He r e ,  they have been linked to the SEA-E subclass (Figure 2).
SEL SaPI3and4 ----
SEK SaPIl ----
SEI Unknown ——
SEH bacteriophage
SED plasmid ......................
SEJ plasmid
SEA  bacteriophage or cliromosomal 
SEE bacteriophage _ _ _ _ _  
SEG unknown 1998
SEB chromosomal or plasmid 
SEC chromosomal
Figure 2. Phylogenic tree showing the relatedness of staphylococcal enterotoxins. Three groups are 
recognisable. Adapted from Orwin et a l (2001)/™ Alouf et al. (1991)/^ and Novick et al. (2001)^ *^ ^
To date, SEA and SED, and to a lesser extent SEB and SEC, are responsible for the 
majority of food poisoning c a s e s . O v e r  the years there has been a gradual shift in the 
carriage of enterotoxins in strains of MRSA. During the 1960’s, the majority of strains 
produced SEB whereas the primary enterotoxin produced by MRSA is highly dependent 
upon country and strain. In Scotland, 70% of MRSA carry SEC and are classified as 
EMRSA-15 whereas strains of EMRSA-16 are primarily carriers of SEA (Dr D. Morrison, 
MRSA Reference Laboratory^ 2002; personal communication). The production of SEA, 
SEB or both in strains o f septicaemic MRSA infections also indicates a putative role for 
enterotoxins in pathogenesis, as does the isolation of SEB, SEC, SEG and SEI in cases of 
menstrual and non-menstrual TSS and SSS.*^*’**^  Recombinant SEK has been shown to
demonstrate lethality in the rabbit model of TSS.
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In 2000 a novel family of at least five enterotoxin-like genes {set 1-set5) was identified 
encoding staphylococcal enterotoxin-like proteins or SET proteins/^*" Four of the set 
genes encode proteins of 227-234 amino acids with 38-53% homology to other known 
enterotoxins and TSST-1. So far SET-1 has been identified in numerous strains of 
S.aureus, but not from S.epidermidis. Activities of recombinant SETl (rSETl) on PMNL 
cells results in cell stimulation and a 10-fold greater production of 11-6 and II-ip compared 
to that produced by SEB at higher concentrations thus suggesting an important role of 
SET-1 in pathogenicity.^*"*" Further studies into the extent of set gene expression amongst 
S.aureus and their putative role as virulence factors are required.
1.2.2.2.3 Exfoliative Toxins
Exfoliative toxins ETA and ETB are chromosomally and plasmid encoded proteins 
respectively, with superantigenic properties.^**^’^'***’^*"*" Production of these toxins by 
bacterial strains present on the skin surface results in the onset of diseases such as 
staphylococcal scalded skin syndrome (SSSS) or Ritter’s disease, primarily in infants and 
c h i l d r e n . T o x i n  expression by S.aureus on the skin causes the formation of skin lesions 
that spread through the destruction of the skin’s intercellular connections separating the 
layers within the epidennis, thus fonning a rash and bullous impetigo. Exfoliative
toxin A was isolated by Kapral and Miller**'* and, Arbuthnott*^ et al. in 1971 followed by 
the characterisation of ETB by Kondo et al. in 1974.*^  ^ Both toxins display 40%-50% 
sequence homology to each other^ ***’^ '^* and 25% identity to staphylococcal V8 protease 
indicating serine protease activity, although conclusive evidence is lacking. **’^ '*^  There is 
also evidence to support activity against melanocyte stimulating hormones (MSH) present 
in the epidennis, a possible target in cases of SSS.^ *** Murine studies indicate that toxin 
susceptibility ceases in mice >7 days old due to efficient clearing of the toxin in serum. 
Insufficient removal of toxins occurs in immunocompromised individuals who are more at 
risk of succumbing to SSSS suggesting a threshold level of toxin is required for skin 
exfoliation.^**
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1.3 Regulation of Virulence
The three phases of bacterial growth, lag phase, exponential phase, and post-exponential or 
stationary phase, are very different with respect to their metabolic requirements. During 
the exponential phase cell metabolism is at its most efficient with its regulation systems 
coordinated to provide constant growth and to maintain cell composition. Upon entering 
the post exponential phase energy is directed more towards long-term survival. Due to this 
enzymes used for the exploitation of enviromnental nutrients are no longer required. They 
become an unnecessary burden and are no longer synthesized in response to restructuring 
of the celTs regulatory systems. It is as a result of this restructuring that pathogenic strains 
of bacteria produce phase dependent virulence factors. In S.aureus surface proteins such 
as protein A, coagulase and fibronectin binding proteins (Fnbp), products of the 
exponential phase, are repressed during the post exponential phase making way for the 
expression of extracellular proteins such as toxins and haemolysins.^**^’^ *^  Similar 
regulatory system reorganization is observed in other bacterial species; Bacillus subtilis 
induces exoprotein synthesis, competence and sporulation in response to nutrient 
deprivation*^^ and the ArcA and FNR systems of E.coli respond to changes in
osmolarity. 328
Characteristically, regulation systems are two component signal-transducing systems with 
a common mechanism of action and shared essential protein sequences. In many cases 
transmembrane histidine kinase signal receptor proteins detect environmental signals 
although some are cytoplasmic and respond to intracellular signals. Activated signal 
receptors undergo allosteric modification activating latent histidine phosphokinase (HPK) 
activity. This triggers an autophosphorylation cascade that ultimately results in the 
phosphorylation of a cytoplasmic response regulator activating it to trigger repression or 
stimulation of target gene transcription.
The ability of S.aureus to produce a multitude of virulence factors is attributed to the 
coordinated activation and regulation of a set of genes contained within the chromosomal 
polycistronic accessory gene regulator {agr) l o c u s . S p e c i e s  of coagulase negative 
staphylococci including S.epidermidis, S.warneri and S.simulans have also been shown to 
carry similar regions of the agr operon of S.aureus.'^'^’^ ^^ ’^ '^  ^ The agr locus, cloned and 
sequenced by Peng et al. (1988), is composed of 2 divergent transcripts RNAII (P2) and
18
RNAIII (P3) transcribed in opposite directions/^^’ A weaker third promoter, PI, lies 5’ 
to P2 and is transcribed constitutively throughout the growth cycle, but as yet, has an 
unknown role/^* In 1986, Recsei et al. demonstrated that the majority o f agr regulated 
exoproteins were weakly synthesized or absent in agr negative mutants, but expression of 
surface protein was increased, indicating a strong correlation between agr regulation and 
the post-exponential p h a s e I t  has also been recognized that agr mutants are less virulent 
in animal models compared to agr wild type strains/’
Figure 3 illustrates a map o f the agr locus and its transcripts. Promoter two and P3 initiate 
transcripts in opposite directions giving rise to a 3.5kb transcript (RNAII) and 0.5kb 
transcript (RNAIII) respectively. RNAII is comprised of 4 unlinked open reading frames 
(ORFs) agrA, agrB, agrC and agrD whilst RNAIII encodes delta (ô)-haemolysin.’^ ’^^ *^*
RNAI < -
RNAII
PI
< ------------------ --------------------------
^ agrA agrDj agr B
P2
RNAIII
P3
hid
Figure 3. S.aureus agr regulatory’ locus. Adapted from Novick et al { \ 995)^
Each of the ORFs encoded on the RNAII transcript are essential for optimal activation of 
the RNAIII promoter.^^** Early data reviewed by Komblum et al. (1990) identified agrB as 
encoding a histidine phosphokinase sensor protein, however this has since been revised.*^** 
It is now accepted that products of agr A and agrC which display homology to components 
o f a classical quorum sensing 2-component signalling pathway encode a response regulator 
and a histidine phosphokinase sensor protein respectively.^^** AgrB and agrD function to 
generate a relatively hydrophobic IkDa autoinducing octapeptide (AIP) with quorum 
sensing p r o p e r t i e s . T h e  gene agrD encodes a putative precursor peptide, AgrD, thought 
to be processed through an unusual intramolecular thioester modification linking the thiol 
group of a central cysteine residue to the C-terminus carboxyl group, and secreted by AgrB, 
an integral membrane protein.^^^’^ *^
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AU stains of S.aureus do not produce the same AJP. Several structures of AIP have been 
identified enabling strains to be grouped by the peptide they produce. As a specific group 
they will activate the agr locus of strains within the same group, but inhibit that of strains 
from other groups and staphylococcal species, for example S.epidermidis.^^^’^ ^^  Despite 
this S.aureus is more sensitive to inhibition from those produced by S.epidermidis than 
vice versa^^^'^'^^ The ability to produce variable AIPs is a result of sequence variability in 
agrB, agrD and agrC thus determining the specificity of the processing reaction, the 
propeptide, and the receptor-ligand reaction.*^* The only conserved region of the AIP is a 
central cysteine residue five residues from the C-terminus linked by an essential thiolester 
bond.^^* Activation of agr is sensitive to the amino acid sequence and stereochemical 
nature of a particular AIP, and it has been proposed that inactivation occurs when a 
different class of peptide binds to AgrC in an alternate orientation blocking binding 
sites.
Polymorphism within the hypervariable region of agrC~agrD~agrB alters the genetic 
sequence of ATP and the response regulator AgrC allowing the classification of strains into 
one of four agr groups. Within each group the genetic sequence of the hypervariable 
region is highly conserved permitting the activation of the agr locus in strains belonging to 
the same agr group but inhibiting the activation of strains from the other groups without 
affecting growth. Interstrain activation or inhibition takes place at the AgrC level. 
Two closely related agr groups are group I and group IV, differing only in the sequence of 
P3 as observed by a weak activation of group I strains by group IV culture supernatants.*^^
Jarraud ei al. (2002) suggested that agr groups could be associated with specific genetic 
backgrounds and that particular agr types were associated with certain diseases.*^* The 
system is not 100% accurate but it is generally agreed that CA-MRSA PVL^ strains 
and tst^ strains belong to agr group III, ET-producing and CA-MRSA mecA' PVL’*' strains 
are group IV (some strains also belong to groups I and II), strains resulting in enterotoxin 
mediated diseases belong to groups I or II, and that agr group II strains are more frequently 
associated with disease in hospitals, including strains of glycopeptide resistant S.aureus 
(GISA).^^’*^ ’^****’^ '**’***** Contradicting reports which support and rebut the latter statement 
were made by Sakoulas et al. (2002)***** who classified all GISA strains as being agr group 
II, and van Leeuwen et al. (2000)*^ *^  who reported that only 6% of MS SA and 5% of 
MRSA clinical isolates belonged to agr groups II and III respectively. No MS SA have 
been isolated that can be classified as agr group IV.^ '**
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Low-level quantities of RNAII transcript are detectable during the exponential phase 
ensuring the presence of low levels of AgrA and AgrC that would be available to respond 
to an external signal along with low levels of AIP. During exponential growth AIP levels 
are increased, ultimately reaching a threshold concentration that triggers RNAII and 
RNAIII transcription. Once activated both promoters become stimulated thus initiating 
auto catalytic activation of RNAII that in turn rapidly increases the level of RNAIII 
transcription and hence increases exoprotein synthesis whilst depressing surface protein 
expression. RNAIII, an antisense RNA effector molecule, is responsible for
regulated transcription of target exoprotein genes and in some cases translation. 
Deletion within RNAIII results in an agr phenotype and the loss of delayed translation of 
ô-haemolysin. RNAIII has also been found to independently regulate translation of a- 
haemolysin tlirough direct mRNA binding. '^*'* It has been elucidated that in the absence of 
a fully functional RNAIII a-haemolysin translation is impaired adopting an untranslatable 
configuration. '^*'*’^ *^  In addition, Janzon and Arvidson (1990) have suggested that the ô- 
haemolysin transcript, when transcribed as part of the RNAIII transcript, plays a role in 
positive and negative regulation of exoprotein synthesis, but its mode of action is still 
under investigation (Figure 4).*^ ** Loss of agr function can arise as a result of a number of 
factors including; point mutation, loss of gene function required for agr expression, agr 
suppression via mutation within promoter regions or a disruption of quorum sensing 
pathways.***** The serial passage of strains of S.aureus has been shown to induce mutations 
within the agrC gene or agrC-agrA region.*^* Some strains of GISA have been identified 
with mutations within agrB but demonstrate no obvious loss of agr and only reduced hid 
function whereas VISA 5836 from the United States has a nonsense mutation in agrA and 
is devoid of agr function.*****
An early study by Wesson et al. (1988) hypothesised that in an enviromnent where low 
levels of AIP are present, cell surface proteins are optimally expressed promoting adhesion 
to host endothelial cells and ingestion. *^  ^ Enclosed within an endosomal membrane AIP 
concentrations may increase due to cell density triggering expression of agr-regulated 
exoproteins that in turn may aid release from the endosome by inducing host cell 
apoptosis.*®^ Quzi et al. (2001) confirmed this hypothesis using green fluorescent protein 
(GFP) and luciferase (lux) reporter c a s s e t t e s . T h e s e  authors reported that the agr P3 
promoter was induced within lOOmins of internalisation releasing replication competent 
cells into the host cell cytoplasm. Similar observations were made by Bay les et al. (1998)
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with bovine epithelial cells therefore it would appear that the agr locus contributes to 
endosomal lysis by ingested bacteria/^ Similarly, the high levels of RNAII and RNAIII 
expression have been reported within vegetations in an experimental endocarditis model 
implicating a role for agr in in vivo invasiveness. Differences in the levels of expression 
were variable depending upon the target tissue, thus suggesting that host factors may play a 
role in gene expression.
In summary, the pattern of gene regulation observed by the agr system is thought to mimic 
that displayed during pathogenic invasion of host cells. Initial infection is characterised by 
adhesion and colonization through cell surface proteins. As a result of cell division, cell 
density increases activating toxin production, some of which degrade surrounding tissues 
allowing for release and spread of infection.
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Figure 4. Agr locus regulation. Adapted from Komblum et al (1990)’’  ^and Cheung et al (1997f
In addition to agr there is a second major regulatory system that, in conjunction with agr, 
forms a complex growth phase-dependent regulatory system. In 1992, Cheung et al.
identified a new putative global regulatory locus through transposon insertion studies. 58
This new staphylococcal accessory regulator {sar), now termed the sarA locus,^^ when
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interrupted by mutation was found to increase a-haemolysin, lipase and serine protease 
production whilst decreasing p- and Ô-haemolysin levels and cell wall proteins with the 
exception o f cell bound protein SarA is required for optimal expression of agr
RNAIII levels and gene activation/**’^ ’^^ *’^ ^
The 1.2kb sarA locus is comprised o f three overlapping transcripts, sarA (0.56kb), sarB 
(0.8kb) and sarC (1.2kb) each with its own promoter, PI, P2, and P3 respectively, but all 
transcripts include the SarA ORF (Figure 5)/^
sarB (P2 transcript)
sarC (P3 transcript)
sarA (PI transcript) 
►
ORF3ORF4
Figure 5. sarA locus promoters and transcripts. Adapted from Bayer et al (IÇÇô)^ *"
Each transcript is not uniformly expressed throughout the growth cycle; sarA and sarB are 
optimally produced during the exponential phase whereas sarC is optimal during the post­
exponential phase/^ Complete transcription of the sarB transcript; a putative 39-amino 
acid (ORF3) and a putative 18-amino acid (0RF4) is essential for the optimum expression 
o f the DNA binding protein SarA, a protein specific for agr P2 and P3 thereby optimising 
expression of RNAII and RNAIII.^ '^*" ’^*^  ^ Of the three promoters PI is the strongest 
promoter and along with P2 is sigma A (cr'^)-dependent. Promoter P3 is a**-dependent but 
contradicting evidence exists to the role o f ct** in the activation of the sarA locus.^^ **'^ ^^  
However, up-regulation o f SarA expression, a-toxin, coagulase and clumping factor 
transcription, but not the agr locus is associated with sigB inactivation, suggesting 
additional urgr-independent activity on target gene activation.^'^’^ ’^^ '* /Igr-dependent and - 
independent regulation has been proposed by Chien et al. (1999) through the discovery of a 
conserved SarA-binding site within the promoter sequences o f agr, fnb, hla, and spa genes 
to which binding exerts the required response whether it is activation or repression/**
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It is now widely accepted that protein A {spa) is co-regulated by agr and sarA loci at the 
transcription level, and that repression via sarA can be agr-dependent or agr-independent 
which may account for variations in protein production/*’^ *^  Strains deficient in either or 
both agr and sarA regulatory systems are less virulent in murine bacteraemia indicating 
that sarA activity is essential for the development of bacteramia.'*^ SarA has also been 
reported to play a role in the initial adherence of S.aureus in rabbit endocarditis and in 
apoptosis of mammalian cells/^’^**’*^ *
As part of the regulatory system SarA is under the control of its own by-products. A 345bp 
transcript designated sarR, which shares 51% sequence homology with SarA, has been 
identified by Manna et al. (2001).^^** These authors report that rSarR binds to sar 
promoters repressing SarA expression, possibly through down-regulation of sarA PI 
transcription.^^*" The joint repression of protein A by sarA and agr led to the assmnption 
by Cheung et al (2001) that there must be a protein that activated protein A expression. 
As a result they discovered another ORF with sequence homology to SarA, this time 
upstream of spa and with the ability to bind to spa promoter. The ORF was termed sarS 
for gene supplemental to SarA (also identified as SarHl by Teginark et a/).***" SarS is 
repressed by agr and sarA, yet increased yields of expression in sarA' and a g f  mutants 
differs between the two regulatory loci.
Yet another homolog to sarA is sarT, a repressor of a-haemolysin {hla) expression and 
repressed by agr and sarA itself.***^  Studies have shown that sarA, but not agr, represses 
sarT promoting a-haemolysin synthesis and that sarT mutants give rise to increased levels 
of RNAin suggesting a negative effect on RNAIII transcription probably through a sarA 
independent mechanism. Transcription of SarT is induced between late exponential and 
post-exponential phases. Prior to this sarA represses it. As a repressor of hla, it was found 
that sarA, and not agr, is able to activate transcription through sarT repression, the details 
of which are very complex (Figure 6).***^  Additional extracellular proteins shown to be 
under the influence of SarA include: V8 serine protease, staphylococcal enterotoxin B 
{seb), and toxic shock syndrome toxin-1 {tst) genes.
From these studies it has been elucidated that the sarA locus and indeed SarA itself exerts 
partial control of the regulation of RNAIII at the transcription level, «gr-dependent and 
independent control of positive and negative gene regulation.
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Figure 6 . Proposed model oisarA  regulation. Adapted from Schmidt et al (2001)305
Further pleiotropic regulatory elements involved in the control of virulence factor 
expression are still being described. One such element is the most recently described sae 
locus, another two-component system {saeRS)}^^ Within sae^ saeR encodes an activator 
gene protein and saeS a sensor histidine kinase protein. Mutations within sae result in 
disrupted transcription of numerous genes including hla, hlh, coa and DNase genes, but 
appear to have no effect on agr or sar. The exact mechanism of action is still being
questioned.'^'* McNamara et al. identified the rot gene, putative toxin repressor that is 
assumed to be inactivated by RNAIII during post-exponential phase although the exact 
mode of action is not clear.^^^ The ArlS-ArlR two-component system described by 
Fournier et al. (2001) is not an auto-regulated system but under the control of the agr and 
sarA systems.'"^ Mutations in either component increase a - and (3-haemolysin, coagulase, 
protein A, serine proteases and lipase suggesting a role in transcription repression.'"* 
Additional regulatory systems that have been identified include the staphylococcal
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respiratory response (ssr) and the extracellular protein regulatory (xpr) systems but their 
role in the regulation of virulence is unclear.
1.4 Antimicrobial Agents
There have been considerable developments in antibiotics since their discovery. Many 
drugs are no longer toxic and many are naturally occurring products of bacteria 
themselves. To date there are over thirteen families of antimicrobial agents including the 
aminoglycosides, (3-lactams, cephalosporins, fluoroquinolones, glycopeptides, 
lincosamides, lipopeptides, macrolides, oxazolidinones, polymixins, quinolones, 
streptogramins and tetracyclines. Each family has its own mode of action that can be 
classified into one of five groups of inhibitors as follows:
1 Protein synthesis
2 Cell wall synthesis
3 Cell membrane function
4 Cell metabolism
5 Nucleic acid synthesis
The majority of antibiotics on the market today target protein synthesis. This thesis will 
study selected inhibitors of protein synthesis, cell membrane function and cell wall 
synthesis.
1.4.1 Protein Synthesis
The process of protein synthesis is a complicated one involving a number of sequential 
stages with each stage dependent upon the completion of the previous stage. Every 
component and protein required by a bacterial cell to function is encoded on individual 
genes, the template for mRNA assembly. The transfer of data from DNA to RNA, the 
process of transcription, requires the presence of ITNA polymerase enzymes that bind to 
specific start codon sequences encoded within the DNA of individual genes. Once bound 
these enzymes uncoil the DNA double helix allowing the attachment of free nucleotides in 
a 5’ to 3’ direction until the transcription of a stop codon. As the mRNA elongates it 
detaches itself from the DNA template allowing recoiling. Translation of mRNA occurs
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with the aid of ribosomes present in the cell cytoplasm along with a pool of amino acids 
and transfer RNA. Ribosomes are composed of two individual subunits, 30S and 50S 
subunits, that remain separated until required for protein synthesis. In the cytoplasm 
mRNA is bound by an fMet initiation signal. This in turn binds to the 30S ribosomal 
subunit, facilitated by IF2 and IF3 accessory initiation factors, to a 50S ribosome to 
complete the 70S initiation complex and stabilized by guanosine triphosphate (GTP). 
Upon formation of the 70S initiation complex the elongation phase commences with the 
aid of GTP and three elongation factors: EF-Tu, EF-Ts, and EF-G. Elongation is a three- 
stage cycle (codon recognition, peptide bond formation, and translocation) with each cycle 
resulting in the formation of a peptide bond and the addition of one amino acid residue and 
eventually the release of a complete protein. Codon recognition involves the formation of 
hydrogen bonds with the anticodon region of aminoacyl-tRNA coupled to its appropriate 
amino acid. Peptidyl transferase enzymes catalyse the formation of peptide bonds between 
the amino acids to form a growing polypeptide chain as the mRNA moves through the 
ribosome during the translocation phase. To complete the process a protein release factor 
bound to the termination codon causes the addition of a water molecule instead of an 
amino acid to the polypeptide, resulting in the release of the polypeptide and separation of 
the ribosome into its 2 subunits ready to start the process again. Figure 7 summarises the 
stages involved in protein synthesis.
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Figure 7. Summary o f the stages involved in protein synthesis 
1.4.1.1 Protein Synthesis Inhibitors
Most protein synthesis inhibitors are bacteristatic by nature with the exception of the 
aminoglycosides that are bactericidal.'^* It is unclear why but it is possibly due to their 
multiple effects on the cell membrane, RNA metabolism and misreading of codons through 
activity at the 30S ribosomal level (Table 5).
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Antimicrobial,,.*
m a Family -
Examples Bacterial 1 
^«Target*
Mode of Action
Aminoglycosides streptomycin, gentamicin,
kanamycin,
neomycin
Gram +ve 
Gram -ve
Codon misreading; translocation 
impairment; RNA metabolism
Chloramphenicol chloramphenicol Gram +ve 
Gram -ve
Inhibits peptide bond formation 
on 50S ribosome; disrupts 
aminoacyl-tRNA binding and 
peptidyltransferase activity
Lincosamides clindamycin
lincomycin
Gram +ve 
Gram -ve
Binds to 50S ribosomal subunit, 
interfering with 
peptidyltransferase reactions.
Macrolides erythromycin
clarithromycin
Gram +ve Premature release of incomplete 
polypeptides from 50S 
ribosomes; inhibits assembly of 
new ribosomal subunits
Oxazolidinones linezolid Gram +ve 
Gram -ve
Inhibits initiation complex 
formation
Streptogramins dal fopristi n/quinupri sti n 
(Synercid)
Gram +ve Inhibits substrate attachment and 
peptidyltransferase elongation
Tetracyclines tetracycline
minocycline
Gram +ve 
Gram -ve
Inhibits cell free RNA translation 
on 30S ribosome; loss of 
membrane transportation; 
oxidative phosphorylation
Table 5. Properties of antimicrobial agents affecting bacterial protein synthesis 
1.4.1.1.1 Oxazolidinones
The discovery of a new class of synthetic protein synthesis inhibitors, the oxazolidinones, 
was made in 1987 by E.I du Pont de Nemours and Co, Inc. Following this the first 
antimicrobial agent, linezolid, was launched into the UK pharmaceutical market in 
February 2001 for use against skin and skin structure infections, bacteraemia and 
pneumonia associated with Gram-positive bacteria.
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Linezolid is bacteristatic by nature with a broad spectrum of activity spanning Gram- 
positive bacteria (MIC=l-4|uig/ml) including multi-resistant species, ^ ^ 1-250.298,306.368,377 
Clostridium species (MIC=0.25-8p,g/ml) and Gram-negative anaerobes for example, 
Bacteroides species (MIC=2-8pg/mi)/^^ However E.coli (MIC>128pg/ml) is unaffected. 
Bactericidal effects have been observed in pre-clinical studies against Streptococcus 
pneumoniae (MIC= 1 -4pg/ml).
The mode of action of this drug is different from that of any other protein synthesis 
inhibitor. Linezolid acts not by affecting peptidyl transferase or translation temiination, 
but by preventing the formation of the N-formylmethionyl-tRNA-mRNA-70S (tRNA^'^^- 
mRNA-70s) on the 30S subunit ternary complex via binding to sites on the 16S or 23S 
ribosomal RNA (rRNA) (Figure 8).^ ^^ '^ ^^  Recent publications have supported the 
hypothesis that linezolid has dual functions. Strong binding of linezolid to the 50S 
ribosomal subunit has suggested that the drug only binds to the 50S subunit inhibiting the 
initiation complex formation and through the binding of 23S within 50S subunits 
preventing the assembly process.
Comparative studies with other drugs have shown that linezolid is as effective as 
vancomycin and p-lactams in clinical cure rates and microbiological success rates in vitro 
and in vivo against antibiotic sensitive and resistant staphylococci and 
enterococci.^^' 104. 180,257,277,297,309 maintenance of drug levels at concentrations greater 
than the MIC appears to be critical for optimal activity in rabbit endocarditis models.
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Figure 8. Mechanism of action o f linezolid
1.4.1.1.2 Streptogramins
Synercid is the first injectable streptogramin combining the two streptogramin derivatives 
of pristinomycin, dalfopristin (Type IIA) and quinupristin (Type lA) in a 70:30 ratio. 
Streptogramins individually inhibit different stages o f the protein synthesis process in a 
bacteriostatic manner. Type A (IIA) is thought to bind only to the free ends of peptidyl 
transferase at the termination-initiation phase, whereas Type B (lA) blocks peptide bond 
synthesis in vitro inducing the release of incomplete protein chains. The combination of 
these individually bacteriostatic compounds gives synercid its bactericidal capabilities.^’^
Inhibition by synercid occurs through an induced conformational change in the 5OS 
ribosomal subunit by dalfopristin. Reversible binding to the peptidyltransferase domain of 
the ribosome and the resulting conformational change improves the binding capabilities of 
the quinupristin subunit at a different site, rendering the drug bound ribosome unable to
carry out substrate attachment and peptidyl transferase elongation stages (Figure 9).217
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Although most staphylococcal and streptococcal species are susceptible to the lethal effects 
o f synercid (MIC=0.12-2 pg/ml), it is only bacteriostatic or weakly bactericidal to 
Enterococcus faecium (MIC<2pg/ml) but not In vitro studies in to
the effectiveness of synercid against strains of VISA, VRE, MSSE, MRSE, and 
ciprofloxacin sensitive and resistant strains of S. aureus compared to other leading 
antimicrobial agents, such as vancomycin, has yielded promising r e s u l t s . T h e  
use of synercid in patients with MRSA and VRE infections failing alternate therapy has 
also provided promising results.^^’^ '*’^ ^^ '^ ^^  Despite this, treatment with synercid has also 
been reported to fail in an endocarditis rat model with erythromycin resistant MRSA due to
the short half-life of dalfopristin in serum. 101
Synercid
(dalfopristin-
quinupristin)
30S & mRNA
50S
Conformational
change
70S Initiation
Figure 9. Mechanism of action of Synercid
1.4.2 Gram Positive Cell Walls and their Biosynthesis
The composition of the bacterial cell wall is not uniform for all species, but can be grouped 
into two main categories: Gram-positive and Gram-negative bacteria, depending upon their 
reaction to the Gram stain. As Gram-positive bacteria are the subject o f this study only the 
Gram positive cell wall structure will be discussed.
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The structure and composition of a bacterial cell wall is influenced by an organism’s 
external environment in order to provide cell integrity. The cell wall of Gram-positive 
bacteria is composed of two layers, a cytoplasmic membrane and a thick (15-80mn) lattice 
like layer of peptidoglycan and teichoic acids. Peptidoglycan is composed of parallel 
chains of glycerophosphate or ribitol phosphate residues linked by (31-4 glycoside bonds 
and cross-linked by pentapeptides. It is the presence of components such as N- 
acetylmuramic acid, D-glutamic acid and D-alanine that give selective toxicity for 
antibiotics like the (3-lactams.
Peptidoglycan biosynthesis only occurs during cell growth and division. It involves 
controlled splicing of existing bonds by autolysins and the simultaneous insertion of new 
pieces of peptidoglycan in a three-stage cycle. Stage one takes place in the cytoplasm 
where cell wall precursors are formed using soluble enzymes. At the cytoplasmic 
membrane the precursors become bound to the recyclable lipid carrier, bactoprenol, which 
gives molecules enough hydrophobicity to pass across the membrane, prior to insertion 
into the cell wall. The third and final stage involves cross linkage of new molecules into 
the pre-existing peptidoglycan network via the transpeptidation reaction. Here, 
transpeptidase enzymes remove a D-alanine group from the new molecule and use the 
exposed peptide bond to cross link with a pentaglycine bridge.
1.4.2.1 Inhibitors of Cell Wall Synthesis
This group of antibiotics includes the penicillins and cephalosporins, which contain a (3- 
lactam ring hence, are designated p-lactam antibiotics. Both target the enzyme 
transpeptidase involved in the transpeptidase reaction of peptidoglycan synthesis. The first 
P-lactam, penicillin G, was primarily a Gram-positive antibiotic. Derivatives of penicillin 
G developed by chemical synthesis possess altered properties that give broader spectrum 
activity that includes some Gram-negative bacteria. Beta-lactam antibiotics bind with 
transpeptidase enzymes, penicillin-binding proteins (PBPs), on the surface of bacterial 
cells tlirough their P-lactam ring rendering them inactive and unable to carry out 
transpeptidase reactions. As a result, cross-linking of the bacterial cell wall is inhibited 
producing a weakened structure that is susceptible to osmotic pressure. Antibiotic-PBP 
complexes have also been found to stimulate the release of the enzyme autolysin 
accelerating cell wall digestion. Production of the enzyme (3-lactamase by bacterial strains
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inactivates the majority of P-lactam antibiotics, however production of semi-synthetic 
penicillins such as oxacillin and methicillin, with altered side chains, renders these drugs 
resistant to |3-lactamase activity. Methicillin is a semi-synthetic penicillin modified by 
penicillin amidase activity to remove penicillin side chains that are replaced with an acyl 
side chain thus providing a broader spectrum of activity and reduced susceptibility to 13- 
lactamase enzymes.
Cephalosporins differ from (3-lactams by the presence of a six-membered dihydrothiazine 
ring in place of a five-member thiazolidine ring. In this study we used cefpirome, an 
example of a 4^ ’' generation cephalosporin with improved anti-staphylococcal activity. Its 
structure is similar to that of the penicillins, but has been modified though the 
‘generations’ to give a broader activity spectrum and resistance to (3-lactamase 
degradation. The addition of a methyl-cyclopentapyridinium hydroxide at position 3 of the 
cephem ring has increased the drugs bactericidal activity to include the staphylococci, 
Enterobacteriaceae and Pseudomonas aeruginosa, including Type 1 (3-lactamase- 
hyperproducer s t r a i n s . T h e  mode of action of these antibiotics however remains the 
same as the penicillins binding ineversibly to PBPs preventing peptidoglycan cross- 
linking.
Glycopeptides were introduced into clinical practice in 1956, but were not widely used due 
to their poor tolerability and toxic side effects. Vancomycin, although a cell wall inhibitor 
targets a different stage of peptidoglycan synthesis from the (3-lactams. Binding of 
vancomycin to the terminal D-alanine-D-alanine amino acids on the undecaprenyl 
peptidoglycan precursors occurs at the bacterial cell membrane surface blocking 
transglycosylase and transpeptidase reactions. Teicoplanin is chemically similar to 
vancomycin, but displays lower toxicity levels and less frequent side effects.
1.4.3 Drugs That Act on Cell Membrane Function
Bacterial membranes are composed of 50-70% protein, 20-30% phospholipid, with the rest 
made up Jfrom glycolipids. Polymyxins and polyenes are the two major groups active 
against bacterial cell membranes. Their structure is similar to that of detergents with a 
polypeptide head and a long hydrophobic tail promoting binding to the cell membrane 
causing leakage of the cell cytoplasm. Unfortunately polymyxin activity is non-specific
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and can cause mammalian cell damage particularly of the liver, kidney, and nervous 
system.
Daptomycin is a semi-synthetic, water-soluble, cyclic lipopeptide or peptolide. Structural 
similarities can be seen with the polymyxins but their modes of action are very different. 
The exact mechanism by which daptomycin exerts its activity is not completely understood 
but the biosynthesis and assembly of peptidoglycan, teichoic acid and lipoteichoic acid 
(LTA) appears to be affected. Other authors have detailed the disruption of cell membrane 
potential through the loss of potassium ions.^’^ ’’ ’^^ ^
The enzymes involved in LTA synthesis are localised at the cytoplasmic membrane. It is 
these membrane proteins that are believed to be the site of daptomycin activity, not LTA 
itself. At concentrations of daptomycin equivalent to the MIC of S. aureus and E.faecal is 
and Efaecium  irreversible binding of daptomycin to the cytoplasmic membrane through a 
calcium bridge has been proposed.'’^  Different phenotypes displayed by enterococci and 
staphylococci in response to daptomycin were also described. These authors report the 
inhibition of growth and peptidoglycan synthesis in S.aureus but not in enterococci, 
however Efaecium  was unable to undergo cell separation forming rod-shaped cells 
whereas S, aureus cells remained unchanged. The inhibition of growth was suggested to 
result from the inhibition of LTA synthesis and resulting loss of LTA function as a carrier 
of teichoic acid or as a regulator of autolysins.'’^  It has been suggested that as LTA are a 
component of adhesins daptomycin may prevent cell proliferation in an adhered state.'’^
The bactericidal activity of daptomycin against Gram-positive organisms is concentration 
dependent but is heavily influenced by calcium concentrations with evidence of reduced 
activity in the presence of serum or albumin, unlike other antimicrobial agents such as 
vancomycin, linezolid and s y n e r c i d . C o m p l i c a t e d  skin and soft tissue 
infections, and bacteraemia have been the focus of clinical trials, especially those caused 
by multi-resistant organisms. Animal models of endocarditis, osteomyelitis and 
bacteraemia caused by strains of VISA, MSSA, MRSA, MRSE, MSSE, NSEfaecium  and 
YPJEfaecium (MIC<2pg/ml) and in vitro studies have all shown positive results with 
daptomycin therapy.'''''""'’'"'’"''’"''"^  '"'
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1.5 Antimicrobial Resistance
Bacterial susceptibility to antibiotics varies dramatically within and between strains. 
Antibiotic resistance can be acquired through the acquisition of transposable resistance 
genes earned on plasmids, transposons and insertion sequences encoding for example (3- 
lactamase enzymes and efflux systems, or through genetic mutations. Some organisms are 
intrinsically resistant to some antibiotics including strains of streptomycetes. 
Streptomycetes naturally produce antimicrobial agents as by-products so resistance 
mechanisms exist within strains towards the antimicrobial that they produce. Additional 
natural resistance traits of a particular organism may be due to: lack of target structure, for 
example Mycobacteria lack a typical cell wall and are resistant to penicillins; agent 
impermeability e.g. Gram-negative bacteria are impermeable to penicillin G.
Examples of resistance in S.aureus include drug inactivation of penicillins but not 
methicillin ((3-lactamase), chloramphenicol (efflux system), and aminoglycosides 
(phosphorylation, acétylation or adénylation of drug).^’’ Multiple resistance characteristics 
can be presented by a single strain. Continual exposure to a particular agent can also 
create a selective pressure for higher levels of resistance among strains particularly within 
a hospital environment. Cross-resistance between groups of antibiotics is also prevalent as 
seen with the MLSg phenotype.
1.5.1 MLSb Resistance
The MLSb phenotype confers multiple resistances to macrolides, azalides, lincosamides, 
and Type B streptogramins. Macrolide resistance arose shortly after the introduction of 
erythromycin into clinical use and is inducible by low concentrations of the drug. There 
are several mechanisms of macrolide resistance, the main type is through the increased 
expression of the ermC gene encoding a methyltransferase enzyme that methylates 23 S 
ribosomal RNA at a site of key importance to the binding of MLSb antibiotics, resulting in 
multiple cross resistance.
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1.5.1.1 Streptogramin Resistance
Resistance to dalfopristin/quinupristin (synercid) is at present relatively low, although 
resistance towards its individual components exists in strains of staphylococci, E.faecalis 
and E.faecium. Resistance to group B streptogramins, including quinupristin, can take one 
of two forms: constitutive or inducible (Table 6). The most common form is constitutive 
resistance conveying cross-resistance to macrolides and lincosamides (MLSr 
phenotype)/’^  For substantial loss of antibacterial activity to be achieved resistance to 
group A streptogramins or both group A and B streptogramins is required, as synercid 
remains active due to the synergy of its components/”
Since synercid was launched into the UK market in 1999 it is interesting that already all 
strains of E.faecalis are resistant to synercid and that clinical isolates of E.faecium (MIC 
>4pg/ml) and isolates of CNS, MRSA and GISA (MlC=2-8pg/ml) have been recovered 
displaying low-level synercid resistance.^’’^ ’’^ '^’ High level resistance (MlC>32pg/ml) in 
E.faecium is associated with the vatD and vaiE genes.^ '^’ The mechanism of resistance in 
E.faecalis remains unknown.
G m t
enterococci vat (D, E) dalfopristin acetyltransferase Group A streptogramin, 
synercid
153,175,
291,363,
staphylococci Vga (A, B) dalfopristin ATP-binding 
efflux pump
Group A streptogramin 14,364
vat
(A, B, C)
dalfopristin acetyltransferase Group A streptogramin; 
synercid
15,91,216,
364
erm
(A,C, Y)
Méthylation of 23S rRNA; M L S b  phenotype; 
quinupristin; synercid
216
msrA quinupristin ATP-binding 
efflux pump
Inducible Macrolide and 
group B streptogramin
295
enterococci
staphylococci
vgh (A,B) quinupristin hydrolase Group B streptogramin 13,41,175,
364,
erm{B>) Méthylation of 23S rRNA M L S b  phenotype; 
quinupristin; synercid
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Table 6. Streptogramin resistance mechanisms using the revised nomenclature proposed by Roberts et al
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1.5.2 Oxazolidinone Resistance
As with synercid, linezolid was only recently introduced into the pharmaceutical market 
and already reports of resistance are emerging in strains of E.faecium and S.aureus. 
Several strains of linezolid-resistant E.faecium (MIC=8-64pg/ml) have been reported in 
individuals taking part in a compassionate use program and in patients receiving long-term 
courses of the drug.’^ ’’^  ^ Strains of E.faecalis (MIC=64|Lig/ml) and S.aureus 
(MIC>32ug/ml) have also been isolated from patients receiving l i n e z o l i d . A n a l y s i s  of 
these strains has revealed mutations within the 23S rRNA encoding for a central loop and 
within the p e p t i d y l t r a n s f e r a s e . T h e  mechanisms providing resistance to linezolid 
have yet to be fully established but no evidence exists of known resistance mechanisms 
conveying resistance to the oxazolidinones.”’’’’^ ’^’
1.5.3 Lipopeptide Resistance
Resistance to daptomycin has been achieved in vitro through serial passage of strains of 
S.aureus, S.epidermidis, S.pneumoniae, E.faecium and E.faecalis at sub-inhibitory levels. 
Spontaneous resistance at x8 MIC concentrations was not docum ented.^Accom panying 
increased MIC values of 8- to 32-fold, variable changes in strain characteristics were 
observed which could be divided in to three categories (Table 7).^”’ The exact mechanism 
of resistance remains to be defined.
Class *
1 Normal growth rate; cross resistance to nisin antibiotic
2 Reduced growth rates on Muller Hinton agar (MHA), poor / no growth on 
chemically defined medium (COM); no antibiotic cross resistance
3 Severe growth defects in Mueller Hinton broth (MHB) and COM; poor or 
no pigmentation on MHA; no antibiotic cross resistance
Table 7. Characteristics o f S.aureus following serial passage in sub-MIC daptomycin
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1.5.4 Methicillin Resistance
Kreiswirth et a l (1993)^’”’ proposed the clonal theory of MRSA evolution, which has been 
disproved, and it is now widely believed Üiat the evolution of MRSA is polyclonal.””’ In 
staphylococci, methicillin resistance is chromosomally encoded on a staphylococcal 
cassette chromosome mec (SCCmec). SCCmec is characterised by inverted and direct 
repeats and site specific recombinase genes {ccrA and ccrB) in addition to the mecA 
complex, the gene responsible for methicillin resistance. Expression of an additional 
78KDa cell wall protein PBP2a (or 2’) encoded by the mecA gene is responsible for 
methicillin resistance. The low affinity of PBP2’ for (3-lactam antibiotics allows 
transpeptidase activity to continue in the presence of (3-lactam concentrations that 
inactivate other PBPs.” ”’^ ^^
To date there have been four groups of SCCmec DNA described with each displaying 
differences in structure and nucleotide sequence but are conserved in the mecA gene: Type 
I - 39kb, Type II - 52kb, Type III - 67KB, Type IVa - 20kb and Type IVb - 24kb.” ”’” ’^^ ^^  
All strains of community acquired MRSA (CA-MRSA) have been found to carry the Type 
IVa SCCmec a much smaller area of DNA that is not associated with additional resistance 
genes seen with the other SCC/nec types, therefore remaining susceptible to numerous 
antibiotics.^ ^’'’^ ”^ ’^ ^^ ’^ '^^
A mecRl-mecI regulator controls the regulation of mec A expression. Strains of 
staphylococci displaying low level methicillin resistance possess a functional mecRi-mecI 
regulator that inhibits the complete expression of the resistance phenotype. Deletion 
of the meci gene through the insertion of IS 1272 and/or a mutated or deleted meci gene 
along with partial deletion of the mecR gene (lS\212-/S.mecRl-mecA~\S^?>XK) de-represses 
mecA t r a n s c r i p t i o n . T h e  latter is commonly found amongst strains of MRSA.
A family of five chromosomally encoded fern genes (fetnA tlirough femE), considered to be 
involved in cell wall metabolism, and essential for the expression of methicillin resistance 
have been described. Inactivation or loss of these genes resulting in reduced levels of
resistance has been demonstrated in agr-mA\ strains and in strains of VISA where 
methicillin resistance is reduced. Inactivation of the femC  gene appears to decrease the 
transcription of the glnA gene involved in glutamine production and the level of
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methicillin resistance expressed.’'’^  The full extent of the involvement of the fern genes in 
the expression of methicillin resistance is unclear.
In addition to the presence of the mecA gene, low-level resistance to methicillin can also 
be achieved through p-lactamase over expression, over production of PBP4, which has 
lower affinity for p-lactams, and mutations of PBP2 .^ ’^’
1.5.5 Vancomycin Resistance
Effective treatment of MRSA is often limited to vancomycin and teicoplanin and until 
recently vancomycin resistance in staphylococci did not exist. Vancomycin resistance has, 
however, existed in strains o f enterococci since 1987 and has rapidly increased since the 
1990s. The transfer of high-level vancomycin resistance from E.faecalis to S.aureus has 
been achieved in vitro, but had not been proven to occur in vivo.^^^ During 1995 the first 
isolate o f S.aureus with reduced vancomycin susceptibility (vancomycin-intermediate 
resistance S.aureus', VISA) was isolated in a French hospital but was not reported until 
1998.^^  ^ The first reported strains of VISA were isolated from a Japanese hospital in 1997 
(strains Mu3 and Mu50).’^ ’ Following this report several isolates of S.aureus displaying 
vancomycin-intermediate resistance (VISA) have been reported across Europe and in the 
United States of
Vancomycin resistance in strains of enterococci is associated with a set of van genes 
taking the form of either the vanA phenotype (plasmid encoded vancomycin and 
teicoplanin resistance) or vaiiB phenotype (chromosomally encoded vancomycin 
resistance) although vanD through vanH genes have also been d e s c r i b e d . T h e  
substitution of D-alanyl-D-alanine with D-alanyl-D-lactate reduces the binding affinity of 
vancomycin up to 1000 fold. The vancomycin resistance mechanisms identified in strains 
of staphylococci, including CNS, appear not to be the same as that found in 
enterococci.^”^ ’^ ”"’^ ^^  In July 2002, a strain of VRSA displaying a vancomycin 
MIC>128pg/ml and a teicoplanin MIC of 32pg/ml was isolated in the United States.^^ 
The strain was recovered from an infection containing VRE and was found to be carrying 
the vanA gene. This is the first staphylococcal isolate reported to carry the enterococcal 
vanA gene suggesting horizontal transfer had occurred between the species during 
infection and that the transfer of genes conferring high level vancomycin resistance is
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feasible in vivo.^^ A second, unrelated, isolate of VRSA (MIC==32|Lig/ml) carrying the 
vanA gene was isolated in the United States in September of 2002 /’ It has not been made 
clear whether this isolate was recovered from a mixed culture containing VRE but it is 
suggested than the gene was acquired through conjugation events with enterococci/’
All of the VISA strains to date, except the UK strains 3700w and 3759v, have been 
isolated from patients who have received vancomycin therapy. Strains of VISA share 
similar characteristics including longer generation times and increased cell walls as 
discussed earlier (section 1.1). Cell wall structure modifications such as increased 
glutamate muropeptides that actively bind vancomycin, and the overall thickened cell wall 
are thought to increase the consumption of vancomycin reducing the amount able to reach 
D-Ala-D-Ala pentapeptide precursor terminus target in the cell m e m b r a n e . B o y l e -  
Vavra et al (2001) could not find consistency in the peptidoglycan composition between 
the Japanese and United States strains and suggested that cell wall composition was not 
solely responsible for resistance.'”’
In studies of Mu3, Mu50 and Mu50© (vancomycin susceptible revertant of Mu50) seven 
novel ORFs identified as vancomycin resistance associated genes (vra), an up-regulation in 
fructose operon genes, and a down-regulation of protein A in Mu3 and Mu50 were 
r e c o r d e d . T h e  genes vraS and vraR encode a histidine kinase and response regulator 
respectively, fonning the components of a two component regulatory system. Additional 
components of the regulatoiy system are encoded by the genes vraA (CoA ligase), vraB 
(acetyl-CoA-acetyltransferase), vraC (unknown), vraD-vraE and vraF-vraG (ABC 
transporters with homology to B.subtilis two-component regulatory s y s t e m s ) . T h e  
cloning of the vraS and vraR genes in to a strain of vancomycin susceptible S.aureus 
(VSSA) was found to reduce the level of vancomycin susceptibility by that strain.^”^  
Homology of the ABC transporters with the glutamine transporter (glnQ) in S.aureus is 
thought to contribute to vancomycin resistance through the increased transportation of cell 
wall amino acids consumed in peptidoglycan synthesis. Increased consumption of acetyl 
CoA during the synthesis of N-acetyl-glucosamine and N-acetyl-muramic acid during 
peptidoglycan synthesis may also be compensated for by the vraA encoded CoA ligase. 
Increased activity of the fructose genes (fruAB) has been shown to correlate with increased 
glucosamine synthase (GlmS) activity for enhanced peptidoglycan synthesis (section 2 .1 ).
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Kuroda et a l (2000) postulated that increased activity could be through the inactivation of 
a repressor but more detailed studies are required/”^
The level of methicillin resistance reported for some strains of VISA is reduced in 
comparison to those of M RSA /’^  Full methicillin resistance is thought to require a 
functional agr regulatory system and fern genes, both of which are absent from agr~null 
strains. Several VISA have been described that have a defective agr locus and as a result 
display reduced methicillin resistance.^””
1.6 The Effects of Sub-Inhibitory Concentrations of Antibiotics on Gram- 
Positive Bacteria
The concentrations at which antimicrobial agents are tested against strains of bacteria can 
be classified into four categories: the minimum antibiotic concentration (MAC), minimum 
bactericidal concentration (MBC), minimum inhibitory concentration (MIC), and the post­
antibiotic effect (PAE). The effects of antibiotics at concentrations lower that that which 
inhibits growth is termed the sub-minimal inhibitory concentration (sub-MIC).
The effect that antimicrobial agents have in vivo is dependent upon the concentration they 
reach within the host. The effects observed at concentrations greater than the MIC are 
vastly different from those seen at sub-inhibitory concentrations. At the MAC and sub- 
MFC, changes in bacterial cell morphology, growth, adherence and protein expression are 
often encountered and the study of these effects is important due to the presence of such 
concentrations during antimicrobial t h e r a p y . T h e  range of sub-MFC’s at which an 
antibiotic is active is highly variable. For example, penicillin will induce morphological 
changes at Vie MIC whereas cephaloridine is only active up to V3 of the MIC.’^ ’ In 
addition, the effects induced by a particular antibiotic may not be the same as those 
induced by all antibiotics of the same group of the same bacterial species, and antibiotic 
effects may be different between bacterial species due to variations in the bacterial 
target.’^’
Numerous authors have demonstrated the activity of antibiotics at sub-MIC levels on both 
Gram-negative and Gram-positive bacteria in vitro. Examination of the morphological
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structure of bacteria by electron microscopy has revealed changes in the bacterial cell wall 
structure induced by both inhibitors of the cell wall and of protein synthesis. The stages of 
peptidoglycan synthesis take place at numerous sites on the cell wall, some of which are 
linked to the extension of the cell wall and are susceptible to protein synthesis inhibitors. 
Other sites that are related to cell wall thickening are independent of protein synthesis, 
thus protein synthesis antibiotics are capable of inliibiting cell wall extension but cell wall 
thickening continues resulting in expression of thickened cell walls.
Alterations of the bacterial cell surface can interfere with adherence to and colonisation of 
host cells. An increase in the release of preformed adhesin, suppression of adhesin 
fonnation and expression, and the induced formation of defective adhesins can all result 
from exposure to sub-MIC antibiotics.
Numerous authors have demonstrated the ability of sub-inhibitory concentrations of 
antibiotics to affect the expression of virulence factors, and susceptibility to 
opsonophagocytosis. The expression of surface bound and extracellular proteins can be 
inhibited or enhanced by protein synthesis inhibitors depending upon the protein in 
question and the antibiotic. As reported with cellular morphology, antibiotic groups other 
than protein synthesis inhibitors can alter protein expression. The interaction of antibiotics 
with phagocytic cells of the immune system is also variable and can occur directly or 
indirectly through their effects on phagocytic cell function or the effects exerted upon the 
infecting bacterium respectively. An example of the latter is shown by the enhancement of 
opsonophagocytic uptake and oxidative metabolism in S.aureus and S.pyogenes by 
clindamycin.^^” ”^”^^ ’^ ^^ ’^ ”^^^  ^The increased levels of phagocytosis have been linked to the 
reduced expression of surface proteins that provide antiphagocytic protection such as, 
protein A and M protein, or those that promote adhesion to s u r f a c e s . S o m e  
contradictory reports have been published where no significant alteration in phagocytosis 
has been observed.
Table 8 summarises the effects of sub-MIC antibiotic concentrations on cellular 
morphology, adherence and virulence factor expression by staphylococci.
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1.7 The Immune System
The defence mechanisms employed by a healthy individual normally provide a harmless 
relationship between host and bacteria. The natural protective properties of the skin and 
antimicrobial substances secreted in sweat and internal secretions such as mucus and tears 
provide a highly resistant barrier to invading organisms. The development of an infection 
and progression to cause disease is usually related to a breach in the skin and/or the 
impairment of the host’s defence mechanisms allowing opportunistic bacteria to become 
pathogens.
The human immune system can be divided into two parts; innate and acquired immunity. 
The innate immune system is present in individuals from birth and provides non-specific 
defence to an array of foreign bodies. The acquired iimnune system on the other hand 
relies on the exposure to foreign bodies to stimulate the proliferation of lymphocyte cells 
expressing specific receptors to the antigen(s) that stimulated their synthesis.
1.7.1 Cells of the immune system
Both innate and acquired immune systems exploit differentiated stem cells albeit for 
different purposes (Figure 10).^”’
The two main groups of phagocytic cells are the polymorphonuclear leucocytes (PMNL) 
and mononuclear phagocytes of the innate immune system. The neutrophils are the most 
abundant and efficient phagocytic cell circulating in the bloodstream, and entering tissues 
in response to infection or injuiy. Mononuclear cells (monocytes) can fmther differentiate 
into macrophages within tissues and adhere to sur faces. The cells of the acquired immune 
system are derived from different precursors to form antigen-specific B- and T- 
lymphocytes.
Recruitment of phagocytic cells to a site of infection is mediated by the release of 
chemotactic factors such as the complement component C5a, histamine and cytokines 
from other phagocytic cells.
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Plasma cell
CDS
T-lymphocyte
CD4"
T-lymphocyte B-lymphocyte
Lymphoid progenitor
Natural killer cells
Stem cell
Myeloid progenitor
Figure 10. Cells o f the immune system. From Weir and Stewart.^
1.7.2 Phagocytosis
Mast cell Basophil Eosinophil Neutrophil Monocyte
Macrophage
Megakarocyte
Platelets
In the presence of a foreign body within the host, for example a bacterium, stimulates 
circulating phagocytes to release cytokines that stimulate the release of other proteins 
including fibrinogen and C-reactive protein that bind to the microbial cell walls thus 
activating the classical complement pathway (Figure 11). Major features of the innate 
immune system are the serum components of the alternative and classical complement 
pathways which are initiated by different stimuli. Antibody-microbe immune complexes 
activate the classical pathway whereas the alternative pathway continually generates the 
component C3b that is inactivated unless it is attached to a foreign body. Component C3b
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deposited on the surface of a bacterial cell opsonises the cell as well as triggering a 
cascade of events leading to the fonnation of a membrane attack complex (MAC) causing 
cell membrane damage and lysis of some bacteria.
Phagocytic cells carry receptors for component C3b facilitating the attachment of 
complement-coated microbes.^ Complement opsonisation of bacteria through the classical 
complement pathway is required for optimal attachment and phagocytosis, opsonisation by 
the alternate pathway occurring at a slower rate.’”^ ’^ ”^
Opsonisation of bacteria increases bacterial surface hydrophobicity whilst decreasing 
surface charge, reducing the repulsion forces between bacterium and phagocyte. 
Attachment of a bacterial cell to a phagocyte stimulates the polymerisation of actin and 
microfilaments within the phagocyte to form a membrane bound phagosome around the 
bacterium.^ Within the phagocyte, the phagolysosomes fuse with intracellular lysosomes 
containing microbicidal enzymes and molecules produced by respiratoiy burst that are 
capable of killing the ingested organism.
The process of phagocytosis increases the oxygen consumption of the phagocytic cells 
increasing the cell’s respiratoiy burst. Enhanced enzymatic activity of NADPH / NADH 
oxidase, and the enzymes superoxide dismutase and myeloperoxidase convert oxygen to 
bactericidal oxygen species such as superoxide anion (O2'), H2O2, singlet oxygen and 
hydroxyl radicals. Damage to the microbial cell wall and cell death occurs as a result of 
exposure to these oxygen derivatives/  ^^ 7.191
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CLASSICAL ALTERNATIVE
C5 convertase
C4b2a3b
Figure 11. Complement activation.
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1.7.3 Resistance to phagocytosis
Many bacterial species have developed cell surface or secreted proteins that can protect the 
cell from phagocytosis. The most coimiion mechanism of resistance is the expression of a 
polysaccharide capsule. Polysaccharide capsules can prevent the binding of complement 
eomponents to bacterial cell walls or inhibit the binding of phagocytes to bound opsonins 
for example, the highly capsulated S.pneumoniae.
S.aureus produces a surface protein, protein A. As mentioned previously in section 
1.2.1.2, protein A binds to the Fc portion of IgG. The release of cell free protein A 
prevents the attachment of IgG to surface bound antigens and subsequently to phagocyte 
receptors. The clotting factor coagulase converts fibrinogen to fibrin to form a fibrin net 
around the bacterium inhibiting phagocytic ingestion.
In some instances species of bacteria do not inliibit ingestion, but once ingested release 
agents that render them resistant to the bactericidal actions of the lysosome, for example 
Salmonella Typhimurium Vi antigen, Mycobacteria and Legionella pneumophila 
cytotoxin, and catalase from S.aureus and Listeria monocytogenes. Intracellular pathogens 
such as E.coli and Salmonella Typhimurium can survive within phagocytes retaining 
structural and functional integrity, but lose the ability to multiply.
The action of antimicrobial agents can also influence a bacterial strain’s resistance to 
phagocytosis. Drug-damaged bacteria display altered characteristics that change the way 
in which phagocytes perceive them through altered antigen expression reducing the 
activation of phagocytic cells and antibody response, altered yields of exotoxins that act 
upon PMN function, abnormal cell morphology, and loss or exposure of surface antigens 
involved in opsonisation and attachment.
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C H A P T E R  T W O
C o m p a r i s o n  o f  the  M o r p h o l o g y  and P h y s i o l o g y  o f  S t ra ins  
o f  S t a p h y l o c o c c u s  a u r e u s  w i t h  I n c r e a s e d  R e s i s t a n c e  to
V a n c o m y c i n
2.1 INTRODUCTION
The structure and composition of the bacterial cell wall is influenced by an organism’s 
external environment in order to provide sufficient cell integrity. The composition of the 
bacterial cell wall is not uniform for all species, but can be grouped into two main 
categories; Gram-positive and Gram-negative species, depending upon their reaction to the 
Gram’s stain. As Gram-positive bacteria are the focus of this study, only the Gram- 
positive cell wall structure will be discussed.
The cell wall of Gram-positive bacteria is composed of two layers, a cytoplasmic 
membrane and a thick (15-80nm) lattice like layer of peptidoglycan and teichoic acids. 
The main constituent, peptidoglycan is unique to prokaryotes and highly conserved 
between bacterial species. The ability to withstand extreme environmental pressures can 
be attributed to cross-linkage of peptidoglycan layers via pentaglycine bridges. The 
structure of the peptidoglycan layer comprises two alternating sugar derivatives N- 
acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) linked by very strong 
glycosidic p-1,4 bonds, and the amino acids L-alanine, D-alanine, D-glutamic acid, and 
lysine fonning glycan pentapeptides.
Biosynthesis of the peptidoglycan layer is a growth phase dependent process involving two 
metabolic pathways: The Bmbden-Meyerhof (BMP) pathway and one that involves the 
uptake of GlcNAc from the enviromnent (Figure 12). In general, the process involves 
three precise stages: Stage one: MurNac-pentapaptide is formed in the cytoplasm by 
soluble enzymes. At the cytoplasmic membrane the nucleotide becomes bound to 
recyclable lipid carriers, uridine diphosphate and undecaprenolphosphate (bactoprenol), 
that provide molecules with sufficient hydrophobicity for passage across the membrane 
prior to insertion into the cell wall. Here GlcNAc and a pentaglycine bridge are bound to 
MurNAc (stage two). The final stage involves cross linkage of new molecules into the pre­
existing peptidoglycan network via the transpeptidation reaction. Ultimately the enzyme 
autolysin precisely cuts (31,4 bonds and new peptidoglycan segments simultaneously insert 
into the existing glycan backbone. Cross links are formed by removal of the terminal D- 
alanine group from the new molecule enabling cross linkage with pentaglycine bridges of 
adjacent glycan chains.
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Figure 12. Peptidoglycan synthesis. Abbreviations: glucosamine synthase (GlmS), glutamine synthetase (GS). 
Adapted fi om Cui et ai. (2000)^®
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Other important components of the cell wall include teichoic acids, lipoteichoic acids, and 
protein A. External to the cell wall some bacterial species synthesise layers of 
glycoproteins and polysaccharides termed the glycocalyx. Together with protein A, the 
glycocalyx is believed to play a role in attachment, phagocytic evasion and resistance to 
dessication whereas the teichoic acids are partially responsible for a cell’s negative charge 
and putatively facilitate the passage of ions across the membrane (Figure 13).
Glycocalyx
Teichoic acid
W all-associated  
proteins
Lipoteichoic acid
Peptidoglycan
Cytoplasmic
membrane
Figure 13. Gram-positive cell wall structure. Adapted from firocA*
The cell wall composition of several strains displaying increased glycopeptide resistance 
including the VISA strains Mu3 and Mu50, and to a lesser extent the 5836 and 5827 has 
been intensively s t u d i e d . T h e  following characteristics of increased cell wall 
thickness, increased glutamine-non-aminated muropeptides and incorporation of GlcNac 
and UDP-N-acetyl-muramylpentapeptides within the cell wall, raised PBP2 and PBP2’ 
expression, decreased cross linkage of peptidoglycan and, elevated or reduced autolytic 
activity have all been reported from strains of VISA. None o f these characteristics are 
uniformly present in all VISA strains indicating two or more mechanisms of resistance
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(Hiramatsu 2002 personal communication). In Mu50 and Mu3 incorporation of GlcNAc 
from the environment is enhanced. However, Mu50 and to a much lesser extent Mu3 also 
utilise glucose and glutamine more efficiently through enhanced glmS activity thus 
presenting a plausible explanation for the differences observed in cell wall thickness 
between the two clonal strains.^^’^ ’^^ '^  ^ The increased glmS activity exerts an increased 
requirement for glutamine that may not be met. Glutamine deficiency has been shown in 
femC  mutants to cause increased nonaminated muropeptides within the cell walls as seen 
in
For this study we employed transmission electron microscopy (TEM) to examine 
morphological changes in several strains of S.aureus exposed to sub-inhibitory 
concentrations of antibiotics
2.2 MATERIALS AND METHODS
2.2.1 Bacterial Strains
Staphylococcus aureus strain Cowan (NCTC 8520) was kindly provided by Prof C. G. 
Gemmell (Glasgow Royal Infirmary, Glasgow) and strains 3700w, 3759v, 5827, 5836, 
Mu3 and Mu50 by Dr D. Morrison (MRSA Reference Laboratory, Stobhill Hospital, 
Glasgow). Each strain was stored on protect beads at -70°C and cultured on Columbia 
blood agar (CBA, Appendix 1) at 37°C prior to use (Oxoid). Strains 3700w and 3759v are 
clinical isolates from Glasgow Royal Infirmai-y (1999) with intermediate resistance to 
vancomycin (VISA).^ '^  ^ Strains 5827 and 5836 are clinical VISA isolates from Michigan 
and New Jersey r e s p e c t i v e l y . M u 5 0 ,  an intennediate vancomycin resistant strain and 
its hetero-vancomycin resistant precursor strain Mu3, were isolated in Japan by Hiramatsu 
in 1997.^^  ^ Strains were periodically characterised by PFGE and phage typing at the 
MRSA Reference Laboratory, Stobhill Hospital (Appendix 2).
2.2.2 Preparation of Bacteria
Bacteria taken from protect beads were transferred on to CBA plates and sub-cultured for 
single colonies on three consecutive days before use and every week thereafter for a 
maximum of three weeks.
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2.2.3 Preparation of Antimicrobial Agents
Antimicrobial agents used were obtained in their white powder form from their 
manufacturers; cefpirome (CEF, Roussel Uclaf, Paris, France), daptomycin (DAP, Cubist, 
Cambridge, Massachusetts, USA), linezolid (LZD, Pharmacia, Kalamazoo, Michigan, 
USA) and Synercid (SYN, Rhône-Poulenc Rorer, Paris, France). Agents were dissolved in 
sterile distilled water to the required concentrations using estimated potencies of 
lOOOpg/ml. Stocks were stored at -70”C until use and discarded after three months.
2.2.4 Minimum Inhibitory Concentration -  Based on NCCLS Methodology
MHB was dispensed in lOOpl volumes in a 96 well microtitre plate. One hundred 
microliters of the antimicrobial agents, at x2 the required concentration, was added to 
column 1 and diluted 1:2 along each row except column 12 (growth control). The bacteria 
were adjusted to McFarland turbidity standard 0.5 through direct broth suspension of 
isolated colonies from a CBA plate. This was further diluted 1:10 in MHB and 5pi added 
to each well of the microtitre plate (final inoculum 5xl0^cfu/ml). Plates were incubated 
overnight at 37°C. Broth used for daptomycin MIC determination and all subsequent 
experiments was supplemented with lOmg/ml C a^  (final concentration) as per the 
manufacturer’s instructions. For vancomycin MIC determination, additional Etest strips 
were used: lOOpl of the bacterial suspension prepared as above was plated on to a fresh 
CBA plate onto which an Etest strip was aseptically placed. Plates were incubated as 
above. MIC’s were carried out in triplicate.
2.2.5 Growth curve
Each strain (five single colonies from a 24hour old CBA plate) was inoculated in to 10ml 
of fresh MHB containing no drug, % MIC and % MIC of the desired antibiotic. Cultures 
were immediately vortexed and an OD^ionm reading of each suspension taken using a 
CE272 linear readout ultraviolet spectrophotometer (Cecil Instruments, Cambridge, 
England). Each suspension was incubated for up to 24his at 3>TC in a shaking incubator 
(150rpm) with OD i^oi^ iTi readings being taken eveiy hour. Samples were vortexed prior to 
each reading. Each experiment was carried out in duplicate.
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2,2.6 Electron Microscopy
Overnight cultures (16hrs) of selected strains were prepared in MHB containing no drug 
and 14 MIC of each antibiotic then centrifuged in a EEC Centra-4x centrifuge (International 
Equipment Company, Dunstable, England) at BOOOrpm for 15mins. Cell culture 
supernatants were discarded and the cell pellet fixed in 500pl 2.5% PBS-glutaraldehyde 
overnight at 4°C. Excess glutaraldehyde was discarded and the cells washed thrice in PBS. 
Pellets were saturated with 1% osmium tetroxide (OsO^) for l-3hrs and washed a further 
three times with PBS. Increasing concentrations of ethanol (30%, 50%, 70%, 90% and 
several changes of 100%) were used to dehydrate the samples before being left overnight 
in Epoxy resin (Epon 812). Samples were transferred into fresh Epoxy resin and left for a 
further 1-2 days at room temperature. Polymerisation was carried out at 68°C over a 
period of 2-3 days after which thin sections, 60-70 mn thick, were cut. Each section was 
stained and counterstained with uranyl actetate (UrAc) and lead citrate respectively. 
Examination of the sections was under a JEOL JEN 1200ExII Electron Microscope with 
LaBô filament. Sample preparation post fixation in PBS-glutaraldehyde was carried out by 
Jim Aitken, Department of Virology, University of Glasgow, Glasgow, UK.
2.3 RESULTS
2.3.1 Determination of Minimum Inhibitory Concentration
To achieve an accurate estimate of the minimum inhibitory concentration a range of 
concentrations were used, the same range being used for each antibiotic. The MIC was 
taken as the lowest concentration that inhibited growth (Table 9).
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Antibiotic linezolid cefpirome synercid daptomycin vancomyx^
broth ‘ broth % broth ^ broth Etest
Cowan (NCTC 8520) 1.56 0.39 0.19 0.125 0.78 2
3700w 0.78 8 0.125 0.78 3 6
3759v 0.78 25 0.5 0.39 3 6
5827 0.78 6.25 0.125 0.78 3 12
5836 0.39 4 0.125 0.39 3 8
Mu3 1.56 6.25 0.39 0.39 1 2
Mu50 1.56 8 0.39 0.39 1.56 8
EMRSA 16 1.56 32 0.5 0.195 0.39 1.25
Table 9. Minimum inhibitory concentrations (fig/ml) of bacterial strains to various antibiotics
The differences in vancomycin MIC values between the broth micro-dilution assay and the 
Etest were not expected but can may be explained by the reduced surface area available to 
vancomycin on the CBA plate and easier detection of hetero-resistant colonies.
2.3.2 Growth curves in the presence of sub-inhibitory concentrations of antibiotics
Growth in the presence of antibiotics was determined by optical density readings over a 
24hour period. Figures 14-21 show the growth of each strain in broth only and in the 
presence of Vz and % MIC linezolid, cefpirome, synercid and daptomycin. Each strain 
used was affected to different degrees by the addition of sub-inhibitory concentrations of 
antibiotics.
Sub-MIC cefpirome was shown to cause a reduction in optical density o ï S.aureus Cowan 
during the first hour of exposure after which exponential growth ensued but remained less 
than optimal. Severe disruption to the growth pattern of 3700w and 3759v was apparent. 
One half MIC exerted bacteristatic properties for 8 and 4 hrs respectively with growth not 
exceeding a l.Sfold increase in optical density. Exponential growth then proceeded with 
24hr readings similar to that of the no drug control. One quarter MIC was also bacteri static 
towards both of these strains but to a lesser extent. Strains 5827 and Mu50 displayed 
marginally restricted growth at both sub-MlC’s of cefpirome whereas slightly increased
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growth was observed with strain 5836. Mu3 appeared unaffected by exposure to 
cefpirome.
Linezolid exposure produced relatively consistent growth characteristics between each of 
the strains tested. Reduced growth rates were noted in strains of Cowan, 3759v, Mu3, 
Mu50 and E16 at % and ‘A MIC, and against 3700w at Vi MIC only. Indeed linezolid was 
the most effective growth inhibitor of Cowan, Mu3 and Mu50. The growth pattern of 
5827 was not shown to be affected whereas a marginal increase in the growth of 5836 
compared to the no drug control was evident.
Synercid {Vz MIC) exerted bacteristatic properties on S.aureus Cowan to the same degree 
as % MIC linezolid whereas Î4 MIC synercid exposed cultures were only slightly inhibited. 
Both concentrations were bacteristatic towards cultures of 3700w resulting in a reduced 
growth rate with cell density increasing by only half a log by 5hrs. Recovery of these cells 
by 24hrs did not take place. VISA 3579v was also inhibited by both Vz and % MIC 
synercid with a 3fold reduction in optical density of Vz MIC treated cells after 8hrs. 
Synercid was the only antibiotic tested to inhibit growth of strain 5836. Exponential 
growth proceeded during the initial 3 hrs of growth after which the generation time of the 
cells was rapidly depressed only increasing 2fold by 8W . Bacteristatic growth conditions 
were observed with E16 at both 14 and % MIC synercid and was the most effective 
antibiotic against this strain also. Marginal inhibition of strain 5827 and no effect on Mu3 
and Mu50 was detected.
The only strain to be seriously inhibited by exposure to daptomycin was VISA 3759v 
which displayed bacteristatic growth for 5-6hrs after which time exponential growth 
occurred resulting in cell densities comparable to the no drug control after 241rrs. S.aureus 
Cowan was also slightly inhibited by 14 MIC daptomycin but not at % MIC. With 3700w, 
14 MIC a slight enhancement of growth of noticeable whereas 14 MIC daptomycin slightly 
reduced growth, these differences were negligible by 6hrs. The remaining strains E l6, 
5827, 5836, Mu3 and Mu50 showed very little response to daptomycin exposure although 
Mu50, 5836 displayed a slight enhancement of growth.
Although measurement of growth by optical density is highly valuable in the determination 
of a bacterial strain’s ability to divide in the presence of sub-inhibitory concentrations of
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antibiotic, it does not provide us with details regarding the state of the cells, for example, 
cell size or clumping.
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Figure 14. Growth o f S.aureus Cowan in the absence and presence o f sub-inhibitory concentrations of
antibiotics
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Figure 15. Growth o f  EMRSA-16 in the absence and presence o f sub-inhibitory concentrations o f  antibiotics
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Figure 16. Growth of VISA 3700w in the absence and presence o f  sub-inhibitory concentrations o f
antibiotics
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Figure 17. Growth o f VISA 3759v in the absence and presence o f sub-inhibitory concentrations o f antibiotics
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Figure 19. Growth o f VISA 5836 in the absence and presence o f sub-inhibitory concentrations o f antibiotics
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2,3.3 Electron Microscopy Studies of Microbial Cell Walls and Cell Surface 
Material
Sections of cell preparations were observed through an electron microscope at a 
magnification of x40000. Random fields of view were chosen and digital images taken of 
typical and atypical cell formations at a magnification of xl 00000. The key feature of this 
exercise was to examine cell wall structure, alterations in cell morphology and the 
presence of any surface material. We found that cell size and the extent of cell division 
among cultures varied between strains (Table 10) and between drug treated cells of the 
same strain (Table 11). Bacterial cultures grown in unsupplemented MHB all showed 
typical growth characteristics with many cells undergoing cell division. Cell wall 
associated material, which is assumed capsular material or slime, was not observed in all 
strains and was not reproducible. Loss of loosely associated slime layers may have 
occurred during handling of cell cultures prior to fixation in PBS-glutaraldehyde.
# Cowan if E16..'iM'iliP;:,-:- 3759v ï iW ? %Mu3^ [Mu5024.5 ±4.3 28.1 ±2.3 27.5 ±3.4 51.2 ±7.4* 30.9 ± 8.3 27.8 ±3.8
Table 10. Comparison of cell wall thickness between strains of S.aureus. Statistical analysis compares strains 
with MSSA Cowan. Readings represent mean +/- standard deviation, * = pvalue <0.05.
Table 11 shows the variation in cell wall thickness associated with antibiotic treatment and 
the presence of cell wall material. Cell wall thickness was calculated using a conversion 
grid where 1mm ^  6.6128 nm. Mean values and standard deviations were calculated by a 
two sample T-test using a Minitab statistical package. Figures 22 and 23 illustrate the 
effects antibiotics have on the morphology of individual cells. The electron microscope 
images presented here are representative of the majority of cells present in a section. 
Photographs at a final magnification of x60000 showing a wider spectrum of cells are 
available upon request.
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— — — / V 1  ^ ■ ■ ■ 1
; No Drug T ‘/2 MIC LZD Î4 MIC CEF % MIC SYN % MIC DAP
Cowan 24.5 ±4.3 31.4 ±5.3 26.4 ± 6.6 32.2 ± 5.7 25.4 ±9.6
E16 28.1 ±2.3 44.4 ± 5.4* 33.9 ±4.2 59.5 ± 6.6* 33.9 ±4.2
3759v 27.5 ±3.4 31 .4± 4 34.2 ± 5 39.5 ± 6.7* 18.2 ± 1.9*
5836 51.2 ±7.4 36 ±4* 51.2±2.3 53 ±2.1 27.8 ±3.8*
Mu3 30.9 ± 8.3 70.5 ± 8.3* 56.2 ± 15.2* 39.7 ±0.01* 34.2 ± 5
Mu50 27.8 ±3.8 86 ± 9.3* 58 ±25.7 65 ±9.5* 26.4 ± 6.6
Table 11. Alteration of cell wall thickness o f strains ofS.aurei4s exposed to Vz MIC linezolid (LZD), 
cefpirome (CEF), synercid (SYN) and daptomycin (DAP). Readings represent mean +/- standard deviation, * 
= pvalue <0.05.
Exposure to Vz MIC linezolid significantly increased the cell wall thickness of strains E l6, 
Mu3 and Mu50 (pvalue <0.05). The largest increases were noticed in strains Mu3 (128%) 
and Mu50 (209%). The cell walls of Mu3 also gave an uneven ‘moth eaten’ appearance. 
In contrast, strain 5836 developed significantly thinner cell walls in response to linezolid. 
S.aureus Cowan and 3759v were not affected. In addition to thickened cell walls, Mu50 
displayed abnormal cell growth characteristics in response to Vz MIC cefpirome. Many of 
the cells were devoid of cytoplasmic material and appeared to have burst; a similar 
phenomenon was observed with the same strain grown in the presence of Vz MIC synercid. 
The increase in cell wall thickness observed in Mu50 was very similar to that of Mu3 
exposed to Vz MIC cefpirome but the differences were found not to be significant and 
significant respectively. Only two images of Mu50 were suitable to take cell wall readings 
from (76.05 and 39.68) resulting in a high standard deviation. Nevertheless, both of these 
measurements are substantially higher than that of the control strain in the absence of 
antibiotic. Strain Mu3 also appeared to be smaller in comparison to the untreated culture. 
The other strains grown in Vz MIC cefpirome displayed normal cell walls and cell size 
although septum formation in strain 5836 was slightly deranged.
Synercid produced variable effects on different strains; the strain most affected at Vz MIC 
levels was 5836. This strain did not show an altered thickness but had ‘moth eaten’ cell 
walls and the majority of cells were seen to be dividing in multiple planes and ‘sticking 
together’. Multiple septum formation was also observed in strain 3759v in addition to a 
thickened cell wall, whilst E16 displayed thickened ‘moth eaten’ cell walls but normal cell
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division. Mu3 again grew with a thicker cell wall whilst S.aureus Cowan remained 
unaffected. Only two strains, 3759v and 5836, displayed altered cell morphology in 
response to !4 MIC daptomycin. Both strains possessed significantly thinner cell walls 
(pvalue <0.05) but, cell size and division were not altered.
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2.4 DISCUSSION
The activity of antibiotics on bacterial growth and cell morphology has been studied 
intensively in recent years, mainly with the p-lactams. At sub-inhibitory concentrations, 
antibiotics can cause a range of effects that are not unique to any individual agent. Such 
effects include: prolonged lag phase, reduction in rate of exponential growth, reduced 
population size reaching stationary phase, the prevention of cross-wall formation and/or 
cell wall division without any effect on viability or rate of cell growth, abnormal cell size 
and multiple thickened cell The Minimum antibiotic concentration
(MAC) according to Gemmell and Lorian is the ‘minimum quantity of antimicrobial agent 
necessary to induce alteration in bacterial structure, as seen by electron microscopy, and/or 
growth producing one-log decrease in cell numbers compared to the control’.
Recently, interest has developed in the cell wall morphology of VISA strains as a possible 
mechanism for increased vancomycin resistance. Strain Mu50 (MIC=8g/ml) has been 
reported to possess a cell wall twice as thick as that of the average staphylococcal cell 
wall, including its related strain Mu3, which was similar to sensitive s t r a i n s . T h e  
results presented in Figur e 23 show that the cell wall of Mu3 is marginally thicker than that 
of Mu50 and that although both have thicker walls than MSSA Cowan it is not significant. 
MHB was used as our growth medium however Hiramatsu (2002 personal communication) 
recommends the use of BFII for the optimum expression of cell wall thickness to be 
achieved through full use of the EhAP-glmS pathway in peptidoglycan biosynthesis as 
detailed in this chapters introduction. This is supported by Cui et a l (2000) who found 
that media containing cell wall component amino acids, and glucose was better for 
supporting vancomycin resistance in VISA although they did not find the cell walls of Mu3 
and Mu50 to be vastly different e ither.M easurem en ts  of 26.17 ± 2.17nm and 31.88 ± 
1.56mn respectively were reported which are similar to our measurements of 30.9 ± 8.3mn 
and 27.8 ± 3.8nm (Mu3 and Mu50) in MHB. Studies of VISA cell walls have found a 
degree of variation between research groups.
In our detennination of the minimum inhibitory concentration (MIC) we used broth micro­
dilution assays with MHB for all antimicrobial agents. It was noticed that by this method 
the vancomycin MIC values were less than those expected for all VISA strains. The use of 
E-test strips however increased the level of resistance range to between 2pg/ral and
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12pg/ml. The use of MHB in the micro-dilution assays and in the above electron 
microscopy experiments may not be providing the strains with adequate nutrients for full 
resistance to be expressed but as vancomycin is not being used here as an investigational 
drug this discrepancy is not of major importance.
Upon examination of sections under TEM we discovered no consistent effects of an 
antimicrobial agent on all of the strains tested. In general, exposure to 14 MIC linezolid, 
cefpirome and synercid resulted in increased cell wall thickness although some strains 
displayed no such increase. The finding that Ipg/ml linezolid caused no morphological 
alterations of GISA were reported by Grif et a l (2001) however in this instance whole 
cells were being examined not sections. In contrast to this, cell walls were reduced 
upon exposure to 14 MIC daptomycin, an expected outcome due to the drug’s ability to 
affect biosynthesis and assembly of peptidoglycan. An interesting observation regarding 
Mu50 treated with 14 MIC synercid was that the majority of cells were devoid of 
cytoplasmic material and that 14 MIC cefpirome caused granulation of the cytoplasm. This 
phenomenon was also reported in S.aureus associated with bone infections, and has been 
attributed to phenotypic modification in response to a changing enviromnent.^^
In relation to growth, again there was no uniform outcome by a particular drug. However 
there is a strong correlation between reduced growth rate and increased cell walls 
irrespective of the antibiotic involved. Strains 3759v and E l 6 exposed to 14 MIC synercid, 
and strains E l6, Mu3 and Mu50 exposed to 14 MIC linezolid are good examples o f this. 
Increased energy consumption involved in increased peptidoglycan synthesis may be a key 
factor to these findings (Hiramatsu 2002; personal communication). The reverse of this 
may also be true in the finding of reduced cell wall thickness and accelerated cell growth 
with strain 5836 exposed to 14 MIC linezolid. Out of all the strains studied, strains 3700w 
and 3759v were the only strains where growth was inhibited by 14 MIC cefpirome. 
However, re-growth occurred by 24hrs and after 4 hrs respectively suggesting low-level 
hetero-resistance within the populations as evidenced by the normal appearance of the cell 
wall of 3759v at 16hrs. In contrast, strain 3700w exposed to 14 and 14 MIC synercid did 
not recover by 24hrs suggesting complete inhibition of growth by synercid at these 
concentrations, the production of an inliibitoiy protein or possible depletion of nutrients.
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C H A P T E R  T H R E E
T h e  E f f e c t s  o f  A n t i m i c r o b i a l  A g e n t s  o n  t h e  E x p r e s s i o n  o f  
V i r u l e n c e  F a c t o r s  a n d  m R N A  T r a n s c r i p t i o n
3.1 INTRODUCTION
The production of virulence factors within a host serves to aid survival of the fittest. The 
production of such factors in an infection process contributes to microbial pathogenicity 
through their interactions with host-defence mechanisms, ability to facilitate establishment 
of an ecological niche and their direct, potentially lethal effects on host tissues.
Here we consider proteins that are considered virulence factors of S.aureus, some of which 
are secreted, attached to the bacterial cell wall, or both. Irrespective of their final 
destination transcription of all of these factors is believed to be regulated by the global 
regulatory system agr. As discussed in section 1.3, cell wall associated proteins are 
transcribed during the exponential growth phase when the agi  ^locus is being repressed. In 
response to an autoinducing peptide the agr system is activated stimulating the 
transcription of extracellular protein genes. Two cell-associated proteins have been 
chosen: clumping factor and protein A, and two extracellular proteins or toxins: Toxic 
shock syndrome toxin (TSST-1) and alpha-haemolysin (a-toxin). In addition, the 
expression of free coagulase and protein A was also investigated.
For each virulence factor a different culture medium is used provide to optimal conditions 
for toxin production although the growth conditions remain constant. For the detection of 
toxins we employed enzyme linked immunsorbent assays (ELISA) and biological activity 
assays both of which provide highly sensitive, reproducible results. We also used a 
fluorescence-activated cell sorter (FACS) and fluorescein isothiocyanate (FITC) conjugate 
probes to detect CD69 surface receptors on human Tcells, a receptor that is over-expressed 
as a result of Tcell stimulation, and therefore an indicator of Tcell stimulation by culture 
supernatants. The levels of protein A and TSST-1 mRNA at a particular time point are 
also investigated using a LightCycler instrument.
3.2 MATERIALS AND METHODS
3.2.1 Bacterial Strains
The bacterial strains used are those referred to in section 2.2.1. Additional strains are used 
as standards due to their ability to produce high levels of particular toxins as detailed in
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Table 12. Minimum inhibitory concentrations for the strains mentioned were carried out 
as described in section 2.2.4.
Toxin proévceti Si il : iiTL:.i.;:i:fi:i. : : : i Si,, S i : SiSi: ai:tei:iiSSJirfts.Si.: i. . :::i8.S: ■ 4 : -1 iiilil
DU5723 Protein A negative 
mutant
Prof. T Foster, Dublin University
Cowan 
(NCTC 8520)
Protein A positive 
TSST-1 negative
Prof. C. Gemmell, University of Glasgow
Wood 46 
(NCTC 7121)
a-Haemolysin Prof. C. Gemmell, University of Glasgow
NCTC 6571 Coagulase Glasgow Royal Infirmary Diagnostic Laboratory
NCTC 11963 TSST-1 Prof. C. Gemmell, University of Glasgow
119993
(clinical strain)
Coagulase negative 
staphylococcus
Glasgow Royal Infirmary Diagnostic Laboratory
Table 12. Standard strains of staphylococci. Abbreviations: Toxic shock syndrome toxin (TSST-1)
3.2.2 Preparation of Antimicrobial Agents
The antibiotics used were cefpirome, daptomycin, linezolid and synercid as previously 
described in section 2.2.3. Each antibiotic was freshly prepared to the required 
concentration in 10ml volumes except for cultures in Todd Hewitt broth (THE) for a-toxin 
detection where 50ml flasks were used. Broth supplemented with 10 mg/ml C a^  was used 
with daptomycin. The minimum inhibitory concentrations of all of the strains in variable 
culture medium (section 3.2.3) were tested and were found to be the same as those 
achieved in MHB.
3.2.3 Preparation of Bacteria
Cultures of the appropriate bacterial strains were grown for I6hrs in the presence and 
absence of !4 and !4 MIC of each antibiotic. The following culture media were used: Brain 
Heart Infusion broth (BHI) -  clumping factor and coagulase; MHB -  Protein A; THE - a - 
haemolysin; Tryptone Soya broth (TSB) -  TSST-1.
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3.2.4 Preparation of Peripheral blood mononuclear cells (PBMC)
The isolation of peripheral blood mononuclear cells (PBMC) was carried out using 
Histopaque 1077 (Sigma, Poole, UK) according to the manufacturer’s instructions. Fresh 
whole blood was obtained by venipuncture from healthy adult volunteers and carefully 
layered in 6ml volumes on top of 6ml of Histopaque 1077 in sterile conical test tubes (Life 
Technologies, Paisley, UK). Centrifugation was carried out in an lEC Centra-4x 
centrifuge (International Equipment Company, Cambridge, UK) at 1900rpm for 30mins. 
Mononuclear cells were present in an opaque layer below the plasma layer. This layer was 
removed using a sterile pasteur pipette and washed with RPMI/10% Foetal Calf Serum 
(FCS) for 15mins at ISOOrpm. The washed cells were pooled, counted in a 
haemocytometer and adjusted to a concentration of 2x10® PMBC/ml with RPMI/10%FCS.
3.2.5 Maintenance of Jurkat Tissue Culture Ceil Line
Jurkat tissue culture cell lines were donated by the University of Glasgow Department of 
Medicine, Glasgow Royal Infirmary, Glasgow. Maintenance of the Jurkat cell line 
required supplementation with fresh RPMJ tissue culture medium twice weekly. Cells 
were centrifuged at 1300Orpin for lOmins then handled under strict sterile conditions in a 
laminar flow cabinet. Spent culture medium was discarded and the cell pellet resuspended 
in 2ml of fresh culture medium. The cell suspension was transferred into a vented flask 
and made up to 40ml with fresh supplemented RPMI medium (Appendix 1). Jurkat cells 
were incubated at 37°C in the presence of 5%C02 for 3 days before being fed again.
3.2.6 Polymerase Chain Reaction (PCR)
Bacterial DNA from sample and PCR control strains (Table 13) was extracted by 
incubating colonies with lOOpl NET buffer (Appendix 1) and lOpl achromopeptidase 
(lOunits/pl) for I5mins at 50"C. The PCR reaction was carried out using ready-to-go PCR 
beads (Amersham) to which 19|ul PCR water (Sigma), 2pi of forward and reverse test 
primers mix (MWG, Appendix 2), 2pi of DNA positive control, nuclease or 16S rRNA, 
primer mix (MWG, Appendix 2), and 2pi of lysed cell suspension were added. One 
reaction bead was used per primer per strain. Amplification conditions for each primer 
were programmed into a Techne Genius thermal cycler (Techne Ltd, Cambridge, UK,
77
Appendix 3). Samples were run on a 1.5% agarose gel in xlO TBE buffer (BioWhittaker) 
for llSmins at 140 volts. Gels were stained with ethidium bromide (Sigma) and 
photographed under ultra violet using a UV transluminator (UVP Ltd, Cambridge, UK) 
connected to an Elonex computer system and analysed by ‘Grab-IT’ version 2.53 software.
S. aureus Cowan 
(NCTC 8520)
spa ' protein A Prof C. Gemmell, University of Glasgow
NCTC 10657 sea/seb  ^ SEA / SEB MRSA Reference Laboratory, Stobhill
NCTC 11963 tst/sec^ TSST-1 / SEC MRS A Reference Laboratory, Stobhill
NCTC 10656 sect SED MRSA Reference Laboratory, Stobhill
FRI 326 see^ SEE Public Health Laboratory, London
ETA eta^ Exfoliative toxin A Public Health Laboratory, London
ETB etb Exfoliative toxin B Public Health Laboratory, London
Wood 46 
(NCTC 7121)
A y a-toxin Prof. C. Gemmell, University of Glasgow
Table 13. PCR standard control strains. Abbreviations: Alpha-toxin (a-toxin); staphylococcal enterotoxin A- 
E (SEA-E); toxic shock syndrome toxin (TSST-1)
3.2.7 Detection of Protein A by ELISA
Sixteen hour bacterial cultures in MHB were centrifuged at 3000rpm for 15mins decanting 
the culture supernatants into sterile universals. Cell pellets were adjusted to an optical 
density, OD62onm = 0.025 (IxlO^cells/ml) in sterile saline. Immulon 4-HB plates (Dynex) 
were coated with lOOpl rabbit monoclonal anti-protein A antibody (MAb anti-SpA) 
(Sigma, 1:10000) overnight at 4"C. Plates were washed thrice in PBS/0.05% Tween-20 
(PBS/T) then blocked for 2hr at 3T’C with PBS/0.05%Tween-20/0.01% Bovine serum 
albumin (PBS/T/BSA, 200pl). Following washing a further three times in PBS/T plates 
were incubated with lOOpl of purified protein A (Sigma) and samples diluted in PBS/T/1% 
normal rabbit serum (NRS), in triplicate, for 2hrs at 3TC. The washing steps were 
repeated as before prior to incubation with lOOpl Biotinylated MAb anti-SpA (Sigma, 
1:40000) for Ihr at 37"C followed by lOOpl Streptavidin Alkaline-phosphatase (Sigma, 
1:1500) for Ihr at 3TC. A final six washes were carried out before incubation with lOOpl
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2Mm p-nitrophenyl phosphate (PNP, Sigma) for 30mins at room temperature. Each plate 
was read using a Titertek® Multiscan Plus plate reader MK II (ICN) at 405mn. 
Experiments were carried out five times.
3.2.8 Immunogold-lahelling of Protein A
Sixteen hour cultures of selected strains were prepared in MHB only and centrifuged at 
3000rpm for 15mins. The cell culture supernatant was discarded and the cell pellets were 
fixed in 4% PBS-paraformaldehyde for Ihr at 4°C. Excess PBS-paraformaldehyde was 
discarded and the samples incubated with SOOpl rabbit anti-protein A (1:500, Sigma) for 
Ihr at room temperature. Rabbit anti-protein A was removed and 250pl anti-rabbit gold 
conjugate (lOmn, Sigma) added and incubated for a further Ihr at room temperature. 
Samples were fixed in 2.5% PBS-glutaraldehyde overnight at 4”C and treated as described 
in section 2.2.6 for viewing by electron microscopy.
3.2.9 Detection of TSST-1 by ELISA
The detection of toxic shock syndrome toxin (TSST-1) was carried out based on a protocol 
from Toxin Technology (Sarasota, USA). Sixteen hour bacterial cultures in TSB were 
centrifuged at 3000rpm for 15niins decanting the culture supernatants into sterile 
universals, discarding the cell pellets. Immulon 4-HB plates (Dynex) were coated with 
lOpg/ml anti-TSST-1 (Toxin Technology) for 12-18hrs in a humid chamber at 37°C, 
washed thrice with PBS/0.05% Tween-20 (PBS/T) then blocked with 200pl PBS/T/bovine 
serum albumin (BSA) for 25mins. Plates were washed with PBS/T then incubated for 2hrs 
at 37‘^ C with lOOpl o f purified TSST-1 (Toxin Technology) and samples diluted in 
PBS/T/normal rabbit serum (NRS), in triplicate. One hundred microlitres horse radish 
peroxidase (HRP) conjugated anti-TSST-1 IgG 1:100 (Toxin Technology) was added post 
washing and incubated for Ihr in a humid chamber at 37°C. A final 5 washes in PBS/T 
was followed by the addition of lOOpl 2,2’-azino-di(3ethybenthiazoline sulphanate) 
solution (ABTS, Sigma) for 30mins at room temperature. Each plate was read on a 
Titertek® Multiscan Plus plate reader MK II (ICN) at 405mn. Experiments were carried 
out five times.
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3.2.10 Activation of CD69 Receptor on Jurkat cells by TSST-1
The number of cells present in fresh culture were counted in a haemocytometer and 
adjusted to a concentration of 1x10^ cells/ml with fresh RPMI medium, 1ml of which was 
added to wells of a 24-well microtitre plate. Stock concentrations of 100 pg/ml, lOpg/ml, 
IjLig/ml, O.lpg/ml and O.Olpg/ml purified TSST-1 made in RPMI and neat culture 
supernatants were added in lOpl volumes to the microtitre plate, one well is always used 
as a blank. Cells were incubated for 241rr at ZTQ, in the presence of 5%C02. Five 
hundred mililitres from each reaction was transferred into two FACS tubes labelled TgG’ 
and ‘FITC’ then centrifuged at 1500rpm for 5mins. Supernatants were discarded and the 
pellet resuspended in residual medium. To the TgG’ tube 5 pi of Mouse IgG-2a fluorescein 
isothiocyanate (FITC) conjugate was added and to the TITC’ tube 5pi of Human CD69 
FITC conjugate. The tubes were incubated for 30mins at 4"C. Cells were washed with 
500pl PBS/1 % foetal calf serum (FCS) at 1500rpm for lOmins, resuspended in 500pl 
PBS/1% FCS, then run through a fluorescence activated cell sorter (FACS) (FACScan, 
Becton Dickinson) and analysed by CellQuest software.
3.2.11 Stimulation of T-cell proliferation by TSST-1
Freshly isolated PBMCs from a healthy donor adjusted to 2xl0^cell/ml were added to 
wells of a 96-well tissue culture plate (Greiner bio-one) in lOOpl volumes. Culture 
supernatants were the same as those used in section 3.2.8. Stock concentrations of 
lOOpg/ml, lOpg/ml, Ipg/ml, and O.lpg/ml purified TSST-1, 1:10 and 1:50 dilutions of 
culture supernatants were in RPMI/10% FCS. Standards and samples were added in lOOpl 
volumes to the 96-well plate in triplicate alongside an RPMI/10%FCS control. 
RPMI/10%FCS was used to buffer the plates to prevent them drying out. Cells were 
incubated for 48hrs at 3T"C, in the presence of 5%C02. Methyl ^^^hymidine (Amersham) 
was diluted 1:20 prior to lOpl being added to each test well and re-incubated for a further 
18hrs at 37®C, in the presence of 5%C02. Tcell proliferation was recorded as counts per 
minute on a radioactive counter (Packard Matrix 96 Direct Beta Counter).
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3.3.12 Haemolytic Activity of alpha-haemolysin
Bacterial cultures (16hrs) in THB were centrifuged at SOOOrpm for 15mins discarding the 
cell pellet. Fresh rabbit blood (in Alsever’s solution 50% v/v stock, SAPU, Diagnostic 
Scotland, Edinburgh, UK) was prepared to a 2% suspension in sterile saline following 
three washes in saline. Sterile saline (50pl) was inoculated into wells of a 96 well V- 
bottomed microtitre plate (Dynex) in which 50pl of sample was mixed and doubling 
dilutions made across the plate. Sterile saline and 1% Tween-20 was used as negative and 
positive controls respectively. To each well 50pl rabbit blood was added and plates 
incubated for Ihr at 3TC. Plates were centrifuged at lOOOxg for lOmins before being read 
visually. The haemolytic titre of a sample was determined as the reciprocal of the dilution 
causing 50% haemolysis compared with the negative control.
3.2.13 Clumping Factor and Cell Free Coagulase Assays
Overnight cultures (16hrs) prepared in BHI were centrifuged at SOOOrpm for 15mins. 
Culture supernatants were decanted in to sterile universals and cell pellets adjusted to an 
optical density, OD62o0 m^ = 0.025 (IxlO^cells/ml) in sterile saline. Culture supernatants 
(cell free coagulase, lOOpl) or cell pellets (clumping factor, 100pi) were added to 96-well 
microtitre plates pre-inoculated with lOOpl BHI/rabbit plasma (E&O Laboratories)/sterile 
saline (Appendix 1) and doubling dilutions made across the plate. The plates were 
incubated in a shaking incubator at 37”C at 150rpm for 8hrs. The coagulase titre was 
determined as the reciprocal of the dilution causing coagulation after 8hrs.
3.2.14 RNA Isolation adapted from TRIzol® Reagent Manufacturer’s Instructions
Four and 12hr cultures of E l6 (50ml) were set up in RNase-free MHB (RF-MHB) only and 
in the presence of Vz MIC linezolid and synercid. Cultures were centrifuged in pre-chilled 
(-70“C) universals at 3000rpm for 15mins at 4^ ’C. The culture supernatants were discarded 
and the cell pellets kept on ice for the remainder of the isolation process. Cell pellets were 
adjusted to IxlO^cells/ml then centrifuged at 3000rpm for 15mins at 4°C. The cell pellets 
were lysed in 1ml TRIzol reagent (Sigma) per 1x10^ cells by vortexing for 5mins. To the 
lysed cells 0.2ml chlorofonn was added, the cells vortexed for a further 15sec and 
incubated for 5min at room temperature. Released RNA was present within the aqueous 
phase of the preparation and was transferred to a fresh 1.5ml eppendorf. The RNA
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preparation was precipitated with 0.5ml isopropyl alcohol overnight at 4*^ 0. The 
precipitate was centrifuged for lOmins at lOOOOxg and the supernatant discarded. 
Washing of the RNA was carried out with 1ml 75% ethanol, vortexed then centrifuged for 
5mins at 7000xg. The RNA pellet was air dried for 5-lOmin. Once dry the RNA 
preparation was dissolved in RNase-free water an incubated for lOmin at 55-60°C. RNase- 
free-DNase (Roche, lOunits/pl) in 500pl dH20 plus IxDNase buffer (Appendix 1) was 
added to the RNA and incubated for Ihr at 3TC. RNA was precipitated overnight in 
0.5ml isopropyl alcohol at 4“C. Samples were stored at -20°C until required.
3.2.15 RNA Isolation using a Qiagen RNeasy (Mini) Isolation kit
RNA isolation was carried out using a Qiagen RNA isolation kit (Qiagen) according to the 
manufacturer’s instructions. In brief, 4hr and 12hr 50ml cultures of E l6 were set up in 
RNase-free MHB (RF-MHB) only and in the presence of % MIC linezolid and synercid. 
Cultures were centrifuged in pre-chilled (-70°C) universals at SOOOrpm for ISmins at 4°C. 
The supernatants were discarded and the cell pellets kept on ice for the remainder of the 
isolation process. Cultures were adjusted to OD62omn = 0.115 in 50ml RF-MHB 
(IxlO^cells/ml) then centrifuged at SOOOrpm for 15mins at 4°C. The cell pellet was 
resuspended in lOOpl lysozyme/TE buffer, vortexed and incubated for lOmins at room 
temperature after which time 350pl RET buffer was added. Cells were vigorously 
vortexed and centrifuged at llOOOrpm for 2mins, then the cell pellets were discarded. To 
the supernatant (approx 450pl), 250pl 100% ethanol was added and mixed thoroughly 
before the sample was transferred (approx 700pl) to an RNeasy mini column in a 2ml 
collection tube. Samples were spun at 1 lOOOrpm for 15sec and the flow through discarded. 
RWl buffer (700pl) was added to the column, spun for a further 15sec at llOOOrpm, and 
the flow through and collection tube discarded. The column was transferred to a new 2ml 
collection tube and 500|li1  RPE buffer was twice added to the column, spun for 15sec at 
llOOOrpm and the flow through discarded each time. The column was transferred to a 
1.5ml eppendorf tube where 50pl RNase-free water was added directly on to the 
membrane and spun for Imin at llOOOrpm. To remove any DNA present in the samples 
500jLil of RF-H2O, 5 0 p l  DNase buffer, and 3pi RNase-free-Dnase (lOOOOUnits stock. 
Appendix 1) were added and incubated for Ihr at 37”C. Isopropylalcohol (500pl) was 
added to the samples and left to precipitate overnight at -20”C. Samples were spun for
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lOmin at >10000rpm and the pellet resuspended in SOpl of RF-H2O RNA samples were 
quantified as detailed below then stored at -20*’C until required.
3.3.16 RNA Quantification
Sample RNA was quantified by spectrophotometry. Dilutions (1:20) of the samples were 
made in RF-H2O and transferred in to a Hellma quartz cuvette (Type 105.202-QS, 
Germany). Readings were taken at wavelengths of 260nm and 280nm and the ratio 
between the readings used to estimate the purity of nucleic acid in the sample (^ °^‘™/280nm)- 
The following calculation was used to quantity the RNA in 50pl of sample where 40pg/ml 
corresponds to the quantity of single stranded DNA and RNA at an OD of 1 :
40pg/ml X 260nm reading x dilution x sample volume
3.3.17 LightCycIer Primer Design
New primers (MWG) for use in the LightCycIer were designed using a LightCycIer probe 
design software version 1.0 (Roche). The gene sequence for each gene was inserted into 
the program from Genbank: protein A accession number JO 1786, TSST-1 accession 
number J02615, 16s RNA accession number X80725, and the program set to generate 
primers 16 bases in length (Appendix 2).
3.3.18 LightCycIer DNA Standards
DNA standards were prepared using the method described in 3.2.5. Several PCR reactions 
of E l6 with LightCycIer primers for 16s RNA, TSST-1 (tsi) and protein A (spa) were 
performed and pooled together.
3.3.19 Real Time PCR
Amplification of RNA was carried out using a LightCycIer (Roche) and an RNA 
amplification kit SYBR green 1 (Roche) according to the manufacturer’s instructions. All 
reagents were kept on ice whilst the reactions were being set up. To each reaction 
capillary tube the following reagents were added; PCR grade H2O (10.2pl), LightCycler-
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RT-PCR reaction mix SYBR Green 1 (4pl), Resolution solution (3pi), MgC^ (6mM stock 
solution, 2.4pl), LightCycler-RT-PCR enzyme mix (0.4pl) plus Ipl each of the appropriate 
forward and reverse primer and 3 pi of the appropriate RNA sample or DNA standard 
(Table 14). The capillary tubes were capped, centrifuged for 5sec at SOOOrpm then placed 
into the LightCycIer carrousel. The cycling conditions are comprised of five programs that 
were followed exactly as stated in the LightCycler-RNA Amplification Kit SYBR Green 1 
instruction manual:
1 Reverse Transcription (RT) of template RNA
2 Dénaturation of cDNA/RNA hybrid
3 Amplification of cDNA
4 Melting curve analysis for product identification
5 Cooling the rotor and thermal chamber
In brief, RT was carried out for lOmins at 55°C followed by the following amplification 
conditions: dénaturation for one cycle at 95"'C for 30sec, 45 cycles at 95"^ C for Osec, 
(temperature transition 20°C/sec), 55°C for lOsec (temperature transition 20°C/sec), 72°C 
for 13 sec (temperature transition 2°C/sec) and fluorescence acquisition at IT Q  in single 
mode. Melting curve analysis was performed during one cycle of 95"C for Osec, 
(temperature transition 20°C/sec), 65°C for lOsec (temperature transition 20°C/sec), 95°C 
for Osec (temperature transition O.KC/sec) with step-wise fluorescence acquisition. 
Sequence-specific standard curves were generated by using 10-fold dilutions of specific 
RNA standards (1:10, 1:00, 1:1000). The quantity of mRNA transcripts from each sample 
were determined using the LightCycIer software version 3.2 (Roche).
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Reaction primer
1 E l6 MHB 4hr culture + spa primers
2 E l6 Vz linezolid 4hr culture + spa primers
3 El 6 V2 synercid 4hr culture + spa primers
4 Blank (no RNA) + spa primers
5 E l6 MHB 4hr culture + 16s RNA primers
6 E l6 Vz linezolid 4hr culture + 16s RNA primers
7 E16 V2 synercid 4hr culture + 16s RNA primers
8 Blank (no RNA) + 16s RNA primers
9 E l6 MHB 12hr culture + 1st primers
10 E l6 Vz linezolid 12hr culture + tst primers
11 E l6 Vz synercid 12hr culture + tsl primers
12 Blank (no RNA) + tst primers
13 E l6 MHB 12hr culture + 16s RNA primers
14 E l6 Vz linezolid 12hr culture + 16s RNA primers
15 E16 Vz synercid 12hr culture + 16s RNA primers
16 spa DNA 1:10 + spa primers
17 spa DNA 1:100 + spa primers
18 spa DNA 1:1000 + spa primers
19 tst DNA 1:10 + fyt primers
20 tst DNA l:\00 + tst primers
21 tst DNA 1:1000 + tst primers
22 16s RNA DNA 1:10 + 16s RNA primers
23 16s RNA DNA 1:100 + 16s RNA primers
24 16s RNA DNA 1:1000 + 16s RNA primers
Table 14. LightCycIer reactions
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3.3 RESULTS
3.3.1 Determination of the MIC of standard strains
The MIC (pg/ml) for the control strains used in this section are shown in Table 15.
diljptomycin linezolid Synereld
Wood 46 0.39 0.20 0.78 0.08
NCTC 11963 0.39 0.13 1.56 0.19
NCTC 6571 0.39 0.20 1.56 0.06
119993 1 0.20 0.78 0.10
Table 15. Minimum inhibitory concentration (ug/ml) of standard strains to various antibiotics 
3.3.2 Detection of Virulence Genes
Each strain was subjected to PCR analysis to determine their genetic complement. In each 
case all the test strains plus a positive control were tested for a single toxin gene at a time. 
The distribution of virulence genes in our strains is displayed in Table 16 where N = no 
gene detected and P = positive gene detection. This distribution was used to determine 
which strains would be used in future experiments.
As expected, the genetic complement varied between strains but all carried the genes for 
protein A and a-haemolysin. The clonal strains Mu3 and Mu50 identically carried genes 
comprising 5 enterotoxins (including enterotoxin-like protein-1 (SET-1)) and TSST-1. 
Strains 3700w and 3759 are also identical but only carried enterotoxin A and SET-1, 
differing from EMRSA 16 by one gene, EMRSA 16 has TSST-1 in place of SET-1. VISA 
strains 5827 and 5836 only carry the genes for enterotoxins SEG, SEI and SET-1.
From these findings we chose to investigate the expression of TSST-1, a-haemolysin, 
protein A, and coagulase. The presence of the coagulase gene was not measured as all 
strains demonstrated a positive slide test.
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TW#; 0 0 0 ^
Comma E l6
ir I:
3700W 3759v m y
‘ '4
5836
hv'
M«3
r " ^
m m
sea 120bp N P P P N N p p
seb 163bp N N N N N N N N
sec 271bp N N N N N N P P
sed 319bp N N N N N P N N
see 178bp N N N N N N N N
fgg 327bp P P N N P P P P
sei 465bp N P N N P P P P
sej 142bp N N N N N P N N
sell 677bp P N P P P P P P
tst 445bp N P N N N N P P
eta 741 bp N N N N N N N N
eta 629bp N N N N N N N N
spa variable P P P P P P P P
hly 535bp P P P P P P P P
nuc 280bp P P P P P P P P
16SrRNA 479bp P P P P P P P P
Table 16. Distribution of virulence genes 
3.3.3 Expression of Protein A
An ELISA-based standard curve of different purified protein A concentrations against 
OD405nm readings was constructed (Figure 24) and used to determine the concentration of 
cell bound protein A (IxlO^cells/ml) and that which is present free in the culture 
supernatant per ml.
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Calibration Graph for Protein A
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Figure 24. Purified protein A concentration and optical density (OD^^nm) calibration graph
For each strain five separate cultures were prepared and used in five separate assays. 
Within each assay a culture was tested in triplicate wells to obtain a mean reading. The 
concentration of protein A detected in each of these assays was then calculated from the 
mean OD^osnm readings using the calibration graph above. Statistical analysis was in the 
form of a Student’s t-test. Mean values and standard deviation are given where n = 5.
Strains of VISA vary greatly in their ability to produce protein A either in a surface bound 
or free form even though all carry the spa gene. The protein A negative mutant DU5723 
was included for assay validity and was negative for both surface bound and free protein 
A. Figure 25 shows the production of surface bound protein A per IxlO^cells/ml for 
strains S.aureus Cowan, El 6 and VISA 5827. It should be noted that the results for strains 
3700w, 3759v, 5836, Mu3 and Mu50 are not shown as levels were below the detection 
limit (lOng/ml) of the assay but do not necessarily indicate no expression.
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Surface bound protein A: i) ELISA
As expected S.aureus Cowan, a high protein A producer, expressed the greatest quantity of 
surface bound protein A at 20.5ng/lxl0^ceüs/ml (Figure 25). In addition, only EMRSA-16 
(E l6) and 5827 produced detectable surface bound protein A but at lower levels than that 
of Cowan, strain 5827 was significantly less (pvalue <0.05). None of the antibiotics tested 
had any significant affect on strain 5827 expression of this protein. S.aureus Cowan and 
E l6 were affected in different ways by some of the antibiotics. Cefpirome was found to 
significantly increase expression of surface protein A in Cowan but not in E l6 whereas 
synercid reduced levels in both strains to undetectable levels, as did linezolid in E l6 alone. 
Daptomycin had no significant effect on any strain. It is interesting to note that six out of 
seven VISA strains produced no surface bound protein A and have been omitted from 
Figure 25. The lack of protein A expression has been described previously for strains of 
MRSA by other research groups. To confirm that protein A is not expressed at the cell 
surface and not just undetectable at the concentration of cells tested here the strains were 
incubated with an anti-protein A gold label.
ii) Immunogold-labelling
Several of the strains tested above, including Wood 46 a known low protein A producer, 
were examined for their ability to display surface bound protein A by iimnunogold- 
labelling. Figure 26, as expected, shows S.aureus Cowan displaying a uniform distribution 
of protein A around its surface whereas Wood 46 produced only a single positive reaction 
in comparison. Strains 3759v, 5836, and Mu50 all gave negative results that correlate with 
those achieved by ELISA. Strain E16 gave a strong positive reaction by immunogold- 
labelling similar to that of S.aureus Cowan but was quantified by ELISA to be slightly less 
than that of Cowan. Mu3 was negative by both ELISA and immunogold-labelling 
therefore is a true non-producer of surface bound protein A.
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Figure 25. Expression of surface bound protein A by strains o f S.aureus in the absence and presence o f ^
MIC antibiotics. Readings represent mean +/- standard deviation error bars. * = pvalue<0.05.
90
i
I
i.— 
% I
:o<
c
I
QCo
§<
l
M M
CJ
&E Dh s
A I
Free protein A -  Preliminary Experiment
To establish the limits at which various drugs had no effect on extracellular protein A, the 
protein was quantified by ELISA in culture supernatants of S.aureus Cowan grown in 
MHB in the presence and absence of Vz, Vs, Vi6 and V32 MIC linezolid and synercid 
(Figure 27 and 28). Each graph represents five individual experiments (1-5) with any 
significant difference indicated (* = pvalue <0.05). It was shown that linezolid is effective 
at V2 and % MIC in 4 out of 5 experiments and that synercid is effective at Vz MIC in 5 out 
of 5 experiments. In some instances over expression of protein A was recorded for Vie and 
V32 MIC linezolid and synercid. This is possibly due to loose association of surface bound 
protein A with the cell wall and its release in to culture supernatants, and is variable 
depending upon factors affecting the culture conditions. From these findings the decision 
was made to examine each drug at V2 MIC only for the effect on protein A expression.
Free protein A
Expression of free protein A in MHB is far greater than that produced by any of the strains 
in a cell bound form. The presence of small amounts of extracellular protein A in strains 
that did not produce detectable levels of surface bound protein A was observed. All of the 
strains tested can be divided into three levels of protein expression. S.aureus Cowan, E l 6  
and VISA 5827 expressed similar levels o f >2000ng/ml protein A in culture media alone 
(Figure 29); VISA strains 3759v, Mu3 and Mu50 produced between 30 and 60ng/ml 
protein (Figure 30) whereas 3700w and 5836 failed to produce detectable levels of protein 
A (<10ng/ml) (not shown).
The protein synthesis inhibitors linezolid and synercid both reduced free protein A 
expression. Linezolid dramatically reduced the quantity of free protein in strains Cowan, 
E16, 5827 and Mu3 (Pvalue <0.05). Strains 3759v and Mu50 also displayed reduced 
expression but to non-significant degrees. Synercid gave similar results to linezolid with 
the exception that strains 3759v and 5827 showed significant and insignificant reductions 
in protein A expression respectively. In contrast, daptomycin was found to increase 
protein A expression albeit only significantly in strain 5827. The cell wall inhibitor 
cefpirome both increased and decreased the quantity of protein A detected. The most 
significant increase was observed with S.aureus Cowan. This may possibly be due to the 
partial disruption of the cell wall releasing surface bound protein A. Other authors have
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discovered that some strains of MRSA express free but not surface bound protein A as was 
clearly illustrated with strains 3759v, Mu3 and Mu50/^^'^^^ As these strains displayed 
<10ng/ml of surface bound an increase in expression would not have been expected and 
indeed levels of free protein A were actually reduced in strains 3759v and Mu3 exposed to 
14 MIC cefpirome (Pvalue <0.05).
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Figure 29. Expression o f cell-free protein A by strains of S.aureus in the absence and presence o f MIC
antibiotics. Readings represent mean +/- standard deviation error bars, * = pvalue<0.05
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Figure 30. Expression o f extracellular protein A by strains o f  S.aureus in the absence and presence o f  !6 MIC
antibiotics. Readings represent mean +/- standard deviation error bars, * = pvalue<0.05
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3.3.4 Production of TSST-1
An ELISA-based standard curve of purified TSST-1 concentration against OD^ognm 
readings was constructed (Figure 31) and used to determine the concentration of TSST-1 
in culture supernatants. Statistical analysis was in the form of a Student’s t-test. Mean 
values and standard deviation are given where n = 5.
Calibration Graph for TSST-1
0.32 0.63 1.25 2.5 5
Concentration (ng/ml)
10 20
Figure 31. Purified TSST-1 concentration and optical density (OD^o^nm) calibration graph
From Table 16 the three strains carrying the tst gene were chosen, as was S.aureus Cowan, 
a TSST-1 negative strain and NCTC 11963, a TSST-1 positive strain. S.aureus Cowan 
was included for assay validity and was negative in all assays. As with the protein A 
ELISA there is a detection limit, in this case of 0.32ng/ml. Again levels below 0.32 are 
depicted as zero but does not necessarily mean no expression.
Figure 32 illustrates the varying extent of TSST-1 expression. By far, strains Mu3, Mu50 
and NCTC 11963 (positive control) produced greater quantities of toxin compared to strain 
E l6. As Mu3 and Mu50 are clonal similar degrees of expression and its response to 
antimicrobial agents might be expected. This was true for the levels of toxin detected in 
TSB culture medium only and in the presence of Vz MIC linezolid and synercid which 
significantly reduced toxin expression (pvalue <0.05). Synercid also reduced expression
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of TSST-1 in NCTC 11963 strain but had no effect on E l6 whereas linezolid had the 
opposite effect of increasing expression in E l6 but had no effect on NCTC 11963. 
Cefpirome both induced and repressed TSST-1 expression in Mu3, E16 and Mu50, NCTC 
11963 respectively. Daptomycin had no significant effect on any of the strains tested.
In order to verify that the toxin measured by ELISA was truly TSST-1 as measured in 
standard biological assays Tcell stimulation and Tcell proliferation assays were carried out 
with both crude and purified toxin preparations.
3.3.5 Activation of Tcell Receptor CD69
Jurkat cells are a Tcell tissue cultuie cell line with similar characteristics to those of 
Tcells. Numerous attempts to activate CD69 receptor failed with both our own culture 
supernatants containing TSST-1 and purified TSST-1 even though stimulation was 
observed with tire phytohaemaggultanin / phorbol myristate acetate (PHA/PMA) positive 
control (Figure 33). The same assay using freshly isolated PBMCs from healthy donors 
was also tried, but this also proved to be an inadequate assay. The cells were being killed 
by components within the culture supernatants. As the TSST-1 has not been purified all of 
the proteins and enzymes expressed by our strains under antibiotic stress are still present 
and clearly have a detrimental effect on human Tcells (Figure 34).
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Figure 32. Expression o f TSST-1 by strains o f  S.aureus in the absence and presence o f  MIC antibiotics.
Readings represent mean +/- standard deviation error bars, * = pvalue<0.05
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Mouse IgG non-specific receptor binding
Background CD69 expression (red)
Stimulation of Jurkat cells with lOng/ml of 
purified TSST-1 (green)
Stimulation o f CD69 by 5ug/ml 
PHA/25ng/ml PMA
FITC Fluorescence Intensity
Figure 33. Expression of CD69 receptor by Jurkat cells following stimulation by 
purified TSST-1 and PHA/PMA.
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Figure 34. Expression of CD69 on PBMC in RPMI culture medium (control) and after exposure to 
the culture supernatants of strain NCTC 1 1963 exposed to 14 MIC daptomycin (stimulated). Viable 
cells from the population are not detected following stimulation with culture supernatants.
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3.3.6 Tcell Proliferation Induced by Culture Supernatants
With the above results in mind the proliferation of human Tcells was examined using the 
same culture supernatants tested in the ELISA. Each culture was tested in triplicate and the 
mean count of methyl ^^^thymidine incorporation calculated and compared to the Tcells 
plus medium control (Figure 35, Table 17).
One in ten dilutions of E l6, Mu3 and Mu50 culture supernatants all stimulated Tcell 
proliferation in excess of typical Tcell proliferation. The degree of proliferation does not 
appear to be concentration dependent as indicated by the TSST-1 standards. The reduced 
level of proliferation seen using lOOpg/ml of purified TSST-1 may be due to killing of the 
PMBCs through apoptosis. With regard to the reduced levels of TSST-1 produced by 
strains upon exposure to V2 MIC synercid as detected by ELISA, there is no apparent 
relationship between the level of toxin produced and the degree of Tcell proliferation 
observed. As we are only looking at the production of one individual toxin the reduction 
in TSST-1 production by V2 MIC synercid may not be true of all superantigens some of 
which may be being stimulated. The high level of proliferation observed with the bacterial 
supernatants is greater than that caused by O.Olpg/ml to lOOpg/ml of purified TSST-1 
indicating that there are other factors present within the culture supernatants that may exert 
specific or non-specific Tcell stimulation, such as the enter otoxins. This would be a fitting 
assumption especially as Mu3 and Mu50 have the capability to express an additional four 
enterotoxins. Strain E l6 only carries SEA in addition to TSST-1 which would agree with 
the reduced levels of Tcell proliferation in comparison with Mu3 and Mu50. Thus it can 
be established that the levels of TSST-1 detected with antibiotic treatment is expressed in a 
biologically active form capable of exerting superantigenic properties upon Tcells.
Standard ihethyl ^"thymidine incorporation ( cpm)
TSB Broth 7141
PBMC 7324
O.lpg/ml TSST-1 27540
Ipg/ml TSST-1 29511
lOpg/ml TSST-1 33898
lOOjLig/ml TSST-1 16512
Table 17. Standards included in an assay o f  PBMC proliferation
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Figure 35. Human peripheral blood mononuclear cell (PBMC) proliferation induced by 1:10 dilutions of 
culture supernatants from strains of S. aureus grown in the absence and presence of MIC o f each antibiotic.
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3.3.7 Haemolytic Activity of Alpha-Haemolysin (a-toxin)
Haemolytic activity in E l6 and the VISA strains, with the exception of Mu50, is very low 
in comparison to S.aureus Cowan and Wood 46 the positive control strain (Table 18). The 
haemolytic activity of the VISA strains ranges from zero to 32 haemolytic units (HU). 
Strains Mu50, Cowan and Wood 46 display titres of 64HU, 64HU and 1024HU 
respectively. VISA 5836 did not have any apparent haemolytic activity in culture medium 
alone and was only detectable with neat culture supernatants in cultures grown in the 
presence of Vi and % MIC of all drugs.
One half linezolid was the only drug to have a uniform effect against all of the strains 
tested reducing activity to between zero and 4HU, and reducing Wood 46 activity from 
1024HU to 512HU. Synercid reduced the level of a-toxin expression at Vi MIC in 16hr 
cultures of S.aureus Cowan, El 6, 3759v and Mu50, had no effect on Mu3, and increased 
expression in strains 3700w and 5827 but only by one dilution. Daptomycin decreased 
activity in Cowan, 3759v and Mu50 and increased it in 5827 and Mu3 but again only by 
one dilution. No effect was observed in cultures of E l6 and 3700w. At Vi MIC, 
cefpirome was most effective at reducing alpha haemolytic activity of Mu50 from 64HU to 
8HU. Other strains with reduced activity were 3700w, 3759v, 5827 and Mu3 by one 
dilution and strain 5836 was increased by one dilution. Haemolytic activity of Cowan and 
E l6 was unaltered. One-quarter MIC’s were also effective against some strains.
W ood# Cow«n Eld 37#w 375^ sa i7 s m MnS
1-!
Mo5»
No drug 1024 64 8 2 32 2 0 16 64
'/2 MIC CEF 1024 64 8 0 16 0 Neat 32 8
'/4 MIC CEF 2048 128 16 Neat 32 4 Neat 64 64
>/2 MIC DAP 1024 32 8 2 16 4 Neat 32 32
% MIC DAP 1024 32 8 4 16 4 Neat 32 128
'/2 MIC LZD 512 2 2 0 4 Neat Neat 4 0
% MIC LZD 512 32 16 4 16 4 Neat 16 8
>/2 MIC SYN 1024 32 2 4 4 4 Neat 16 8
% MIC SYN 1024 64 2 4 8 4 Neat 16 64
Table 18. Haemolytic activity o f alpha-haemolysin against rabbit erythrocytes. Results represent the mean of  
4 experiments
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3.3.8 Coagulase
3.3.8.1 Clumping Factor
Table 19 shows the Shr coagulase titres for clumping factor present on the surface of 
IxlO^celIs/ml following growth in the absence and presence of % and % MIC linezolid, 
cefpirome, synercid and daptomycin. The activity of clumping factor was determined after 
8hrs incubation as this time proved optimal; later readings (24hrs) were not taken as the 
microtitre plate contents had dried out.
Linezolid had the greatest effect on clumping factor expression by S.aureus Cowan 
increasing titres from 1024 units to 8192 units with % MIC. Strains 3700w and Mu3 were 
the only other strains to produce increased levels of expression but only by a single 
dilution. The remaining strains all displayed reduced expression. Strains E l6, 3759v, 
5827 and Mu50 all displayed reduced clumping factor activity when grown in the presence 
of Vi MIC cefpirome and surprisingly clumping factor titres of Cowan, 5836 and Mu3 were 
reduced by one or two dilutions when grown in the presence of % MIC but not Vi MIC 
cefpirome. Clumping factor production by strain 3700w remained unaffected by 
cefpirome. Synercid was also a potent reducer of coagulase activity in all strains with the 
exception of Cowan and 3700w grown in the presence of % MIC. Daptomycin generally 
had little impact on the production of clumping factor; activity of strains 3759v and 5827 
was reduced by V2 MIC and both V2 MIC and % MIC respectively. The remaining strains 
showed no real variation in their titres of clumping factor.
"*N,,^ STRAIN p p i w i
1 iij : , (
m » r n
i. ; 1
p i iM M
-, 'f
MiiSO PCTCv
«571
No drug 1024 4096 128 128 256 32 128 256 256
'/2 MIC CEF 1024 1024 128 64 64 32 128 64 256
% MIC CEF 512 4096 128 128 64 8 64 256 512
>/2 MIC DAP 1024 4096 128 64 128 32 256 256 512
'/4 MIC DAP 4096 2048 128 128 128 32 64 256 256
'/2 MIC LZD 2048 1024 256 128 32 16 128 64 128
% MIC LZD 8192 512 256 64 64 16 512 128 256
'/2 MIC SYN 512 256 64 32 64 16 32 128 128
'/4 MIC SYN 4096 512 256 64 64 16 64 128 256
Table 19. Clotting activity of staphylococcal clumping factor. Results represent the mean of 4 experiments
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3.3.8.2 Cell Free Coagulase
Figures 36-39 illustrate the titres of cell free coagulase in 16hr culture supernatants from 
bacteria grown in the absence and presence of V2 and % MIC linezolid, ceipirome, synercid 
and daptomycin. Each graph represents the mean (of four assays) titre of coagulase.
Titres of free coagulase were generally found to be lower than those of clumping factor. In 
response to the presence of antibiotics in the growth medium the majority o f strains 
exhibited reduced coagulase titres. Exceptions were observed in cultures of S.aureus 
Cowan where greater activity in the presence of % and % MIC linezolid was recorded. 
Coagulase expression by strains 3759v and NCTC 6571 was increased in the presence of 
all of the antibiotics. Strain Mu50 was unaffected by the presence of daptomycin in the 
culture medium.
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3.3.9 RNA Quantification
RNA isolation from cell cultures proved to be difficult. Several attempts were made to 
isolate RNA using a method adapted from the manufacturer’s instructions for TRIzol 
(Sigma). However, this method was time consuming and laborious and was substituted by 
the Qiagen RNeasy Mini RNA isolation kit due to its rapid isolation procedure.
Several preparations of RNA were made although RNA was undetectable by 
spectrophotometry and on agarose gels. Those preparations that were quantifiable are 
detailed in Table 20.
ODamam " • / « Yield og/ail
E l6 4hr No drug 0.44 0.24 1.8 11
E16 4hr % MIC LZD 0.40 0.27 1.45 10
E16 4hr% M lC SYN - - - -
E16 12hr No drug 0.5 0.4 1.25 12.5
E l6 12hr'/2 MICLZD 0.33 0.25 1.32 &25
E l6 12hr‘/2MIC SYN 0.17 0.095 1.79 4.25
Table 20. Quantification of RNA isolated from cultures o f EMRSA-16.
For each time point, 4hrs and 12hrs, a culture of El 6 in RF-MHB only and in the presence 
of V2 MIC linezolid and V2 MIC synercid were prepared and the RNA extracted. Using the 
following calculation: 40pg/ml x 260nm reading x dilution x sample volume (0.05ml), 
the purity of nucleic acid and the yield of RNA from each culture was determined. RNA 
from 4hr cultures of E16 in the presence of Vi MIC synercid could not be quantified by 
spectrophotometry but RNA was visible on agarose gels (Figure 40).
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Figure 40. RNA extracted from 4hr and 12hr cultures of El 6 in the absence (lanes 2 and5) and presence of 
MIC linezolid (lanes 3 and 6) and synercid (lanes 4 and 7) respectively
3.3.10 Transcription of spa and tst mRNA
Cultures of EMRSA-16 were set up at two time points, 4hrs and 12hrs in drug free medium 
and in the presence of Vi MIC linezolid and synercid. From this the levels of spa (protein 
A) and tst (TSST-1) mRNA transcripts were quantified respectively. Difficulties with non­
specific annealing of the tst primers were encountered using a range of annealing 
temperatures (50-55”C) resulting in primer-dimer and non-specific PCR products. Figures 
41 and 42 show the melting curves and DNA products produced using the RNA isolated 
from 12hr cultures of E l6 and tst primers with annealing temperatures of 54“C and 50”C 
respectively. As illustrated in Figure 41 there are two main products in the TSST-1 DNA 
standards with a different set o f peaks being observed in the three RNA samples. The 
products were run on an agarose gel (Figure 41) and were found not to be of 467bp, the 
expected size of any TSST-1 product. As some of the products are probably as result of 
mispriming and primer-dimer formation the annealing temperature was lowered to 50°C 
and the experiment repeated using the same samples of RNA (Figure 42).
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Reducing the annealing temperature to 50®C did not improve the specificity of the tst gene 
primers. Here, the products amplified in the DNA standards were all the same but differed 
from those found in the sample of RNA. From the melting curve it would appear that there 
is veiy little product in the three RNA samples so the products were run on an agarose gel 
(Figure 42). No products could be detected in the RNA samples. Why the tst primers 
should amplify multiple products is unclear. One reason may be the lack of specificity of 
the primers but this should not be the case as the primers were designed using the 
LightCycler probe design software.
The above problems were not encountered with the 4hi' RNA samples. Although some 
primer-dimer products were obsei"ved, the main product amplified from the protein A DNA 
standards and the thi’ee RNA samples were identical. Using 16S mRNA as the reference 
transcript it was shown, that after 41ns incubation, growth in MIC linezolid gave rise to 
twice as much spa mRNA as that present in drug free cultures, and that cultures with 14 
MIC synercid produced double the quantity of spa mRNA (Figure 43). In Chapter Two 
partial inhibition of bacterial growth due to exposure to 14 MIC linezolid and synercid was 
found such that at 4hrs, growth was reduced by more than 14 a log by 14 MIC linezolid and 
Hog by 14 MIC synercid. This has not, however, appeared to have had an effect on mRNA 
synthesis. It is surprising therefore that, according to the findings by ELISA, both surface 
bound and extracellular protein A are reduced upon exposuie to these antimicrobial agents, 
thus suggesting that the mRNA is transcribed, but is not translated into mature protein.
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DNA 1:10DNA 1:100
DNA 1:1000No drug
V2 MIC synercid 
Vi MIC linezolid
blank X
B
1 2 3 4 5 6 7 8  9
lOObp DNA ladder
tsî 467bp 500bp
400bp
Figure 41. A: Melting curve analysis of mRNA isolated from 12hr cultures of El 6 in the absence and 
presence of 16 MIC linezolid and synercid. Annealing temperature 54°C. B: LightCycler products producing 
the melting curve in A run on an agarose gel. Key: lanes 1+9 = DNA ladder, lane 2 = no drug, lane 3 = 16 
linezolid , lane 4 = 16 synercid, lane 5 = blank, lane 6 = 1:10 DNA standard, lane 7 = 1:100 DNA standard, lane 
8 = 1:1000 DNA standard
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DNA : 0
DNA : 000
blank
' / 2  MIC synercid
No drug (blue) I I V2 MIC linezolid (green)
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500bp
400bp
tst 467bp
Figure 42. A: Melting curve analysis of mRNA isolated from I2hr cultures of EI6 in the absence and 
presence of V2 MIC linezolid and synercid. Annealing temperature 50°C. B: LightCycler products producing 
the melting curve in A run on an agarose gel. Key: lanes 1+9 = DNA ladder, lane 2 = no drug, lane 3 = V2 
linezolid , lane 4 = V2  synercid, lane 5 = blank, lane 6 = 1:10 DNA standard, lane 7 = 1:100 DNA standard, lane 
8=1:1000 DNA standard
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Figure 43. Expression o f protein A (spa) mRNA transcripts by EMRSA-16 in comparison with optical 
density of 4hr cultures in the absence and presence o f  !6 MIC linezolid (LZD) and synercid (SYN).
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3.3 DISCUSSION
Although the precise mechanism of action is known for the antibiotics linezolid, cefpirome 
and synercid, the bacterial target of daptomycin remains to be clarified. Studies in to the 
efficacy of these agents in animal infection models and in compassionate use programs 
against Gram-positive bacteria have provided promising results. Their effects on protein 
and toxin biosynthesis remain to be clarified.
The strains of vancomycin-intermediate S.aureus (VISA) used in this study differ from 
strains of MRSA and MSSA in their phenotypic characteristics. In Chapter Two I showed 
that several of the VISA strains exhibited thickened cell walls in comparison to a strain of 
MRSA, EMRSA-16, and MSSA S.aureus Cowan. In this chapter it was noticed that only a 
single strain of VISA, strain 5827, was capable of expressing surface bound protein A. 
Several strains, including strain 5827, expressed extracellular protein A. Strains 3700w 
and 5836 were negative for both forms of protein A. It has been described previously that 
some strains of MRSA do not express cell bound but extracellular protein A. The reasons 
for this are unclear but is a phenomenon mirrored here in strains of VISA.
The action of other antimicrobial agents on the expression of surface proteins and
exotoxins from numerous bacterial species has been extensively reported. The activity of
antibiotics has been demonstrated to vary between bacterial species and strains often with
contradictory results. For example, sub-inhibitory concentrations of clindamycin inhibit
the production of coagulase, protein A, TSST-1 and a-haemolysin by S.aureus but can also
stimulate the expression of enterotoxins in other Gram-positive and Gram-negative 
bacteria. 117.123.124.127.130.152.211.266,304,310
The results presented here indicate that the activity of the antimicrobial agents cefpirome, 
daptomycin, linezolid and synercid varies towards different strains of S.aureus. In each of 
the experiments employed here the quantification and/or activity of surface proteins and 
extracellular toxins was measured follovring the incubation of strains in sub-MIC 
antibiotics for 16hrs. Sub-MIC linezolid and synercid were found to have no effect or 
reduce the expression of surface proteins protein A, and coagulase/clumping factor in the 
majority of strains but differed in their effect on alpha-haemolysin and TSST-1 activity.
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Synercid increased alpha-haemolysin activity in three out of eight strains and reduced it in 
three out of eight strains, whereas linezolid reduced alpha-haemolysin activity in seven out 
of the eight strains. Both reduced TSST-1 expression in two out of three strains, Mu3 and 
Mu50. A recent publication by Gemmell and Ford (2002) showed that linezolid reduced 
alpha-haemolysin and coagulase expression at concentrations of !4 MIC to Vg MIC in two 
strains of MSSA.^^^ As yet, no reports of any activity of synercid on virulence factor 
expression have been published. However its ability to inhibit protein biosynthesis albeit 
at a different site from linezolid, would suggest similar results. This was not the case. 
Sub-MIC synercid increased alpha-haemolysin expression in strains 3700w, 5827 and 
5836, but it should be emphasised that in the absence of any drug, haemolysin expression 
was very low and that increases were by a single dilution only.
Quantification of protein A messenger RNA {spa mRNA) transcripts from 4hr cultures of 
strain E l6 was carried out to establish whether sub-MIC linezolid and synercid affected 
the levels of mRNA expression in addition to the levels of protein. At 4hrs, the presence 
of !4 MIC linezolid and synercid exerted bacteristatic properties on the growth of E l6; 
however, the number of copies of spa mRNA was increased in comparison to the no drug 
control. This would suggest that these protein synthesis inhibitors inhibit the translation of 
mRNA in to mature protein resulting in decreased levels of protein A expression. These 
findings support the mechanisms of action suggested for linezolid and synercid
A hypothesis to the variable expression of virulence factors in response to clindamycin was 
proposed by Gemmell (1982). It was suggested that the ribosomes involved in the 
transcription of mRNA are dispersed through out the bacterial cell, some of which are 
associated at the cell membrane. It is the ribosomes present at the cell membrane that 
would interact with and be affected by antibiotics penetrating the bacterial cell allowing a 
degree of protein expression to be carried out by ribosomes present in the cell cytoplasm 
(Figure 44). It is also possible that protein synthesis inhibitors may influence toxin 
expression, in part, through the impainnent of growth.
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Figure 44. Proposed model to explain how protein synthesis inhibiting antibiotics might affect expression of 
proteins and toxins in S.aureus
Daptomycin, an antibiotic with cell membrane activity, had no effect on the expression of 
protein A in either form from any strain or on clumping factor in five out of the eight 
strains. A possible reason for our findings may be that at MIC neither the expression of 
protein A and clumping factor is sufficiently affected nor is peptidoglycan biosynthesis 
sufficiently affected at this concentration for any effects on the cell wall and the 
incorporation of surface proteins to be detected. Extracellular coagulase activity, however, 
was reduced in the majority of strains suggesting that daptomycin inhibited the release of 
extracellular coagulase through interference of the bacterial cell membrane potential. 
Nevertheless why the export of extracellular protein A should not be affected is unclear; it 
is possible that the protein had become detached from the cell surface. Daptomycin 
exposure did not alter the expression of TSST-1 in any strain and only altered the 
expression of alpha-haemolysin by a single dilution.
The bacterial target for daptomycin is believed to be lipoteichoic acid (LTA) synthesis at 
the cell membrane although instances of cell membrane disruption and inhibition of 
peptidoglycan synthesis have also been proposed as sites for daptomycin activity. It has 
been demonstrated that daptomycin cannot enter the cytoplasm so its effects can only be
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exerted on those proteins present at the cell membrane. In the presence o f daptomycin at 1 
X MIC S.aureus has been shown to display inhibited growth but strains of enterococci grew 
equally as well as cells in no drug cultures suggesting that daptomycin is bacteristatic."*^ In 
this study only strain 3759v was inhibited at V2 MIC daptomycin but as the aforementioned 
study was carried out at 1 x MIC, sub-inhibitory concentrations may not be sufficient to 
inhibit growth in S.aureus.
Should sub-MIC daptomycin be sufficient to disrupt bacterial cell membrane potential, 
leakage of the cell cytoplasm would occur releasing any intracellular proteins and toxins. 
As this was not the case it would suggest then, at V2 MIC and % MIC, daptomycin does not 
influence the expression o f virulence factors through the disruption o f the bacterial cell 
membrane. It is possible that as certain aspects of protein synthesis do take place at the 
cytoplasmic membrane, daptomycin may exert an effect on protein synthesis. Strain 3759v 
appears to react differently from the other strains in response to the stress exerted upon the 
cell by daptomycin. Growth inhibition and the increased expression of cell free coagulase 
may result indirectly from LTA inhibition as proposed by Canepari et al (1990/^ or 
directly through an action on ribosomes at the cell membrane (Figure 45).
Bacterial Cell Membrane
daptomycin
Cell wall
Cytoplasmic ----- ^
membrane
Cytoplasmic 
ribosomes ---------^
Inhibited LTA synthesis 
and destabilisation of 
cell membrane
Binding of 
daptomycin to 
membrane 
associated 
ribosomes
Figure 45. Proposed model for daptomycin inhibition o f lipoteichoic acid (LTA) synthesis and low-level 
expression of proteins and toxins in Gram-positive bacteria
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The cell wall inhibitor cefpirome was found to increase the expression of both surface 
bound and extracellular protein A on strain S.aureus Cowan, probably as a result of 
disruption of the cell integrity releasing fragments in to culture supernatants. All of the 
other strains found to express extracellular protein A and the expression of clumping factor 
by all strains were either unaffected or expressed at reduced levels. Disruption of the cell 
wall may be responsible for reducing the incorporation of surface proteins in to the 
bacterial cell wall. Toxin and cell free coagulase expression was found to be reduced in 
the majority of strains. Alpha haemolysin expression was only altered by a single dilution 
in all strains except for strain Mu50 where expression was reduced 3 fold.
In a report by Ohlsen et al (1998) on the expression of alpha-haemolysin by S.aureus strain 
Wood 46 in the presence of % MIC of |3-lactam, cephalosporin and aminoglycoside 
antibiotics, alpha-haemolysin production was found to be increased due to increased hla 
mRNA expression. In the same study, glycopeptides were found to have no effect on 
alpha-haemolysin expression whilst protein synthesis inhibitors had variable effects.
Using % MIC methicillin and strains of MSSA and MRSA, it was possible to demonstrate 
that increases in hla mRNA were strain specific and that strain specific regulatory 
mechanisms determined the extent of alpha-haemolysin expression in the presence of 
methicillin. Non-stimulation of alpha-haemolysin expression by a p-lactam with no anti- 
staphylococcal activity suggests induction of hla expression may depend upon interaction 
of p-lactams with PBPs inducing a signal transduction mechanism that activates the toxin 
promoter (Figure 46).^ "^ *^  It was also established that the enhanced expression observed in 
the presence of p-lactam antibiotics is specific, independent of RNAIII regulation, and not 
due to the destabilization of the bacterial cell wall or accumulation of cell wall 
precursors.^^^
In contrast to the above findings, we found that toxin expression was inhibited by the 
presence of % MIC cefpirome. It is possible that as the strains studied here display 
vancomycin-intermediate resistance in addition to being strains of MRSA that the signal 
transduction mechanisms have an altered function in strains of VISA in response to 
additional factors that differentiated VISA from strains of S.aureus and hfRSA.
1 2 2
Bacterial Cell
Penicillin binding 
proteins (PBPs)
Binding of P-lactam 
antibiotic to PBPs
Active
ribosome Mature protein
Increased hla 
mRNA expression
P-lactam antibiotic
Figure 46. Proposed model for the activation of alpha-haemolysin expression in the presence o f P-lactam 
antibiotics in Gram-positive bacteria
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C H A P T E R  F O U R
D o  A n t i m i c r o b i a l  A g e n t s  I n f l u e n c e  B a c t e r i a l  S u s c e p t i b i l i t y
to P h a g o c y t o s i s ?
4.1 INTRODUCTION
As discussed in section 1.6, neutrophils will form phagosomes around opsonised bacteria 
attached to their surface. Once contained intracellularly, the phagosome is fused with 
lysosomes fonning a phagolysosome. During the process of bacterial ingestion, 
extracellular oxygen is taken in leading to an increased respiratory burst. It is this process 
of respiratory burst, the breakdown of oxygen into O2' + H2O2, that can be measured as an 
indicator of bacterial ingestion and presumably killing. Resistance to phagocytosis can also 
be measured.
In 1972, Allen et al. first described the phenomenon of PMNL chemiluminescence during 
bacterial phagocytosis and it has been used in many applications since, one of which is as 
an indicator of leukocyte metabolic activity and has been used to screen for oxidative 
metabolism defects in neutrophils such as those occurring in patients with chronic 
granulomatous disease (CGD).^^ Chemiluminescence provides simple, wide ranging yet 
highly sensitive measurements. The reaction is dependent upon the availability of oxygen, 
O2 ' and H2O2, and the activity of oxidase and myeloperoxidase (MPO).^^^
Chemiluminescence originates from the relaxation of singlet oxygen and electronically 
excited oxidative radicals such as H2O2, O2' and hydroxyl radicals produced by metabolic 
burst. Relaxation of these excited molecules back to the ground state dissipates energy 
as light emission. Light emissions can be amplified by the addition of luminol, increasing 
sensitivity. In the presence of substrates such as uric acid and glucose, luminol is oxidised 
to aminophthalic acid generating hydrogen peroxide (H2O2). Relaxation of aminophthalate 
anions results in light emission.”  Luminol-enhanced chemiluminescence is primarily 
from myeloperoxidase (MPO) dependent production of H2O2 although hypochlorous acid 
(HOCL) formation from H2O2 and CL by MPO may diffuse from the PMN aiding the 
conversion of luminol to aminophthalate anion and light.
To assess the susceptibility of our strains to phagocytic ingestion we pre-incubated each 
strain with pooled human serum so that complement components, mainly C3b, bind to the 
bacterial surface as in an in vivo infection, promoting phagocytic ingestion. Isolation of 
fresh human PMNL cells from blood donations provided phagocytically active neutrophils.
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4.2 M ATERIALS AND M ETHODS
4.2.1 Bacterial Strains
The bacterial strains used are those referred to in section 2.2.1. Strains S.aureus Cowan, 
EMRSA-16, VISA 3700w, 3759v, 5827, 5936, Mu3 and Mu50 were maintained on fresh 
CBA plates and grown for 16hrs in MHB only, and in the presence of % or % MIC 
concentrations of each of the antimicrobial agents, in a shaking incubator at 3TC  150rpm 
prior to each experiment. Cells were washed tlirice in sterile saline and adjusted to 
OD62onm^ IxlO^cells/ml.
4.2.2 Preparation of Antimicrobial Agents
The antibiotics used were cefpirome, daptomycin, linezolid and synercid as previously 
described in section 2.2.3. Each antibiotic was freshly prepared to the required 
concentration in 10ml volumes of MHB. Broth supplemented with lOmg/ml C a^  was used 
with daptomycin.
4.2.3 Serum Isolation
Fresh blood from healthy adult donors was obtained by venipuncture and allowed to clot. 
The serum of five donors was pooled and aliquoted after centrifugation at lOOOrpm for 
15min. Aliquots were stored at -70°C until use.
4.2.4 Opsonization of Bacteria
Prior to use bacteria were adjusted to the required optical density then opsonised in an 
equal volume of 10% normal pooled serum (NPS) (Appendix 1) for 15mins in a shaking 
incubator at 37"C 150rpm. Cells were centrifuged at SOOOrpm for 15min and re-suspended 
in their original volume of gel-Hank’s (Appendix 1) for immediate use.
4.2.5 Preparation of Polymorphonuclear Leukocytes
The isolation of polymorphonuclear leukocytes (PMNL) was carried out according to the 
method described by Boyum et Fresh whole blood was obtained by venipuncture 
from healthy adult volunteers and carefully layered in 5ml volumes on top of 5ml of
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polymorphprep (Nycomed Pharma AS, Oslo, Norway) in 10ml sterile conical test tubes 
(Life Technologies, Paisley, UK). Centrifugation was earned out in an lEC Centra-4x 
centrifuge at ISOOrpm for 30min. Two layers of white blood cells are visible, the lower of 
which contains the PMNL. This layer was removed using a sterile Pasteur pipette and 
washed with gel-Hanks at ISOOOrpm for 15min. The washed cells were pooled, counted in 
a haemocytometer and adjusted to a concentration of 1x10^ PMNL/ml with gel-Hank’s 
(Appendix 1).
4.2.6 Phagocytic Ingestion
Phagocytic ingestion of bacteria was examined using cytospin preparations. Equal 
volumes of opsonised bacteria (1x10^) and PMNL (1x10^) were incubated in a Stuart 
orbital shaking incubator SI50 (Bibby Sterilin Ltd, Stone, Staffordshire, England) at 3TC, 
at 150rpm for 30min. Ice-cold PBS was used to stop the reaction and to wash the cells 
three times to remove any unphagocytosed bacteria. Cells were re-suspended in their 
original volume of gel-Hanks from which 100pi was removed into 1ml PBS to dilute 
samples. Five hundred microlitres of this solution was transferred to a cytospin chamber 
assembled with silane coated slides (Appendix 1) according to the manufacturer’s 
instructions. Slides were spun at 500rpm for 5min in a Cyto-tek centrifuge (Miles Inc, 
Elkhart, Indiana, USA), air dried, then stained with Leishman’s stain (Appendix 1). PMNL 
with ingested bacteria were examined at xlOOO magnification.
4.2.7 Measurement of Chemiluminesence
One hundred microlitres of opsonised bacteria (5x10^) were incubated with 50pl freshly 
isolated PMNLs (IxlO^cells/ml) and 50pl luminol (10'^ M) (Merck, Darmstadt, Germany) 
to give a ratio of 100:1. The luminescence output was recorded continuously for 75min in 
a Bio-Orbit Luminometer 1251 (Bio-Orbit, Turku, Finland) connected to an IBM PS/1 
computer terminal with ‘MultiUse’ software package installed. The reaction was carried 
out at 37”C and the peak activity expressed in mV.
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4.3 RESULTS
4.3.1 Phagocytic Ingestion of Bacteria
Phagocytic ingestion was measured by counting the number of bacteria within 100 
randomly selected PMNL and the average number of bacteria per cell calculated. The 
percentage of PMNL ingesting bacteria was also calculated using the same 100 randomly 
selected cells (Figures 48-49, Tables 21 and 22). Readings represent the mean +/- standard 
deviation for 3 experiments as determined by a Student’s T-test using a Minitab statistical 
package.
^  . A
Figure 47. Bacterial ingestion by PMNL x7000 magnification
The mean number of bacteria per PMNL was between 7 and 10 for all strains grown in 
culture medium alone occurring within 35 to 61% of PMNL. A higher proportion of 
PMNL (>50%) ingested strains E l6, Mu3 and Mu50 compared to the other strains even 
though the numbers of bacteria per cell were similar. Strain 5827 was the only strain to 
have its uptake affected by antimicrobial action. Cefpirome, linezolid and synercid each 
increased the number of bacterial cells per PNML (pvalue <0.05) however, the apparent
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increased susceptibility to opsonophagocytosis was not correlated with an increased 
percentage of PNML actively phagocytosing strain 5827. Significant differences in the 
percentage of phagocytosing PMNL were noted with PMNL exposed to V2 MIC cefpirome 
and linezolid treated Mu3 and V2 MIC cefpirome, linezolid and synercid treated Mu50. It 
is possible that the 1:1 ratio of bacteriaiPMNL was insufficient and that the majority of 
available bacteria have been ingested as seen by the consistent counts, and that the variable 
PMNL activity is representative of the different ingestion capabilities observed with 
PMNL preparations.
Cowan " E16 3700w 3759v 5827* &S836 Mu3 MuSO
Bacteria Per 
PMNL
8 . 2  ± 1 . 2 7.6 ± 1.3 9.7 ± 1.3 9.1 ± 1.8 7.3 ±0 .7 9.3 ± 1.6 7.8 ± 1.4 6.8 ±0.5
% ingestion 
by PMNL
37.7 ± 7 57+11 38.7 ± 14 49.7 ±8.5 36.3 ± 19 41 ± 6 61 ±8.9* 55.3 ±7.2
Table 21. Mean number of ingested bacteria per PMNL and the percentage (%) of PMNL ingesting bacteria 
in comparison with MSSA Cowan. Readings represent mean +/- standard deviation. *= pvalue <0.05.
% No drug cefpirome daptomycin i  linezolid synercid
Cowan 8.2 ± 1.2 8.7 ± 1.2 8.9 ± 1.5 7.3 ±1.4 6.9 ±2.5
E16 7.6 ± 1.3 6.9 ± 1.3 8.3 ±1.7 7.3 ±0.8 6.1 ±0.7
3700w 9.7 ± 1.3 13.8 ±2.8 10.7± 1.5 11.7±2.7 10.9 ±0.8
3759V 9.1 ± 1.8 6.8 ± 1.2 8.6 ±0.6 7.8 ±0.7 7.2 ± 1.5
5827 7.3 ±0.7 14.9 ±2.8 ♦ 9.7 ± 1.3 13.1 ±0.3 * 12.5 ± 1.7*
5836 9.3 ± 1.6 11.4 ± 1.6 10.3 ± 1.1 10.9 ± 3 10.4 ± 1.9
Mu3 7.8 ± 1.4 6.2 ± 0.9 10 ±0.04 6 ±  1.3 6.1 ±0.7
Mu50 6.8 ±0.5 6.3 ±1.3 8.8 ± 2 5.7 ± 1.3 5.3 ± 1.5
Table 22. Mean number of ingested bacteria per PMNL, Readings represent mean +/- standard deviation, *= 
pvalue <0.05. It should be noted that a variety of PMNL preparations were used in the above experiments and 
comparisons should be made within an experiment.
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4.3.2 Phagocytic ingestion of bacteria as determined by the release of a 
chemiluminescence response
Table 23 and Figures 50 and 51 illustrate the chemiluminescence peak response (mV) 
elicited by E l6 and the VISA strains in comparison to Cowan, and the effect of drug 
treatment on this response within strains respectively. The peak response represents the 
maximum light emission, in millivolts (mV), achieved by each strain that can be 
interpreted as maximal respiratory burst and therefore phagocytic uptake. As more oxygen 
is taken up from the environment during phagocytosis there is more available for 
conversion to H2O2 and detected by chemiluminescence. Statistical analysis was in the 
form of a Student’s t-test. Mean values and standard deviation are given where n = 10.
Cowan 3700W 37S9V 5*27 5836 M «3 MnSe a : 6
Peak Response 
(mV)
27.1 
(s.d 14.3)
29.4 
(s.d 7.2)
9.05 
(s.d 5.7)
24.9 
(s.d 11.9)
29.3 
(s.d 8.5)
34.7 
(s.d 13.4)
40.7 
(s.d 13.1)
42.6 
(s.d 8.7)
F-value ***** 0.653 0.003 0.717 0.687 0.237 0.041 0.011
Table 23. Chemiluminescence response (mV) by strains of S.aureus compared to that of MSSA Cowan 
standard strain
In comparison to S.aureus Cowan VISA 3759v produced a much lower 
chemiluminescence response whilst Mu3 and Mu50 produced elevated responses (pvalue 
<0.05). Observations not recorded by the microscopic assay of stained cells.
Growth of cultures in the presence of V2 MIC and % MIC cefpirome, daptomycin, linezolid 
and synercid did not alter the opsonophagocytic susceptibility of strains S.aureus Cowan, 
3700w, 5827 or 5836. Daptomycin in particular made no significant impact on any of the 
strains tested. Cefpirome both increased and decreased chemiluminescence responses 
with 3759v at V2 MIC, and with E l6 and Mu50 at V2 and % MIC respectively. Linezolid 
and synercid effectively reduced chemiluminescence at V2 MIC and % MIC concentrations. 
Linezolid expressed activity against E16 and Mu50 at both sub-MIC’s and Mu3 exposed to 
V2 MIC only. One half MIC and % MIC synercid exposed E l6 also produced reduced 
chemiluminescence responses.
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4.4 DISCUSSION
Both of the investigations conducted in this section sought to examine the susceptibility of 
VISA to opsonophagocytosis by human PMNL cells. Discrepancies were seen between 
manual counts of ingested bacteria and the automated quantification of respiratory burst as 
an indicator of phagocytic uptake. This could be due to a number of reasons including the 
different ratios of bacteriaiPMNL used, test variability and human error.
Some correlation was found in the reduced percentage of PMNL ingesting bacteria and the 
reduced chemiluminescence response produced by linezolid and celpirome treated Mu50 
and cefpirome treated Mu3. Antibiotic treatment of EMRSA16 produces a marked 
reduction in chemiluminescence response that is not observed statistically by bacterial 
counts however, if it were not due to high experimental variance a reduction in ingestion 
of linezolid and synercid can clearly be seen. Similar correlations between phagocytosis 
and chemiluminescence have been described by Gemmell and O’Dowd (1983).^^^ 
Investigations by Bramley ei al. (1989) reported the ingestion of many bacteria by some 
PMNL and none by others in a mouse mammary gland m o d e l . T h e y  suggested that this 
might reflect the arrival of PMNL into the gland at different times or different phagocytic 
potential of neutrophil subpopulations. The latter could be an explanation of the variable 
numbers of PMNL phagocytosing bacteria in our study.
Research by other authors has investigated the effects of various protein synthesis 
inhibitors and cell wall antibiotics on bacterial ingestion, the most extensively studied drug 
being the protein synthesis inhibitor clindamycin (din). The discovery that sub-MIC’s of 
lincosamides and the macrolide erythromycin (ery) potentiates bacterial uptake of several 
species including staphylococci and streptococci has been made, and is generally 
correlated to the loss of an antiphagocytic surface protein. ^  19,122,127,129,237,352 wall
inliibitors have produced more varied results with reports of either increased uptake or no 
effect.'" ''''''
The process of respiratory burst and chemiluminescence is one that progresses rapidly 
during the initial lOmins of contact with bacteria and can be influenced by the age of 
PMNL preparation.^''"® Neutrophils from individuals with bacterial infections can also 
affect results as their activity can vary and as a result variability in study populations and 
methods can occur. For the purposes of this study our PMNL cells were isolated from
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healthy blood donors and used within half an hour of their isolation. In our assay we have 
utilised the peak response as our indicator of maximal respiratory burst; however Allen 
(1977) has suggested that the efficacy of phagocytosis measured as a rate of ingestion 
(mV/cell/min) ealculated over the initial 10 minutes is a more accurate estimate of 
phagocytic activity.^' The use of PMNL preparations from blood donors results in PMNL 
with variable activity. In each of the experiments here, a single PMNL preparation was 
used to examine one strain under all experimental conditions therefore comparisons should 
be made within an experiment.
Protein A is considered to confer antiphagocytic properties upon a bacterial cell. In 
Chapter Three it was found that all of the VISA strains, with the exception of strain 5827, 
did not express surface bound protein A. A feature observed with some strains of 
MRSA.^®'’"®' Extracellular protein A was more readily detected in the VISA strains with 
strains 3759v, 5827, Mu3 and Mu50 recorded as positive producers by ELISA. EMRSA- 
16 expressed less but not significant, levels of protein A to S.aureus Cowan, a high protein 
A producer. The chemiluminescence response elicited by these strains was significantly 
different (pvalue <0.05) with E l6 inducing a higher level of respiratory burst suggesting 
that the strain was more readily phagocytosed than the Cowan strain. In contrast strain 
5827 produced significantly reduced levels of surface bound protein A but produced a 
chemiluminescence response similar to S.aureus Cowan. This suggests that protein A 
alone is not sufficient to alter the phagocytic susceptibility of these strains to ingestion by 
PMNL. Exposure to sub-MIC ce%irome, linezolid, and synercid were found to reduce the 
chemiluminescence response of PMNL incubated with strains E l 6, Mu3 and Mu50 but not 
to the same extent. One half MIC cefpirome was shown to significantly increase ingestion 
of strain 3759v. The increased susceptibility to phagocytosis of strains exposed to 
antibiotics does correlate with reduced levels of cell free protein A observed for 
cefpirome, linezolid and synercid exposed strain of E l6, 3759v, Mu3 and Mu50. This 
suggests that these antibiotics are altering the bacterial cells, in addition to reducing 
protein A expression, affecting phagocytic susceptibility.
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C H A P T E R  F I V E
G E N E R A L  D I S C U S S I O N
Ailments and diseases resulting from staphylococcal infection are numerous and variable 
in severity from folliculitis and boils, to food poisoning, toxic shock syndrome (TSS), 
scalded skin syndrome (SSS) and bacteraemia amongst others. The onset and progression 
of a diseased state is multifactorial involving the production of factors that aid in the 
primary attachment of a bacterium to host cells, invasion and spread of the bacterium 
within host tissues.
Strains of S.aureus are commonly associated with invasive diseases through the production 
of cell-bound and/or extracellular vimlence factors. Expression of particular proteins and 
toxins can sometimes be associated with specific symptoms and disease, for example, the 
enterotoxins are food poisoning agents, TSST-1 causes TSS and the exfoliative toxins are 
the causative agents of SSS. The carriage of genetic elements encoding virulence factors 
as well as those encoding antibiotic resistance is highly variable amongst staphylococci 
and does not necessarily complement the observed phenotype. Whether it is the expression 
of proteins and toxins or resistance, the genes that encode them are under tight regulation 
by a number of mechanisms. The well-documented agr and sarA regulatory loci of 
S.aureus are the key regulators of virulence factor expression although homologous 
components of the agr locus have also been identified in strains of CNS. It is believed that 
the agr locus functions in vivo to activate extracellular toxin transcription in response to 
increasing levels of auto-inducing peptide to aid the destruction of host tissues and spread 
of the bacterium.
Antibiotic resistance is regulated by the expression of antibiotic specific mechanisms that 
can inactivate, prevent binding of, or export the antibiotic out of the bacterial cell. The 
oecurrence of antibiotic resistance is widespread among bacteria and is increasingly 
problematic in the effeetive treatment of severe infections. The development of resistance 
to methicillin in S.aureus (MRSA) in the 1960s reduced the number of antibiotics available 
for use against S.aureus, leaving vancomycin as the drug of choice in many clinical 
situations. Resistance to vancomycin is already prevalent in strains of enterococci due to 
the carriage of van genes. The prospect of vancomycin resistance spreading to 
staphylococci is one that has caused concern among clinicians. In 1992, Noble et al. 
demonstrated that vancomycin resistance could be transferred from Enterococcus faecalis 
to S.aureus but not between strains of S.aureus in vi/ro."® The first in vivo isolate of 
S.aureus displaying reduced susceptibility to vancomycin (VISA) was reported in Japan in 
1995 and has been followed by several strains throughout the Western world, MlC=2pg/ml 
to 16pg/ml. None of these isolates carried the enterococcal van genes conferring high-
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level resistance but were phenotypically different from strains of MRSA. Two isolates of 
S.aureus from the United States have recently been reported to carry the enterococcal vanA 
gene displaying vancomycin MIC’s of SOpg/ml to >128pg/ml, thus having the designation 
VRSA. One of the isolates was isolated alongside E. faecalis and it is thought that the 
genes were transferred to S.aureus in v/vo.'*’"
Common characteristics shared by the VISA strains is the production of cell walls that vary 
in composition and in many cases are thicker than those of normal strains of methicillin 
sensitive S.aureus (MSSA) and MRSA. The consistency of some of the characteristics 
between VISA isolates has led researchers to believe that the cell walls may fonn a barrier 
to vancomycin preventing it from reaching its true target. Other features in addition to 
thickened cell walls have been reported suggesting that there may be one or more 
mechanism of resistance. The VISA strains used in this study were isolated in Japan (Mu3 
and Mu50), the United States (5827 and 5836) and the United Kingdom (3700w and 
3759v). All displayed vancomycin MIC’s of 2-16pg/ml.
With the appearance of VISA and VRSA strains, the development of new antimicrobial 
agents with novel modes of action towards Gram-positive bacteria is increasingly 
important. An advance in new drug development has been made within the oxazolidinone, 
streptogramin, and iipopeptide antibiotic groups. The protein synthesis inhibitors linezolid 
(oxazolidinone) and synercid (streptogramin), and daptomycin (Iipopeptide), a cell 
membrane inhibitor, have each shown promising results in the treatment of Gram-positive 
infections. Here, the effects of these antibiotics plus the cephalosporin cefpirome, at sub- 
inhibitory concentrations, were examined for activity against the aforementioned VISA 
strains, MSSA S.aureus Cowan and a local isolate of EMRSA-16 (E l6). The phenomenon 
of antibiotic stress, as examined here, can be related to how an organism reacts to an 
unfavourable situation. The addition of antibiotics at sub-inhibitory concentrations to the 
culture medium will have variable effects on different bacterial strains depending upon 
their ability to cope with this form of stress. Bacteria that have been exposed to antibiotics 
in the past, for example strains of MRSA and VISA, may be expected to react differently 
than strains that have had no prior contact to antibiotics, for example S.aureus Cowan due 
to the expression of compensatory mechanisms.
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5.1 Bacterial Growth and Cell Morphology
Since the isolation of the Japanese strains Mu3 and Mu50 by Hiramatsu et a l interest in 
the phenotype of these strains, in particular the thickened cell wall has developed. 
Abnormal levels of glutamine-non-aminated muropeptides, N-acetylglucosamine, and 
UDP-N-acetyl-muramylpeptides, reduced peptidoglycan cross linkage and enhanced 
expression of the penicillin binding proteins PBP2 and PBP2’ have been described. It is 
interesting to note that not all of the characteristics mentioned occur in eveiy VISA isolate.
The mechanisms conveying vancomycin resistance to S.aureus have not been fully 
characterised. It is thought however, that the thickened cell wall plays a major role. 
Investigations into the Japanese sti ains Mu3 and Mu50 established that activity of the glmS 
pathway involved in the conversion of fructose-6-phosphate and glutamine to glucose-6- 
phosphate was enhanced and more efficient, suggesting a role in thickened cell wall 
expression.'^ Glutamine deficiency resulting from increased demand may account for the 
levels of nonaminated muropeptides within the cell wall. '^'® The type of medium used to 
examine cell wall production has been reported to produce variable results with medium 
containing high levels of amino acids and glucose for example. Brain Heart Infusion (BHI) 
broth is regarded to be the best medium for the expression of cell wall features.'^
In this study the growth kinetics of the VISA strains, MSSA S.aureus Cowan and E l6 
were studied over a twenty-four hour period in the absence and presence of sub-inhibitory 
concentrations (V2 and % MIC) of the antibiotics linezolid, cefpirome, synercid and 
daptomycin. Representative strains were also examined under electron microscopy to 
identify the characteristic thickened cell walls of the VISA strains and to study the effects 
that V2 MIC of the antibiotics had on the bacterial cell wall. It was shown that none of the 
antibiotics exerted a uniform effect on all of the strains either during giowth or on the 
bacterial cell wall.
As previously mentioned the use of BHI is recommended for investigations of the bacterial 
cell wall structure. In this study Mueller Hinton Broth (MHB) was used, as this is the 
medium of choice for NCCLS antibiotic susceptibility testing. The use of MHB as the 
culture medium of choice was made prior to the recommendations by Cui et al?^ The 
culture medium was not changed in light of these findings due to the quantity of work that 
had already been carried out and the financial constraints surrounding the electron 
microscopy work. As the aim of this section was to examine the effects of % MIC
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antibiotics on the bacterial cell wall in comparison to no drug controls and strains of 
MSSA and E l6, the culture medium used it not critical. However, it would be interesting 
to re-examine the VISA isolates following culture in BHI to ascertain whether any 
differences in cell wall morphology occur in comparison to our findings in MHB.
Under electron microscopy, the cell wall thickness of strains S.aureus Cowan, E l6 ,3759V, 
Mu3 and Mu50 was very similar. The cell wall of strain 5836 was found to be 
significantly thicker than all o f the other strains. In response to 14 MIC of antibiotics each 
strain reacted differently. Only the clonal stiains Mu3 and Mu50 were affected in the same 
manner by the same antibiotics. Sub-MIC linezolid, cefpirome and synercid each 
significantly increased cell wall thickness. Other strains to be affected by 14 MIC linezolid 
were strains E l6 and 5836 whose cell walls were found to have increased and been 
reduced respectively. Cell walls of strains E16 and 3759v were also increased by 14 MIC 
synercid. Daptomycin produced interesting results in that exposure to 14 MIC reduced the 
cell wall size in strains 3759v and 5836. It is likely that the ability of daptomycin to inhibit 
the incorporation of peptidoglycan into the cell wall by its action on cell membrane 
function is a contributing factor to these findings.
When comparing the growth of the strains in 14 and 14 MIC antibiotics a strong relationship 
was found between cell wall thickness and growth rate observed over the initial eight hours 
of the growth cycle. For strains Mu3 and Mu50, the most dramatic increase in cell wall 
thickness was observed following exposure to 14 MIC linezolid. When examining the 
growth patterns of these strains it was found that both of these strains displayed impaired 
growth in the presence o f 14 and 14 MIC linezolid compared to the no drug controls. Strain 
E16 also produced similar patterns of growth inhibition with the greatest degree of 
inhibition correlating to the degree of cell wall thickening in response to 14 MIC synercid 
followed by linezolid and ce%irome. Gemmell and Lorian have also reported thickened 
cell walls in response to sub-inhibitory levels of synercid. Although, this was not 
always the case as seen with other cell wall changes, it would appear that a thickened cell 
wall exerts a burden upon growing cells.
The minimum antibiotic concentration (MAC) has been defined by Lorian as the minimum 
concentration of antibiotic necessary to induce alterations in bacterial structure as seen by 
electron microscopy, and/or growth producing one log decrease in numbers compared to 
the no drug control. It would appear that the MAC for linezolid, cefpirome, synercid
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and daptomycin for the majority of VISA strains used in this study is observed at 
concentrations of Vz MIC.
5.2 Virulence factor expression
Humans, as a host, provide a niche for numerous conunensal organisms that help to 
maintain the health of an individual. Infection by an organism does not necessarily lead to 
disease, but depends on the pathogenic nature of the organism and the host in question. 
The ability of a bacterium to express proteins, enzymes and toxins inadvertently makes 
them potential pathogens. Infection by S.aureus is multifactorial due to the vast spectrum 
of virulence factors that can be carried on its genome and subsequently expressed. The 
ability of an organism to colonise a host relies upon evasion of the host’s defence 
mechanisms. The initial barrier to bacterial colonisation is the skin and antimicrobial 
secretions. Following attachment to the epithelial cell layer or breaching of the skin 
through injury, a bacterium is able to invade cells through the production of enzymes and 
toxins that destroy host cells releasing nutrients for growth and spread through host tissues.
The effects of antibiotics on the expression of virulence factors has been explored 
extensively in an attempt to evaluate how antibiotics contribute to the cure of an infection, 
and the advantages and disadvantages of using a particular antibiotic in particular 
situations. Evidence for the latter scenario is given by the preferred use of clindamycin, an 
inhibitor of TSST-1 production, in place of p-lactam antibiotics due to its strong inhibitory 
effects.'®® Protein synthesis inhibitors are generally regarded to have inhibitory effects on 
most virulence factors, although increased extracellular protein A expression has been 
reported with sub-MIC clindamycin, as has the enhanced expression of toxins by other 
bacterial species.^"
Using the polymerase chain reaction (PGR) for the detection of virulence genes, each strain 
was examined for carriage of the staphylococcal enterotoxins (SE) A thr ough J, exfoliative 
toxins (ET) A and B, staphylococcal enterotoxin-like proteins (SET-1), alpha-haemolysin, 
TSST-1 and protein A genes. Coagulase expression was determined by a positive reaction 
on a slide agglutination test. The genetic complement of each of the VISA strains was 
shown to be different in comparison to each other and to either S.aureus Cowan or E l6. 
The only strains to carry identical genes were the clonal strains Mu3 and Mu50. From the 
genes detected, protein A (surface bound and extracellular) clumping factor, cell free
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coagulase, alpha-haemolysin and TSST-1 were chosen to be examined further. A time 
point of sixteen hours was chosen to quantify the proteins and toxins to allow optimal 
expression and for convenience.
Enzyme-linked immunosorbent assays (ELISA) employ simple and reliable methodology 
to detect immune complexes fonned with the desired antigen and detected by a coloured 
substrate. Here, we used sandwich ELISA’s to quantify the levels of TSST-1, surface 
bound and extracellular protein A. Biological assays with rabbit plasma and rabbit 
erythrocytes were used to determine the activity of clumping factor and cell free coagulase, 
and alpha-haemolysin respectively.
5.2.1 Protein A
The expression of surface bound protein A was found to be absent from all of the VISA 
strains with the exception of strain 5827. The levels of extracellular protein A were 
detectable in some of the VISA strains but were dramatically lower than those expressed 
by S.aureus Cowan and E16. Strains 3700w and 5836 did not express either form of 
protein A. The lack of surface bound protein A expression, but expression of extracellular 
protein A by strains of MRSA and coagulase negative staphylococci (CNS) has previously 
been described.^®'’"®' The presence of thickened cell walls in strains 3759v, 5836, Mu3 
and Mu50 in comparison to the high protein A producers S.aureus Cowan may be 
responsible for the lack of cell bound protein A. However, strains 3759v, Mu3 and Mu50 
were of similar thickness to the protein A producer E l 6.
The exposure of S.aureus Cowan to 14 MIC synercid and E l6 to 14 MIC linezolid and 
synercid resulted in significant increases in their cell wall thickness but reduced the 
amount of detectable surface bound and extracellular protein A. Similar results were 
observed in the levels of extracellular protein A from 3759v and Mu3 following antibiotic 
exposure suggesting that protein A expression may be being inhibited directly and that a 
thickened cell wall may reduce the quantity o f protein A able to be expressed. It would 
have been interesting to examine the cell wall of strain 5827, the only VISA to produce 
both forms of protein A, under the electron microscope to determine any altered structure 
that may account for its difference from the other VISA strains in protein A expression. 
Unfortunately it was not chosen for inclusion in the limited electron microscopy study.
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5.2.2 dumping factor and Cell Free Coagulase
The expression of clumping factor by all of the VISA strains was relatively low (32 units 
to 256 units) in comparison to S.aureus Cowan and E l6 (1024 units and 4096 units). None 
of the antibiotics tested affected clumping factor expression by any of the strains by more 
than one or two dilutions, with the exception of strain E l6. The exposure of strain E16 to 
sub-MIC cefpirome, linezolid and synercid reduced titres of clumping factor from 4096 
units to 1024, 1024 and 256 units respectively. Why the VISA isolates should have 
reduced levels of clumping factor expression is unclear, however, reduced coagulase 
activity in strains of VISA has been previously reported and it has been indicated that 
misidentification of VISA isolates could occur if the coagulase test is not incubated for 
greater than four h o u r s . T h e  levels of cell free coagulase expressed by the VISA strains 
were also significantly lower than those produced by S.aureus Cowan and E l6. Strain 
Mu3 was an exception with a titre of 512 units, the same as the Cowan and E l6 strains. Of 
the low producers, titres ranged from 16 units in strain 3759v to 256 units in strain Mu50. 
The exposure of strains to Vi and !4 MIC cefpirome reduced titres considerably, with the 
exception of strain 3759v where coagulase expression was increased by Vz and % MIC. 
Daptomycin also reduced the expression of coagulase in several strains but not to the same 
extent as cefpirome. Neither Vi nor % MIC daptomycin made any impact on the expression 
of coagulase by Mu50. The protein synthesis inhibitors linezolid and synercid were also 
found to exert inhibitory effects upon the strains but to varying degrees. It was interesting 
to note that strain 3759v and the positive standard strain NCTC 6571 expressed more 
coagulase with decreasing antibiotic concentration of all the test antibiotics. The most 
notable effects were observed in % MIC linezolid and 14 MIC daptomycin treated cultures 
of strain 3759v (increased titre from 16 units to 256 units) and 14 and 14 MIC linezolid, 
daptomycin and synercid treated cultures o f NCTC 6571 (increased titre from 64 units to 
256 units).
Why is strain 3759v different from the other VISA strains? Strain 3759v expressed the 
lowest level of cell free coagulase in the absence of antibiotics yet antibiotics with three 
different modes of action stimulated coagulase expression. The cell walls of strain 3759v 
are increased in thickness by the presence of 14 MIC linezolid, cefpirome and synercid, but 
reduced by daptomycin. The thickest cell wall is observed under the influence of 14 MIC 
synercid that also reduces the clumping factor titre, and gives the lowest rise in cell free 
coagulase expression. It is possible that the cell wall density of strain 3759v may differ 
from that of the other VISA strains in its ability to allow the secretion of proteins. The
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degree of peptidoglycan cross-linkage can detennine the resulting density of the cell wall. 
If this is altered by antibiotic stress the expression of cell components in culture 
supernatants may be different from the levels expressed in the cell cytoplasm with the 
effects observed governed by the ability of the bacterium to transport them from the cell. 
For example, should the degree of peptidoglycan cross-linkage be reduced, it would be 
conceivable that larger and/or more proteins can be transported out o f the cell. This would 
only apply to cell free proteins as cell wall bound proteins would require binding to cell 
wall components for expression. In this instance it could be suggested that peptidoglycan 
cross linkage is being reduced therefore reducing the quantity of surface proteins that can 
be attached but allows the export of proteins out of the cell. The reduction in cell free 
protein A expression is probably due to the effects of the antibiotics on protein synthesis.
5.2.3 Alpha-Haemolysin
Alpha-haemolysin is one of four haemolytic toxins produced by S. aureus. The haemolysin 
is produced by 95% of S.aureus strains, and is generally linked to the coagulase-positive 
phenotype.^’"' In vitro, rabbit erythrocytes are the most sensitive cell type to the lytic 
action of alpha-haemolysin."®’^ ' Fresh suspensions of rabbit erythrocytes were incubated 
with serial dilutions of culture supernatants to determine the haemolytic titre of the strains. 
S.aureus Cowan and the VISA Mu50 were found to produce the highest haemolytic titres 
(64 HU) followed by the VISA strains 3759v (32HU) and Mu3 (16HU). The other strains 
of VISA and E16 were very low producers of alpha-haemolysin with titres ranging from 
zero to 8HU. The absence of haemolysin activity by strains of glycopeptide resistant 
S.aureus (GISA) has been attributed to a loss of function in haemolysin production and/or 
an inability to secrete the haemolysin through the thickened cell wall."®® The classification 
of GISA as agr-mA\ strains provided evidence for the low expression of proteins and 
toxins."®® (Richard Novick 2002; personal communication)
The presence of sub-MIC cefpirome in the culture medium reduced haemolytic titres by a 
single dilution or had no effect with the exception of reduced expression (64HU to 8HU) 
by Mu50. Increased haemolysin expression has been described previously in strains of 
staphylococci and streptococci during exposure to glycopeptide and p-lactam antibiotics 
r e s p e c t i v e l y . L i n e z o l i d  and synercid inhibit expression by the majority of 
strains. It is likely that the activity of linezolid and synercid is a result of their activity on 
protein synthesis, inhibiting alpha-haemolysin {hla) mRNA translation albeit through 
different mechanisms. Gemmell and Ford have also reported reduced expression of
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haemolysin by another strain of S.aureus (Wood 46) by sub-MIC linezolid. Daptomycin 
reduced titres by one dilution or had no effect on strains.^" The ability of daptomycin to 
disrupt bacterial cell membrane potential is obviously insufficient to increase the levels of 
haemolysin detected and has no apparent effect on the translation and expression of alpha- 
haemolysin.
5.2.4 Toxic shock syndrome toxin-1 (TSST-1)
TSST-1 is responsible for the symptoms of toxic shock syndrome (TSS) although 
involvement of the enterotoxins SEA, SEB and SEC has been reported."^’"®^’"'^ The 
classification of TSST-1 as a superantigen as a result of its biological properties makes it 
an interesting virulence factor to study. Only three of our strains, E l6, Mu3 and Mu50, 
carried the tst gene. Detection and quantification of TSST-1 in culture supernatants in 
these strains was performed by ELISA.
The initial levels of toxin detected in drug-free medimn were found to be significantly 
higher in the VISA strains than in E l6 (Mu50>Mu3>E16). The fact that strains Mu3 and 
Mu50 are both high producers of TSST-1 and alpha-haemolysin with respect to the other 
VISA strains contradicts many reports detailing the lack of dual expression of these toxins. 
It is widely reported that TSS isolates cany the gene for alpha-haemolysin but fail to 
express detectable levels of the haemolysin due to a single, reversible, gene mutation.'"’'®' 
Non-clinical strains however express both toxins.'" Mu3 and Mu50 are clinical isolates but 
were not associated with TSS so phenotypically they fall into the latter categoiy. Strains 
Mu3 and Mu50 behaved similarly in response to 14 MIC linezolid and synercid where 
toxin levels were significantly reduced. E16 on the other hand expressed significantly 
increased levels of toxin when grown in the presence of 14 MIC linezolid. One half MIC 
cefpirome was also found to increase toxin levels in strains E l6 and Mu3 but reduced them 
in strain Mu50.
The ability of the protein synthesis inhibitors to reduce TSST-1 expression in the two 
VISA strains indicates an effect on toxin translation as has been demonstrated with the 
protein synthesis inhibitor clindamycin.^^’^ "’""’" ' ’"®'^ ’"'^ '’""  Why 14 MIC linezolid should 
increase toxin expression and synercid should have no effect in E16 is unclear considering 
that both of these antibiotics inhibited normal cell growth. Both of these drugs also 
induced thickened cell walls thus the release of TSST-1 could be affected by altered cell 
wall density as previously mentioned. Alternatively, the ribosomal organisation of E l6
144
may differ from Mu3 and Mu50 and the levels of expression result from antibiotic activity 
on TSST-1 translation at or near to the cell membrane.
Despite the effects of the antibiotics on TSST-1 expression, the ability of culture 
supernatants to stimulate Tcell proliferation, a property of superantigens, was not affected 
to the same extent. There is no apparent relationship between the level of toxin expression 
and mitogenic activity. From the standards included in the assay (range O.lpg/ml to 
lOOpg/ml) it is clear that Tcell proliferation induced by TSST-1 is not concentration 
dependent. It is likely that, as the culture supernatants were used in their crude form, other 
superantigens may be present in since the genes for enterotoxin A (SEA), SEG and SEÏ are 
carried by the three strains and additionally SEC by strains Mu3 and Mu50. The potential 
expression of the enterotoxins may contribute to the levels of Tcell proliferation observed.
5,2,5 Protein A (spa) mRNA transcription
Determination of the levels of protein A (spa) mRNA from E l 6 during giowth for 4hrs in 
the absence and presence of 14 MIC linezolid and synercid showed that the levels of spa 
mRNA transcript were actually increased even though the growth rate of E16 was severely 
inhibited in comparison to the no drug control. The significantly reduced levels of surface 
bound and extracellular protein A, as measured by ELISA, in response to linezolid and 
synercid suggests that mRNA transcripts are being produced but not being transcribed into 
mature protein. The increased levels of transcript observed may be due to a backlog of 
untranscribed mRNA but this is usually degraded suggesting that the antibiotics may be up 
regulating transcription or that degradation enzymes are being inhibited. Although the 
levels of mRNA for the other proteins and toxins studied in this thesis were not determined 
it seems logical to assume that, as all four of the antibiotics were found to reduce the 
expression of both extracellular toxins and surface bound proteins in the majority of 
strains, inhibition of mRNA translation is taking place.
5.3 Susceptibility to Phagocytosis
Phagocytosis is a key process in the eradication of infecting bacteria from a host. Many
bacterial species express surface components that mask phagocyte binding sites or form a
protective barrier around the cell preventing the adherence of opsonic complement factors.
Numerous authors have investigated the process of phagocytosis and the effects that
antibiotics have on the process. Of interest is the ability of antibiotics to modify a
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bacterium such that its susceptibility to phagocytic uptake by polymorphonuclear cells 
(PMNL) is increased. There are several studies of the effects of clindamycin on strains of 
staphylococci and streptococci and their subsequent susceptibility to phagocytosis. The 
loss of protein A and M protein expression by these species by sub-MIC clindamycin 
increased their susceptibility to phagocytosis.^"^’"®’""
In staphylococci the antiphagocytic protein of interest is protein A. The ability of protein 
A to bind the Fc portion of immunoglobulin (IgG) reduces activation of complement and 
thus IgG-mediated opsonisation of the bacterial cells, a crucial requirement for rapid 
phagocytic ingestion."^’""
The process of chemiluminescence was used to measure the quantity of light being emitted 
in response to PMNL respiratory burst, a process closely related to bacterial ingestion. It 
was noticed that strain 3759v produced a significantly reduced chemiluminescence 
response in comparison to S.aureus Cowan and all of the other strains whereas Mu3 and 
Mu50 produced significantly enlianced responses suggesting reduced and enhanced 
susceptibility to phagocytosis respectively. This would indicate that these strain 3759v 
expresses additional characteristic(s) that are different from the other strains enabling it to 
inhibit opsonophagocytosis more effectively. Strains Mu3 and Mu50 on the other hand do 
not express such effective antiphagocytic properties. Incubation of the strains in V2 and 14 
MIC linezolid, cefpirome and synercid produced variable but reduced chemiluminescence 
responses of strains E16, Mu3 and Mu50 only. Cultures of strain 3759v in 14 MIC 
cefpirome demonstrated increased susceptibility to PMNL ingestion.
The presence of protein A is considered to confer antiphagocytic properties upon a cell but 
reduced protein A expression by S.aureus Cowan in response to 14 MIC synercid does not 
alter the PMNL chemiluminescence response to the treated organism. This strain does 
however possess a slightly thicker cell wall in the presence of synercid. The balance 
between protein A expression and cell wall thickness and/or composition appears to be 
important in the determination of phagocytic susceptibility. Thickened cell walls are 
present in strain Mu3 exposed to 14 MIC linezolid, and strain Mu50 exposed to 14 MIC 
linezolid and synercid. The levels of protein A expressed by these strains were also 
significantly reduced by these antibiotics as is the chemiluminescence response, thus 
suggesting that modification of the cell walls may compensate for the lack of protein A in 
terms of susceptibility to phagocytosis. The presence of a thickened cell wall alone is not 
sufficient to induce antiphagocytic properties upon a cell as demonstrated by the reduction
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in cell wall thickness and lack of protein A expression by strain 5836 in response to 14 MIC 
linezolid and daptomycin, but no alteration in the PMNL ingestion of this strain. This 
would suggest that other surface and cell free proteins not included in this study are being 
expressed and/or that the actual composition and density of the cell wall plays a role in the 
susceptibility of VISA strains to phagocytosis by PMNL. This conclusion was supported 
by the irregular observation, by electron microscopy, of electron dense material loosely 
associated with the cell wall. These observations were in addition to, and apparently 
unrelated to any expression of protein A.
There are no doubt other characteristics of the VISA strains that contribute to their 
resistance to phagocytic ingestion as the absence of protein A expression by these strains 
does not appear to render them more susceptible to opsonophagocytosis. This is evidenced 
by the characteristics of strain 3759v. In normal cell culture strain 3759v possesses a cell 
wall that is slightly thicker than that of S.aureus Cowan. It is a non-producer o f surface 
bound protein A but produces low levels of cell free protein A, clumping factor and 
coagulase, and produces moderate levels (32HU) of alpha-haemolysin but is the most 
resistant strain to opsonophagocytosis.
5.3 Relationship of Present Study to Previous Investigations
The effects of sub-MIC antibiotics have been studied on both Gram-positive and Gram- 
negative species of bacteria. The activity of the lincosamine, clindamycin, is perhaps the 
best studied of the protein synthesis inhibitors. Sub-MIC clindamycin, in addition to 
chloramphenicol and erythromycin, have been reported to reduce the expression of 
fibronectin binding proteins (Fnbp) in S.aureus thereby reducing the strains susceptibility 
to p h a g o c y t o s i s . I n  contrast, clindamycin inhibits the expression of protein A in 
S.aureus and M protein in S.pyogenes increasing opsonophagocytosis.""^’"'®’""  
Extracellular proteins and toxins including coagulase, alpha-haemolysin, TSST-1 and 
nucleases of S.aureus, E.coli haemolysin and shiga-like toxin, and the glycocalyx of 
S.aureus, E.coli and Bacillus species are also subject to inhibition by 
clindamycin."®’"'"’''" ’^"®'"’"'"' The latter plays a role in the inhibition of bacterial adherence to 
bone surfaces and potentiation of phagocytosis.""’"®'’'®'"’'®'’'"®’"'"’"'"
Exposure to some antibiotics stimulates protein and toxin expression. For example, 
clindamycin enhances expression of Clostridium difficile enterotoxin,"'^ synercid increases
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the expression of the ica operon (involved in adhesion) in S.epidermidis^^^ and lincomycin 
has been shown to increase the expression of heat labile toxin and choleragen by E.coli and 
Vibrio cholerae respectively.'"" Erythromycin and chloramphenicol have no effect on 
toxin expression and phagocytosis of group A streptococci.""^
It is interesting to note that Milatovic et al. (1982,1983) reported thickened cell walls in 
isolates of S.aureus exposed to sub-MIC clindamycin.'"’'"^ Increased binding of the 
complement component C3 leads to enhanced phagocytosis of the bacterium. It was 
hypothesised that the thickened cell wall exposed more C3 binding sites thus promoting 
phagocytosis.
The cell wall active antibiotics have also been shown to affect protein biosynthesis. 
Increased levels of Fnbp in S.aureus have been reported during exposure to the p-lactams, 
cephalosporins, vancomycin, and ciprofloxacin, probably due to the inhibition of 
peptidoglycan cross-linkage thus exposing more Fnbp."'"’'®' Enhanced levels of alpha- 
haemolysin occur in the presence of methicillin"® and increased phagocytosis of 
Pseudomonas aeruginosa has been reported to coincide with altered morphology through 
p-lactam action.""
5.4 Summary
Throughout this thesis I have endeavoured to characterise the variable morphology and the 
extent of surface protein and extracellular toxin expression by strains of S.aureus 
displaying intermediate resistance to vancomycin in comparison to a strain of methicillin 
susceptible S.aureus and a local isolate of methicillin resistant S.aureus, and to determine 
the effects that antibiotic stress has on the above factors.
The results presented here suggest that strain- and species-dependent effects take place in 
response to antibiotics at sub-inhibitory concentrations. The ability of strains of VISA to 
express thickened cell walls is believed to play a role in the strain’s resistance to 
vancomycin though the binding of vancomycin molecules at the peripheral cell wall may 
prevent bactericidal activity. A thickened cell wall may also hinder the passage of 
antibiotics into and proteins and toxins out of the bacterial cell. The composition of the 
cell wall is also of major hnportance. A lower degree of peptidoglycan cross-linkage in the 
cell wall, a common characteristic of VISA strains, affects the density of the cell wall and
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it is plausible that the passage of molecules and proteins through the cell would also be 
affected. In instances of reduced cross-linkage the passage of molecules through the cell 
wall would be expected to be more efficient and vice versa (Figure 52). A similar efflux of 
proteins out of the cell may be expected to occur in response to peptidoglycan cross 
linkage i.e. cell walls with low-level cross linkage should allow the passage of a greater 
number and indeed larger molecules out of the cell.
The increased levels of toxin expression by selected strains in this study may be due to the 
above hypothesis or the inhibition of the enzymes that degrade toxins in the culture 
supernatant as proposed by Levner et a l (1977).'"" However, most strains of S.aureus 
produce one or more proteolytic enzymes"" and without actually measuring the levels of 
protease produced by different VISA strains this idea is difficult to prove or disprove. As 
the majority of strains reduce surface protein and extracellular toxin expression in response 
to antibiotic stress it is likely that this is a result of antibiotic effects on protein synthesis as 
demonstrated by the effects of linezolid and synercid on spa mRNA and the reduced levels 
of protein A detectable by ELISA.
Normal peptidoglycan cross-linkage 
in S. aureus
Reduced peptidoglycan cross-linkage 
as seen in VISA
N-acetylglucosamine 
^  Antibiotic molecule
^ N-acetylmuramic acid pentaglycine cross-link
Figure 52. Proposed model of the passage of antibiotic molecules through cell walls that differ in their 
intrinsic density
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FUTURE WORK
To develop this research further the following avenues may yield interesting results:
To examine the cell wall morphology and extent o f  cross-linkage o f VISA 
isolates to attempt to explain protein secretion and antibiotic resistance in 
relation to the transportation o f  molecules across the cell wall
To establish w hether there are pools o f proteins in the cytoplasm o f VISA 
strains in the presence and absence o f antibiotic induced stress in order to 
support the hypothesis o f  inhibited protein transportation through the cell 
wall.
To measure mRNA synthesis in strains o f VISA in relation to the proteins 
and toxins examined in this study during linezolid, synercid and daptomycin 
stress
To establish if  there any similarities between strains o f VISA and VRSA in 
their ability to express surface bound and cell free proteins and toxins and 
their consequent susceptibility to phagocytosis
To establish what effects these agents have on linezolid resistant MRSA?
Carry out further investigations into protein A positive VISA 5827 as this 
strain was the only VISA is this study to express protein A.
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A P P E N D I X  O N E
R E A G E N T S
Achromopeptidase solution
1ml TE buffer (x l)
1 vial achromopeptidase powder (100,000 units/ml)
Vortex, leave in 50^C waterbath 15min make sure powder is dissolved ->100 units/iul 
Dilute to 10 units/pl;- add 90pl TE buffer or PCR water to 10|al achromopeptidase (100 
units/jul). Store -20°C
Anti-rabbit IgG gold conjugate Buffer
0.1% BSA
0.05% Tween 20
5% Foetal calf serum
Dilute in O.SMNaCl
Coagulase Tubes
120ml BHI
20ml Rabbit plasma
60ml sterile saline
xl DNase buffer
50|ul xlO DNase
500(11 RF-H 2O
Gel-Hank’s solution
■
lOml lOx Hank’s balanced salt solution (HBSS) (ICN)
10ml 1% Gelatin
80ml dHsO
Adjust pH with 0. IM NaOH
Leishman’s Stain
Soak slides in 100% Leishman’s stain for 5 minutes 
Soak slides in 50% Leishman’s stain in Methanol for 5 minutes 
Rinse off with dH20 
Air diy
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1,77mg Luminol (5-amino-2,3-dihydro-1,4 phthalazinedione)
1ml Dimethyl sulphoxide
Dilute to lO’^ M with sterile PBS before use.
NET Buffer
1ml Tissue Culture Water
1ml TE Buffer (xl)
200pl 5MNaCl
Store at room temperature
Phosphate Buffered Saline (xlO PBS)
3.54g KH2PO4
14.8g NaHP0 4  anhydros
85g NaCl
Dissolve in 1 Litre ddH2 0  and filter sterilise.
PBS/0.05% Tween-20
100ml xlOPBS
0.5ml Tween-20
900ml ddHzO
PBS/Tween 20/Bovine Serum Albumin (PBS/T/BSA)
IL PBS/0.05% Tween-20
10.8 g Bovine Serum Albumin
PNP (Stock O.IM PNP)
0.026318g p-nitrophenyl substrate 
10ml IM Tris
Dilute 3ml 0. IM PNP in 7ml IM Tris -> 2mM PNP
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RPMI medium (Supplemented)
500ml RMPI-1640 (Sigma)
5 ml penicillin (5000U/ml)/streptomycin (5000U/ml)
5ml L-glutamine (200mM)
2.5ml fungazome
2% heat inactivated foetal calf serum
Silane Coated Slides
Soak slides in 2% Decon overnight
Rinse and leave for 1 hour in dH20
Soak in acetone for 5 minutes
Soak in 2% Silane in Acetone for 5 minutes
Rinse in dH20 for 30 minutes
Diy in an oven before use
O.IM Sodium Hydrogen Carbonate (NaHCOj pH 8.2)
8.4g NaHCOs
IL ddH20
O.OIM NaHCOj
0.84g NaHCOg
IL ddH20
IM Tris
30.2758g TrizmaBase
220ml ddHzO
Dissolve and make up to 250ml
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A P P E N D I X  T W O
P h e n o t y p i c  a n d  G e n o t y p i c  C h a r a c t e r i s a t i o n  o f  B a c t e r i a l
S t r a i n s
A. Restriction enzyme digests (smal) of S.aureus Cowan, E16 and strains of VISA by 
Pulse Field Gel Electrophoresis (PFGE).
1 8 10
Key: lanes 1 + 10 = NCTC 8325 control strain, lane 2= S.aureus Cowan, lane 3 = E16, lane 4 = VISA 3700w, 
lane 5 = VISA 3759v, lane 6 = VISA 5827, lane 7 = VISA 5836, lane 8 = VISA Mu3, lane 9 = VISA Mu50
B. Phage Type and antibiogram of bacterial strains
S tr a in  O r ig in S tra in ANTIBIOGRAM MEIU
(MIC)
PHAGETYPE
Glasgow VISA 3700W
Japan VISA MU3
LHI T ype E16
USA VISA 5827
Glasgow VISA 3759V
USA VISA 5836
Japan VISA M U50
Cowan Strain 8530
PnM tCxErGnCpT rSuT eKmStTbAk 
Pn MtCx ErClGnCpT e KmT bAk 
PnM tCxErClCpK m Tb 
PnM tCxErClGnCpT rKmTb(SuAk) 
PnM tCxErClGnCpSuT cRfKmStTbAk 
P n M t ErClCp Rf KmT b 
PnM tCxErClGnCpT eRfKmTb(Ak) 
Fully sensitive.
R
R
R
R
R
R (3 2 )
R
S (0.094)
Not T ypable 
6ih/85ih 
83Cw/29ih/75w/77/83A 
932ih/6ih/54w/85ih 
83Q42E/47/53/54/75/77/83 A/84/85/88 A/81 + 
Not T ypable 
6ih/85ih 
29W/52/52A/80
180
A P P E N D I X  T H R E E
P C R  and L I G H T C Y C L E R  P R IM E R S
A. Preparation of Primer Stocks
Each primer was adjusted to a concentration of lOOpmol/pl in tissue culture water (Sigma) 
according to the Oligo synthesis report provided (MWG primers).
Alpha-Haemolvsin (hid) -  535bp 265
Forward 5’ GGT/ TTAI GCC/ TGG/ CCT/ TC 3’ 
Reverse 5’ CAT/ GAG/ G A A IGTG/ GTT/ GG 3’
Enterotoxin A (sea) - 12Qbp
Forw ard 5’ TGG/ GAA/ AGG/ GTT/ AAA/ AGG/ AA 3’ 
Reverse 5’ GAA/ GGT/ TGG/ GAT/ GAA/ AAA/ GA 3’
Enterotoxin B Ge6) - 163bp Ref Lab
Forward 5’ GTAI TGG/ TGG/ TGT/ AAG/ TGA/ GG 3’ 
Reverse 5’ CCA/ AAT/ AGT/ GAG/ GAG/ TTA/ GG 3’
Enterotoxin G (^gc) - 271 bp MRSA Ref Lab
Forward 5’ GTG/ AAG/ AAG/ TAG/ AGA/ TAA/ AAG/ GTA/ GG 3’ 
Reverse 5’ TGA/ AAA/ TGG/ GAT/ TAA/ GAT/ TAT/ GG 3’
Enterotoxin D (sed) - 319bp MRSA Ref Lab
Forward 5’ GTA/ GTT/ TGG/ TAA/ TAT/ GTG/ GTT/ TAA/ AGG 3’ 
Reverse 5’ TTA/ ATG/ GTA/ TAT/ GTT/ ATA/ GGG/ TAA/ AGA/ TG 3’
Enterotoxin E (see) - 178bp 345
Forward 5’ GAG/ TAG/ GTA/ TAG/ ATA/ AAG/ TTA/ AAA/ GAA/ GG 3’ 
Reverse 5’ TAA/ GTT/ AGG/ GTG/ GAG/ GGT/ TG 3’
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Enterotoxin G (seg) - 327bp ^
Forward 5’ CGT/ CTC/ GAG/ GTG/ TTG/ AAG/ G 3»
Reverse 5’ GGA/ AGT/ GAT/ TGT/ GTA/ TTG/ TGG 3’
Enterotoxin H iseh) - 36Qbp ^
Forward 5’ GAA/ GTG/ GTG/ ATT/ TAG/ GTG/ AG 3’
Reverse 5’ GTG/ GAA/ TGA/ GTA/ ATG/ TGT/ AGG 3’
Enterotoxin 1 (sei) - 465bp
Forward 5’ GAA/ GTG/ GAA/ TTT/ TGA/ AGA/ GTT/ AG 3’ 
Reverse 5’ GAG/ GGA/ GTG/ GAT/ GTG/ GTG 3’
Enterotoxin J (sei) - 142bp
Forward 5’ GAT/ GAG/ AAG/ TGT/ TGT/ TGG/ GGT/ AG 3’
Reverse 5’ GTG/ AAT/ TTT/ AGG/ ATG/ AAA/ GGT/ AG 3’
ExfoliativeToxin A (etd) - 741 bp M RSARef Lab
Forward 5’ GTA/ TTT/ AGT/ GTA/ GGA/ GGT/ AG 3’ 
Reverse 5’ ATT/ TAT/ TTG/ ATG/ GTG/ TGT/ AT 3’
Exfoliative Toxin B - 629bp MRSA RefLab
Forward 5' ATA/ GAG/ AGA/ TTA/ GGG/ ATA/ AT 3’ 
Reverse 5’ GAA/ AGT/ GTG/ TGG/ AAA/ AGT/ AT 3’
Nuclease (nue) ~ 280bp MRSA RefLab
Forw ard 5’ GGG/ ATT/ GAT/ GGT/ GAT/ AGG/ GTT 3’ 
Reverse 5’ AGG/ GAA/ GGG/ TTG/ AGG/ AAG/ TAA/ AGG 3’
1 8 2
Panton-Valentine Leukocidin {pvt) -  433bp
Forw ard 5’ ATC/ ATT/ AGG/ TAA/ AAT/ GTG/ TGG/ AGA/ TGA/ TGG/ A 3’ 
Reverse 5’ GGA/ TGA/ AST/ TGT/ ATT/ GGA/ TAG/ GAA/ AAG/ G 3’
Protein A Variable X-region (spa) - variable
Forward 5’ TGT/ AAA/ AGG/ AGG/ GGG/ AGT/ GGT/ AAA/ AAG/GTA/ AAG/ 
GAT/ GG y
Reverse 5’ GAG/ GAA/ AGA/ GGT/ ATG/ AGG/ GGA/ GGA/ AAT/ AGA/ GTT/ 
GTA/ GG 3’
Toxic Shock Syndrome Toxin (tst) - 445bp RefLab
Forw ard 5’ AAG/ GGG/ TTT/ GTT/ GGT/ TGG/ G 3’ 
Reverse 5’ ATG/ GAA/ GTT/ TGG/ GGG/ ATA/ GTT/ T 3’
Staphylococcal Enterotoxin like-nrotein (set-G - 677bp 366
Forw ard 5’ GAA/ TTG/ AGA/ TTG/ GGA/ GAA/ TAA/ TAG/ TAT 3’ 
Reverse 5’ AGA/ TGT/ GAA/ GGT/ TTG/ ATG/ GTT/ AAG/ GTG/ G 3’
16SrRNA-479bp
Forward 5’ GGA/ ATT/ GAA/ A(T:G 1:1)G/ AAT/ TGA/ GGG/ GGG/ G 3’ 
Reverse 5’ GGG/ GAT/ GGG/ AGG/ GGG/ GGG/ AAG/ GTA/ TTG/ AG 3’
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B. LightCycler Primers
Each primer was adjusted to a concentration of lOOpmol/pl in tissue culture water (Sigma) 
according to the Oligo synthesis report provided (MWG primers).
16sRNA-58Qbp
Forward 5’ TAT/ TGG/ AGA/ ATG/ GGG/ G 3’
Reverse 5’ GGA/ ATT/ AAA/ GGA/ GAT/ GGT 3’
Protein A (spa) -  556bp
Forward 5’ GAG/ GAT/ GGT/ TGG/ GTG/ A 3’
Reverse 5’ TGG/ GGA/ GTT/ TGT/ GGT/ A 3’
Toxic shock svndrome toxin (tst) -  467bp
Forward 5’ GGA/ GAA/ GTG/ GTA/ GAG/ AT 3’
Reverse 5’ TGA/ GTT/ AGG/ TGA/ TGA/ GG 3’
C. Thermal Cycler Programs for PCR Detection of Genes
Toxins, nuclease and 16s RNA
1 cycle 95°G 5min
30 cycles 95°G 30sec, 55^C 30sec, 72°G Imin
1 cycle 72^G 5min
10°G HOLD
Staphvlococcal exotoxin-like protein 1 (SET-1)
1 cycle 94^G 5min
30 cycles 94^G Imin, 45®G Imin, 72^G Imin
366
1 cycle 72°G lOmin
10°G HOLD
184
Protein A
1 cycle 95°C 5min
25 cycles 95^C Imin, 60°C Imin, 72^C Imin
1 cycle 72 C 5min
iq Oc  h o l d
Enterotoxins G-J
1 cycle 95°C lOmin
15 cycles 95°C Imin, 68°C 45sec, 72°C Imin
16 cycles 95°C Imin, 64°C 45sec, 72°C Imin
1 cycle 72 C lOmin
10"CHOLD
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